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Breast cancer is the most common cancer type amongst women in the United States and will account for
approximately 7% of all cancer-related deaths each year. For most breast cancer patients, conventional
genotoxic therapy is the standard of the care. Unfortunately, as breast cancer progresses it becomes treatment
resistant and incurable. Therefore, understanding mechanisms of treatment response and resistance are of
paramount importance. Stromal communication with cancer cells is a major determinant of progression and
treatment response. We show that stromal and breast cancer (BrCa) cells utilize paracrine and juxtacrine
signaling to drive progression and conventional therapy resistance. Upon heterotypic interaction, exosomes
are unidirectionally transferred from stromal to breast cancer cells. Breast cancer cells stimulate stromal cell
upregulation of RNA polymerase III through activation of stromal NOTCH1 and MYC. This results in a
subsequent increase in stromal 5’triphosphate RN7SL1, an SRP RNA, in exosomes. Unlike cytoplasmic
RN7SL1 that is shielded by RNA binding proteins (RBPs), RN7SL1 in exosomes produced after breast
cancer cell interaction lack RBPs like SRP9 and SRP14. Consequently, unshielded stromal RN7SL1 in
exosomes, which is also found in cancer patients, is transferred to breast cancer cells to stimulate the pattern
recognition receptor RIG-I and activate STAT1-dependent anti-viral signaling.
In parallel, stromal cells also activate NOTCH3 on breast cancer cells. The paracrine anti-viral and juxtacrine
NOTCH3 pathways converge as STAT1 facilitates transcriptional responses to NOTCH3 and expands
therapy resistant tumor-initiating cells. Primary human and mouse breast cancer analysis support the role of
anti-viral and NOTCH3 pathway crosstalk in maximal activation of NOTCH signaling and stromal-mediated
resistance. Stromal-mediated therapy resistance can be overcome by combination of conventional therapy
with γ-secretase inhibitors. Thus, RBPs shield endogenous POL3-driven RNA from RIG-I, a process
circumvented when breast cancer cells coerce stromal cells to propagate anti-viral signaling through exosomes.
Anti-viral and NOTCH3 signaling then converge to enhance tumor growth, metastasis, and therapy
resistance.
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ABSTRACT 
EXOSOMES FROM THE TUMOR MICROENVIRONMENT PROMOTE BREAST 
CANCER PROGRESSION AND THERAPY RESISTANCE THROUGH UNSHIELDED 
NON-CODING RNA 
Barzin Y. Nabet 
Andy J. Minn 
 
Breast cancer is the most common cancer type amongst women in the United 
States and will account for approximately 7% of all cancer-related deaths each year. For 
most breast cancer patients, conventional genotoxic therapy is the standard of the care. 
Unfortunately, as breast cancer progresses it becomes treatment resistant and incurable. 
Therefore, understanding mechanisms of treatment response and resistance are of 
paramount importance. Stromal communication with cancer cells is a major determinant 
of progression and treatment response. We show that stromal and breast cancer (BrCa) 
cells utilize paracrine and juxtacrine signaling to drive progression and conventional 
therapy resistance. Upon heterotypic interaction, exosomes are unidirectionally 
transferred from stromal to breast cancer cells. Breast cancer cells stimulate stromal cell 
upregulation of RNA polymerase III through activation of stromal NOTCH1 and MYC. This 
results in a subsequent increase in stromal 5’triphosphate RN7SL1, an SRP RNA, in 
exosomes. Unlike cytoplasmic RN7SL1 that is shielded by RNA binding proteins (RBPs), 
RN7SL1 in exosomes produced after breast cancer cell interaction lack RBPs like SRP9 
and SRP14. Consequently, unshielded stromal RN7SL1 in exosomes, which is also found 
in cancer patients, is transferred to breast cancer cells to stimulate the pattern recognition 
receptor RIG-I and activate STAT1-dependent anti-viral signaling.  
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In parallel, stromal cells also activate NOTCH3 on breast cancer cells. The 
paracrine anti-viral and juxtacrine NOTCH3 pathways converge as STAT1 facilitates 
transcriptional responses to NOTCH3 and expands therapy resistant tumor-initiating cells. 
Primary human and mouse breast cancer analysis support the role of anti-viral and 
NOTCH3 pathway crosstalk in maximal activation of NOTCH signaling and stromal-
mediated resistance. Stromal-mediated therapy resistance can be overcome by 
combination of conventional therapy with γ-secretase inhibitors. Thus, RBPs shield 
endogenous POL3-driven RNA from RIG-I, a process circumvented when breast cancer 
cells coerce stromal cells to propagate anti-viral signaling through exosomes. Anti-viral 
and NOTCH3 signaling then converge to enhance tumor growth, metastasis, and therapy 
resistance. 
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CHAPTER 1: INTRODUCTION 
Breast Cancer is the Leading Cause of Female Cancer-Related Deaths 
Cancer is a significant global public health problem and is the leading cause of 
death for adults aged 40 to 791. As populations age, it is increasingly important to 
understand mechanisms of cancer treatment resistance and develop novel tools to meet 
these challenges. In the United States, breast cancer is the most common cancer type 
amongst women and will account for approximately of 15% of all new cancer cases and 
7% of all cancer-related deaths each year. One in eight women will be diagnosed with 
breast cancer in her lifetime, meaning over three million women will be living with breast 
cancer each year. Advances in the implementation of screening technologies has resulted 
in earlier detection of disease; thus, relative survival rates for breast cancer are high for 
early stage disease. However, advanced breast cancer can be treatment resistant and 
incurable2. Conventional therapies are the current standards of care for the large majority 
of breast cancers3.   
Breast cancer is classified into three heterogeneous subtypes: hormone receptor 
(HR) positive, epidermal growth factor (HER2) positive, and triple negative breast cancer 
(TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 
expression. These subtypes currently form the basis for diagnosing and treating the 
disease4. Targeted therapies have allowed for incremental advances in the treatment of 
HR and HER2 positive breast cancers. In the case of ER positive breast cancers, adjuvant 
therapies targeting either ER itself, or effector pathways such as mTOR and CDK4/6 have 
demonstrated significant advances in treatment5–7. For HER2 positive disease, a 
monoclonal antibody approach has resulted in significant improvements in patient 
survival8,9. Unfortunately, the majority of patients treated with these targeted therapies will 
develop resistance. Basal-like and TNBC are the most heterogeneous subtype of breast 
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cancer with the highest rate of relapse and shortest overall survival4. Further, no targeted 
therapy has been approved for its treatment and conventional treatments remain the only 
viable options. Therefore, elucidation of conventional therapy resistance mechanisms in 
TNBC and biomarkers to classify this heterogeneous disease is of chief importance.  
The Tumor Microenvironment is a Major Determinant of Cancer Progression and 
Treatment Resistance 
The tumor microenvironment is an active participant of all stages of cancer 
initiation and progression. All hallmarks of cancer such as sustaining proliferative signals, 
evading growth suppression, avoiding immune recognition, activation of the invasion and 
metastatic cascades, resisting cell death, inducing angiogenesis, and deregulation of 
cellular energetics are directly and indirectly influenced by the tumor microenvironment10. 
Further, the tumor microenvironment is being increasingly appreciated to participate in 
therapy resistance. For example, conventional chemo- and radiation therapy induce 
stromal cells to increase production of canonical Wnt ligands. These Wnt ligands can then 
signal in a paracrine fashion to cancer cells to promote their survival and ultimate disease 
progression11. Similar resistance mechanisms have been identified in response to 
targeted therapies. For example, tumor and stromal production of distinct growth factors 
that bypass the initial target have been demonstrated to overcome initial sensitivity to 
inhibitors targeting a wide range of receptor tyrosine kinases12–14. In total, the tumor 
microenvironment can amplify critical oncogenic pathways in cancer cells to promote 
tumor progression, metastasis, and resistance15. Thus, it is imperative to account for 
stromal contribution to therapy resistance in the design of novel and combinatorial 
strategies to target tumors.  
The tumor microenvironment is a complex ecosystem of several cell types. A 
dominant component of the cancer microenvironment are fibroblasts, known as cancer-
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associated fibroblasts (CAFs)16. Fibroblasts are well-suited to actively supporting cancer 
cells due to their resistance to stress, plasticity, and function in wound healing and fibrosis. 
In the context of wound healing, fibroblasts function in concert with immune cells to 
implement an inflammatory response to promote angiogenesis and deposition of 
extracellular matrix (ECM)17. Should these insults be prolonged, this repair response may 
continue unabated and result in tissue fibrosis. The role of fibroblasts in these processes 
is remarkably similar in the initiation and progression of cancer. In cancer, fibroblasts can 
be tumor-promoting as well as tumor-restrictive. Fibroblasts can promote tumorigenesis 
by altering the microenvironmental secretome18,19. The CAF secretome can mediate 
immune reprogramming to suppress immune activation, sustain fibroblast activation, and 
directly engage cancer cells sustain their proliferation and enhance their invasiveness. 
Moreover, CAFs promote invasiveness of cancer cells by producing matrix 
metalloproteinases that reshape the ECM of the tumor microenvironment20. The tumor-
restrictive properties of fibroblasts are less understood, but they may function by reducing 
hypoxia and modulating the innate and adaptive immune system21,22. Moreover, 
fibroblasts critically influence cancer therapy response and resistance. CAFs can alter 
therapy response by directly altering cancer cell-ECM interactions, stromal cell-ECM 
interactions, cytokine and chemokine release, enhancement of cancer cell resistance 
pathways, and indirectly by increasing intratumoral interstitial fluid pressure to such a high 
degree that drugs can no longer be delivered effectively23. Specifically in the case of 
TNBC, a gene signature indicative of fibroblast activation is predictive of tumor relapse 
after conventional therapy24. In total, CAFs are a crucial component of both tumorigenesis 
and resistance to conventional and targeted therapies.  
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Notch Pathway Activation Underlies Breast Cancer Tumorigenesis and Progression 
One pathway that allows for breast cancer cells to survive in harsh environments 
is the Notch pathway. Originally discovered in Drosophila melanogaster, the mammalian 
Notch receptor family consists of four type I transmembrane receptors (NOTCH1-4)25. This 
family of proteins are synthesized and activated in a similar fashion. First, Notch proteins 
are synthesized in a precursor form that are cleaved to generate the mature receptor, 
which is comprised of two subunits, an extracellular domain and an intracellular domain. 
The extracellular domains prevent ligand-independent signaling. Generally, Notch 
signaling is initiated by engagement of a Notch ligand to a Notch receptor in the event of 
cell-to-cell contact26. Notch ligands include jagged 1 (JAG1), JAG2, Delta-like 1 (DLL1), 
DLL3, and DLL4. Once bound to the Notch receptor, the ligand induces a conformational 
change, exposing a cleavage site in the extracellular domain to for cleavage by the 
metalloproteinase tumor necrosis factor-α-converting enzyme (ADAM17). After this 
cleavage, the intracellular domain of Notch is cleaved by the presenilin-γ-secretase 
complex. This final cleavage allows for the release of the intracellular domain of Notch 
and subsequent nuclear translocation. There, Notch recruits its transcriptional co-activator 
protein mastermind-like 1 (MAML1). Notch proteins exert their wide-ranging functions by 
initiating a transcriptional cascade. Notch transcriptional targets include Notch receptors, 
Notch ligands, cyclins, and MYC. In total, Notch activation regulates tumorigenesis, 
progression, and therapy resistance in a context and cell-type dependent manner.  
In different cancers, Notch pathway activation can have oncogenic or tumor 
suppressive roles27. In breast cancer, Notch pathway activation has long been implicated 
as an oncogenic driver. Early work found that the Notch locus is a common integration site 
in MMTV-induced tumors and expression of Notch4 in the mammary epithelium results in 
mammary tumor formation28. Notch activation in breast cancer has been further implicated 
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in various stages of tumor progression. Notch signaling can promote transformation of 
mammary epithelial cells by transcriptionally regulating Cyclin D129. Similar to the role of 
the Notch pathway in stem cell maintenance, it has been demonstrated that Notch 
signaling can regulate the stemness of breast cancer tumors and result in therapy 
resistance30–32. Interestingly, Notch can also cooperate with other oncogenic signaling 
pathways such as RAS to enhance proliferative capacity and transformation33. Expression 
of active forms of Notch results in the activation of the phosphoinositide 3-kinase/Protein 
kinase B (PI3K-AKT) signaling axis, to further amplify tumorigenic capacity by suppressing 
apoptosis34. Interestingly, in developmental systems, crosstalk between Notch signaling 
and janus kinase signal transducer and activator pathway (JAK-STAT) results in a 
proliferative response that is responsible for stem cell self-renewal and differentiation35. 
Therefore, we hypothesize that in breast cancer cells, Notch pathway activation by the 
tumor microenvironment may cooperate with existing oncogenic pathways to maximize 
their oncogenic potential. Due to the necessity for proteolytic cleavage for activation, 
inhibition of the presenilin-γ-secretase complex with small molecule inhibitors (GSI) is an 
attractive therapeutic target for Notch-driven cancers36. However, clinical application of 
GSIs has yet to find success due to a lack of a companion biomarker that would identify 
patients that would benefit from Notch pathway inhibition37. Therefore, we expect that in 
certain conditions, treatment with GSIs will be able to reverse the oncogenic potential 
conferred by Notch pathway activation.  
Interferon-Stimulated Genes Are Effectors of Cancer Progression and Viral Defense 
Another pathway that has been implicated in tumorigenesis, progression, and 
therapy resistance in a variety of cancers are interferon-stimulated genes (ISGs). ISGs 
are best studied in the context of viral infection; however, cancer therapies induce ISGs 
through previously undefined mechanisms. Conventional radiation therapy is known to 
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induce ISGs in many cancers, including breast cancer, and contribute to resistance. 
Previously, through in vivo selection for resistance to radiation therapy, our lab 
demonstrated the biological relevance of an experimentally derived gene program. This 
gene network consists of a network of ISGs that clinically predict chemotherapy and 
radiation resistance across multiple human cancers38,39. Functionally, several of these 
ISGs were shown to influence treatment resistance in cell lines and mouse tumor models. 
For breast cancer, high ISG expression is the strongest predictor of resistance to 
chemotherapy or RT. These results suggest that ISGs may be a major determinant of 
clinical breast cancer treatment resistance.  Further, chemotherapy40 and DNA 
methylation inhibitors also induce ISGs in cancer and stromal cells41,42. In these studies, 
it is suggested that DNA methylation inhibitors can de-repress endogenous double-
stranded RNA (dsRNA) species that are recognized by cellular pathogen-sensing 
machinery to activate an ISG response. In addition to therapy resistance, ISG induction in 
breast cancer cells and the brain metastatic microenvironment aids in the establishment 
of metastases by enhancing colonization capabilities43. Here, breast cancer cells that are 
colonizing the brain transfer cyclic GMP-AMP (cGAMP) to resident astrocytes via 
connexion junctions. cGAMP can then directly activate stimulator of interferon genes 
(STING) in the recipient astrocytes, which leads to tumor necrosis factor (TNF) and 
interferon production, which then activate ISGs in the breast cancer cells in a paracrine 
fashion. While the induction of ISGs in breast cancer cells appears to be a crucial element 
of cancer progression and therapy resistance, both the mechanisms of their activation and 
their effector functions in cancer have remained elusive.  
Activation of ISGs is best studied in the context of viral infection. The first line of 
defense to any pathogen is detection. In mammalian cells this is accomplished by pattern 
recognition receptors (PRRs) that are fine-tuned to detect pathogen-associated molecular 
patterns (PAMPS) and trigger intracellular signaling cascades that result in the 
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upregulation of ISGs44. PRRs include Toll-like receptors (TLRs), RIG-I-like receptors 
(RLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs). Toll-like 
receptors include 12 transmembrane receptors that localize to either the plasma 
membrane or endolysome and can detect lipoproteins, lipopolysaccharides, flagellin, 
DNA, and RNA of viral, bacterial, protazoal, and self-origin. NOD-like receptors are 
cytoplasmic and recognize bacterial peptidoglycans, while CLRs are plasma membrane 
localized and recognize microorganismal carbohydrates. RLRs are near-ubiquitously 
expressed in all cell types, localize to the cytoplasm, and include RIG-I, MDA-5, and LGP2. 
RLRs are canonically activated by viral RNA originating from DNA and RNA viruses. RIG-
I is best characterized to be activated by short, double-stranded, 5’triphosphorylated RNA 
of viral origin45. Pathogenic DNA has been implicated to indirectly activate RIG-I by is 
transcription by RNA polymerase III46,47. In this context, viral DNA can be recognized by 
RNA polymerase III and transcribed. Based on its sequence, these transcripts will form 
double-stranded structure, and consistent with all RNA polymerase III transcripts, maintain 
a 5’triphosphorylated (5’ppp) moiety. Therefore, this endogenously-produced RNA can 
activate RIG-I and ISGs. 
Interferon-stimulated genes include PRRs, interferon regulator factors (IRFs), and 
several signal transducing proteins involved in the JAK-STAT signaling pathway48. These 
proteins are present as baseline, but their expression markedly enhances upon 
pathogenic insult. Downstream of JAK-STAT signaling, many ISGs function to restrict viral 
activity, reinforce ISG expression, and promote cell survival. ISGs such as the interferon-
induced Mx family of proteins restrict viral entry49, while interferon-induced proteins with 
tetratricopeptide proteins (IFITs) and protein kinase R (PKR) can directly inhibit viral 
translation. Furthermore, the ubiquitin-like protein, interferon-stimulated gene 15 (ISG15), 
can function to both directly destabilize viral proteins while also promoting or repressing 
other ISG expression and function50. Other ISGs such as the OAS/RNaseL pathway can 
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function to amplify ISG expression by nondiscriminate cleavage of endogenous RNAs to 
serve as RIG-I ligands and further enhance RIG-I activation51. Collectively, in the case of 
viral infection, a multi-tiered signaling cascade that initiates with nucleic acid recognition 
by PRRs, such as RIG-I, and results in the enhanced expression of effector ISGs 
culminates in the restriction of viral activity and cell survival.  
RIG-I Discrimination of Self from Non-Self RNA 
The initiators of any host response to pathogenic insults are PRRs. RIG-I and other 
PRRs are maintained in an inactive state until contact with a ligand52. For maximal 
activation, a strict set of requirements must be met for sensing of a nucleic acid as foreign, 
or non-self. Broadly, these requirements include availability of the ligand, localization of 
the ligand, and the structure of potential nucleic acid ligands. All three aspects contribute 
to the reliable recognition of pathogenic nucleic acids as foreign and restrict inappropriate 
recognition of self nucleic acids. In the context of RIG-I, many of these aspects are well 
studied. First, RIG-I is exclusively localized to the cytoplasm; therefore, any nucleic acid 
ligand must also be present in the cytoplasm53. Other cytoplasmic RNA sensors include 
melanoma differentiation-associated protein 5 (MDA5), IFIT1, PKR, and 2'-5'-
oligoadenylate synthase (OAS) family members, which can recognize discrete and 
overlapping structural RNA elements54. Endosomal RNA sensors include the TIR-domain-
containing adapter-inducing interferon-β (TRIF) dependent TLR, TLR3, and the myeloid 
differentiation primary response gene 88 (MYD88) dependent TLRs, TLR7 and TLR8. 
Second, for RIG-I activation after encountering an RNA ligand in the cytoplasm, the ligand 
must be present at a high local concentration. Many endogenous nucleic acid ligands can 
be present at high levels, but are recognized and degraded by endogenous nucleases to 
prevent inappropriate activation of anti-viral signaling55,56. RIG-I and other PRRs recognize 
a restricted set of structural features to discriminate self from non-self RNA. RIG-I is best 
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characterized to recognize short, dsRNA, with a 5’ppp end. However, recent quantitative 
structural studies have demonstrated that RIG-I can recognize a wide array of end 
modifications, albeit with lower affinity. For example, RNA modifications such as 2-O-
methylation are determinants of RIG-I recognition, irrespective of a 5’ppp or capped 
ends57,58. These structural preferences illuminate the necessity for a variety of RNA PRRs. 
In the cytoplasm, RIG-I and MDA5 function in concert to recognize short (<300bp) and 
long (>300bp) dsRNA, respectively, with similar downstream ISG outcomes. In 
endosomes, TLR3 largely recognizes dsRNA, while TLR7 and TLR8 recognize ssRNA. In 
total, these guiding principles allow for efficient recognition of non-self RNA, while 
restricting inappropriate immune activation.  
While studies assessing RNA features and requirements for optimal RIG-I 
activation have been extensive, they are based on synthetic and/or artificial RNAs. 
Therefore, the requirements for sensing endogenous RNA may be more nuanced. Various 
cellular RNA transcripts are present in the cytoplasm, at high levels, and have all the 
structural features capable inducing RIG-I. However, these transcripts do not ubiquitously 
induce ISG responses. These potential RIG-I ligands are largely RNA polymerase III 
transcripts which are generally short, double stranded, and contain 5’ppp moieties59,60 and 
include SRP RNAs, Y RNAs, tRNAs, and certain snRNA species. Therefore, other 
characteristics must govern their relative innocuousness. Similar to shielding of viral 
genomes by viral RNA binding proteins (RBPs) is shielding of endogenous RNA by cellular 
RBPs. The vast majority of RNA polymerase III transcripts that are best suited to act as 
endogenous RIG-I ligands function in ribonucleoprotein (RNP) complexes; thus, they are 
likely entirely shielded from recognition by RIG-I61. Whether protein shielding of RNA is a 
major determinant of PRR activation remains unclear. While PRRs can recognize a wide-
array of distinct nucleic acid ligands, their purpose remains unified, to serve as the 
initiators of an anti-viral response within infected cells.  
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Exosomes are Mediators of Cell-Cell Communication 
Recent evidence reveals that in addition to cell intrinsic anti-viral responses that 
occur after viral infection, mechanisms exist to propagate an anti-viral response from 
infected to uninfected cells via exosomal transfer of anti-viral cargo62,63. Exosomes are 
small (<150nm), extracellular vesicles of endosomal origin that are implicated in a myriad 
of biological and pathological processes64. Exosomes form by a dynamic endocytic 
process. First, early endosomes mature into late endosomes and begin accumulating 
intraluminal vesicles (ILVs) via ESCRT-dependent and independent processes. These 
late endosomes containing ILVs are referred to as multivesicular endosomes, or MVBs. 
The ILVs that form from this double invagination are lipid-bilayered in the same orientation 
as the plasma membrane and contain directly sorted and stochastically acquired 
cytoplasmic contents. Under most cellular contexts, MVBs will fuse with lysosomes and 
their contents will be degraded and/or recycled. Some MVBs will fuse with the plasma 
membrane and release their vesicular content. These vesicles are known as exosomes. 
The processes that regulate this secretion are not well understood; however, several 
exosome secretion-stimulating conditions have been identified. For example, dendritic 
cells increase exosome secretion after interaction CD4 T lymphocytes65. Neurons will 
secrete exosomes after depolarization and stimulation by neurotransmitters66,67. 
Exogenous stimuli such as irradiation can also stimulate exosome release68,69. Once 
secreted, exosomes are stable both in and ex vivo and can then be internalized by 
recipient cells by endocytosis, phagocytosis, or fusion to the plasma membrane70. Several 
receptor-ligand pairings have been implicated in the targeting of exosomes to recipient 
cells such as cell adhesion molecules, integrins, and tetraspanins. Exosomes can then 
elicit responses in recipient cells simply by their adherence to recipient cells or 
transference of their cellular content after endocytosis or fusion.  
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Exosomes contain DNA, RNA, lipids, and proteins and harbor evidence of directed 
sorting of their contents64. Exosomes are classically identified by their protein markers of 
their biogenesis such as endosomal tetraspanins such as CD9, CD81, and TSG101. 
Beyond exosome proteins that result from their shared origins, cell-type specific exosomal 
proteins of largely cytoplasmic origins can also be found, including adhesion molecules, 
cytoskeletal proteins, enzymes, and other transmembrane proteins. Lipids are also a key 
component of exosomes. Specifically, sphingomyelin, phosphatidylserine, cholesterol, 
and saturated fatty acids have been demonstrated to be enriched in exosomes when 
compared to cells71–73. Collectively, the enrichment of specific lipid and protein contents in 
exosomes suggests a targeted mechanism of content sorting.  
Exosomes are also enriched in nucleic acids. While, genomic and mitochondrial 
DNA has been reported to be found in exosomes74–76, best characterized are the vast 
complexity of RNA species in exosomes. Exosomal RNA differs from cellular RNA in that 
is largely bereft of full-length ribosomal RNA (rRNA) that makes up greater than 95% of 
the human transcriptome77. While functional mRNAs are present in exosomes, they make 
a small fraction of the total exosomal RNA contents, which are largely non-coding RNA 
(ncRNA). These RNAs are resistant to RNase digestion, suggesting they are contained 
within exosomes, rather than on the surface. The advent of next-generation sequencing 
(NGS) technologies has allowed for an explosion of reports of exosomal RNA contents, 
but, few unifying properties other than a general enrichment for ncRNA have been 
identified to date. In total, the functional of content of exosomes is context specific and 
remains unclear.  
Exosomes in Viral Infection and Cancer 
In the context of propagation of anti-viral signals and amplification of ISG 
responses, exosomal RNA is crucial to this process. Secretion and transfer of exosomes 
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to uninfected bystander cells can result in exosome-transferred viral RNA by PRRs. For 
example, in cells infected with an Hepatitis C virus (HCV) strain that is incapable of 
producing virions, HCV genomic RNA is transferred via exosomes to uninfected cells78. 
This HCV RNA is then recognized as PAMP by recipient cells and ISGs are activated in 
the absence of direct virus infection. Similarly, adenoviruses can cause an increase in 
exosome transfer containing PRR activating cargo that results in ISG upregulation and a 
short-range anti-viral response79. In the case of latent Epstein-Barr virus (EBV) infection, 
exosomal transfer of EBV RNA can alert neighboring cells of an infection80. Here, latent-
infected cells can trigger an anti-viral ISG response in neighboring cells by the transfer of 
EBV 5’ppp RNA that is bereft of any shielding RNA-binding proteins. Together, these 
studies demonstrate that exosomes can mediate ISG induction within uninfected cells and 
tissue-level amplification of the anti-viral response.  
Exosomes and exosomal contents have been implicated in a host of processes 
related to the progression of various cancer types. In the initial stages of glioma 
tumorigenesis, cells bearing the activated EGFRvIII receptor can transfer this protein to 
wild-type cells to aid in their transformation81. Notably, exosomes derived from patients 
and breast cancer cell lines containing RNA-induced silencing complex-associated (RISC-
associated) miRNAs can also induce tumor formation by the non-tumorigenic mouse 
mammary cells82. In established tumors, glioblastoma exosomes can transport functional 
mRNA that are able enhance tumor growth83. Exosomes have been best characterized to 
enhance the metastatic potential of cancer cells by various mechanisms. First, exosomes 
reshape the pre-metastatic niche through mobilization of various stromal subtypes at 
distant metastatic sites84,85. Moreover, these processes can specify organ-specific 
metastatic potential through integrin interactions86. Exosomes can also enhance invasion 
of cells into vasculature by destruction of endothelial cell junctions87. Stromal-derived 
exosomes can also increase breast cancer cell invasion by activating Wnt-planar cell 
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polarity signaling to dramatically induce metastases88. Lastly, exosomes can enhance 
colonization of distant sites after extravasation by augmenting the surrounding ECM to 
better support metastatic outgrowth89. Exosomes of stromal and cancer origin have been 
implicated in resistance to conventional therapies, largely by transfer of functional 
miRNAs90,91. Further, exosomes can also impact therapy response by shuttling 
chemotherapeutics out of target cells92,93. In total, exosomes of cancer and stromal origin 
can have profound impacts on all stages of cancer progression.  
Host Mimicry in Viral Infection and Virus Mimicry in Cancer 
Besides transferring viral RNA, the ability to horizontally transfer damage-
associated molecular patterns (DAMPs) may also be an important feature of virus 
infection. As described, host cells utilize exosomal machinery to transport viral nucleic 
acids to propagate anti-viral signals. Virions have also been described to contain an 
abundance of host RNA polymerase III transcripts in the absence of canonical RBP 
partners94–97. The role of these non-viral RNAs in virions has not been well characterized; 
however, it has been postulated that they might stimulate innate immune signaling98. 
Therefore, whether in virions or in exosomes, cells under viral attack ensure a broad anti-
viral response by packaging endogenous DAMPs alongside viral RNA PAMPs. In support 
of this concept, recent studies show that cells infected by certain viruses can package the 
nucleoside second-messenger cGAMP into secreted virions and extracellular vesicles to 
trigger a STING-dependent ISG response in recipient cells99,100. Altogether, these 
observations suggest that horizontal transfer of DAMPs to promulgate anti-viral signaling 
as a means of host mimicry by virions. 
Cancer cells may also utilize a process of virus mimicry, whereby they can provoke 
an anti-viral response in surrounding cancer and stromal cells. For example, stromal PRRs 
have been demonstrated to recognized exosomal RNA (exoRNA) in the tumor 
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microenvironment101,102. Here, exosome-derived miRNAs can function as PRR ligands 
and help establish pre-metastatic and maintain post-metastatic niches. Moreover, under 
stress conditions such as chemo and radiation therapy, it has been demonstrated that 
endogenous nucleic acids can act as endogenous PRR ligands and elicit an ISG 
response. As described, DNA methylation inhibitors can de-repress endogenous dsRNA 
species to activate stromal and cancer cell PRRs41,42. Chemotherapeutic anthracyclines 
may also induce endosomal localization of dsRNA for recognition by TLR340. Radiation 
therapy may also induce endogenous RNA for PRR recognition103,104. Finally, in 
autoimmune states, endogenous RNAs are also de-repressed and recognized as foreign, 
further amplifying autoimmunity55,105. These studies have illuminated a common theme of 
virus mimicry and ISG activation across multiple cancer types; however, the nature and 
identity of the PRR activating nucleic acid ligand, functional consequences of ISG 
activation, and the mechanisms by which endogenous DAMPs are mobilized have yet to 
be delineated.  
Project Aims and Summary 
The central aims of this project were to demonstrate why and how the tumor 
microenvironment propagates anti-viral signaling in cancer cells and to further elucidate 
how anti-viral signaling influences cancer progression and response to therapies. We 
hypothesized that stromal cells could be responsible for ISG activation in breast cancer 
cells by the transfer of exosomes containing endogenous ncRNA that act as RIG-I ligands. 
In turn, activation of ISGs can then aid in tumor progression and therapy resistance. While 
others have demonstrated that endogenous RNA can act as DAMPs, the identity of 
specific RNA and mechanism by which they are available for recognition is unknown. 
Further, there has been extensive work characterizing the functional effects of exosomes; 
however, few studies have identified a specific mechanism by which exosomal cargo 
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exerts its effects in recipient cells. In total, our work aimed to understand specific 
mechanisms for tumor-stromal signaling cascades initiated by exosomal contents that 
result in cancer progression and therapy resistance.  
In Chapter 2, we examined the role of fibroblasts in inducing anti-viral responses 
in a subset of basal-like and triple negative breast cancers. Utilizing in vitro and in vivo 
breast cancer models as well as primary patient data, we identified a complex signaling 
cascade that was reminiscent of tissue-level propagation of anti-viral signals in viral 
infection. To do so, breast cancer cells induce exosome secretion by stromal fibroblasts. 
These exosomes are enriched in 5’ppp RNA, which when taken up by breast cancer cells, 
activate RIG-I and induce ISGs. In parallel, this heterotypic interaction induces a juxtacrine 
signaling pathway centering on NOTCH3. These pathways converge, as STAT1 and 
NOTCH3 transcriptionally cooperate to achieve maximal activation of NOTCH target 
genes that mediate stemness capabilities in breast cancer cells. In total, activation of the 
paracrine anti-viral and juxtacrine NOTCH pathways results in breast cancer progression 
and therapy resistance. In Chapter 3, we delved deeper into the virus mimicry occurring 
in the breast cancer tumor microenvironment. Here, we identified an abundant RNA 
polymerase III transcript, RN7SL1, as a potent RIG-I ligand that is transferred from stromal 
cells to breast cancer cells via exosomes. The major determinant of RN7SL1 function as 
a DAMP in stroma-derived exosomes was its relative lack of shielding; whereas, in all cells 
examined, RN7SL1 is entirely shielded as part of the signal recognition particle (SRP). 
Moreover, we demonstrate that deployment of RN7SL1 as an unshielded RNA DAMP 
results from breast cancer mediated activation of stromal NOTCH1 and subsequent MYC 
and RNA polymerase III activation. In vivo, unshielded RN7SL1 can function to enhance 
tumor progression and metastasis. Further, many of the above findings were validated 
with human breast tumor-derived CAFs and found in patient-derived exosomes harvested 
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from serum. In total, our work delineates a mechanism and function of endogenous RNAs 
as DAMPs in the breast cancer tumor microenvironment.  
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CHAPTER 2: EXOSOME TRANSFER FROM STROMAL TO BREAST CANCER 
CELLS REGULATES THERAPY RESISTANCE PATHWAYS 
Sections of this chapter have been adapted from the following manuscript with permission 
from Elsevier: Boelens, M.C.*, Wu, T.J*, Nabet, B.Y.*, Xu, B., Qiu, Y., Yoon, T., Azzam, 
D.J., Twyman-Saint Victor, C., Wiemann, B.Z., Ishwaran, H., ter Brugge, P.J., Jonkers, J., 
Slingerland, J., Minn, A.J. Exosome Transfer from Stromal to Breast Cancer Cells 
Regulates Therapy Resistance Pathways. Cell 159, 499–513 (2014).  
*Co-first author 
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STAT1 and NOTCH3 transcriptional studies. Y.Q. and A.J.M. analyzed the sequencing 
studies. A.J.M., B.Y.N, and T.J.W. wrote the manuscript.  
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Introduction 
The elucidation of resistance mechanisms to chemotherapy and radiation is an 
important goal in improving cancer survival. Previously, we characterized a gene signature 
for radiation (RT) and chemotherapy (chemo) resistance that was discovered through in 
vivo selection for RT resistant tumors38,39. Because the majority of the genes identified 
were interferon-stimulated genes (ISGs), which normally are activated as part of an anti-
viral response, we termed this signature the Interferon-Related DNA Damage Resistance 
Signature (IRDS). Several IRDS genes, including the transcription factor STAT1, influence 
RT/chemo resistance in cell lines and mouse tumor models. Interrogation across the most 
common human cancers revealed that a large proportion of untreated primary tumors 
express the IRDS. In breast cancer, IRDS expression measured by a clinical classifier 
comprised of seven IRDS genes (STAT1, MX1, ISG15, OA2, IFIT1, IFIT3, IFI44) identifies 
patients whose cancers are resistant to chemo and RT. Thus, the IRDS may represent a 
common and inherent mechanism of resistance across various human cancers. How the 
IRDS is regulated and how ISGs can protect against RT/chemo is unclear. 
A common way that ISGs are activated is through pattern recognition receptors 
(PRRs) that are triggered by pathogen-associated molecular patterns such as viral nucleic 
acids44. PRRs include toll-like receptors (TLRs) and RIG-I-like receptors. Typically, RIG-I 
is activated by 5’-triphosphate viral RNA after viruses gain entry into immune and non-
immune cells. However, PRRs can also be activated through alternative routes by 
exosomes, which are small membrane vesicles capable of transferring contents between 
cells to function in cell-cell communication106. Exosomes can transfer viral RNA from 
infected cells to trigger an interferon response in immune cells, presumably through TLRs, 
to enhance viral suppression78,79. In cancer, exosomes secreted by tumor cells can 
increase metastasis through interaction with cells of the microenvironment84,101. 
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Alternatively, exosomes from mesenchymal cells can be transferred to cancer to promote 
metastasis88. Thus, these recent data suggest that PRRs and exosomes orchestrate 
heterotypic cell-cell communication to regulate anti-viral responses or to aid cancer 
progression. Whether cross-talk between cancer and the tumor microenvironment can use 
exosomes and PRRs to similarly control ISG/IRDS expression or influence treatment 
resistance is unknown. 
The importance of the tumor microenvironment in dictating treatment response is 
increasingly evident. Stromal cells, which are primarily fibroblasts but can also be other 
cell types, can promote survival after genotoxic and targeted therapy through the secretion 
of paracrine factors13. Many of these interactions between stromal cells and tumor cells 
may support the maintenance of cancer stem-like cells (i.e., tumor-initiating cells) 
analogously to how normal stem cells depend on a niche107. Since tumor-initiating cells 
are resistant to RT/chemo, and their survival would allow efficient tumor regrowth, 
understanding how the stromal microenvironment can influence these therapy resistant 
cells may provide promising new drug targets. 
The NOTCH family of receptors activates developmental signaling pathways that 
have multiple roles in cancer, including drug resistance108,109 and the regulation of tumor-
initiating cells110. Activation requires cell-cell contact and engagement of NOTCH ligands, 
such as JAGGED proteins. Given the properties of the NOTCH pathway in cancer, there 
is a significant interest in targeting the pathway as a cancer therapeutic. Activation of 
NOTCH occurs through the cleavage of its intracellular domain and can be blocked by a 
gamma secretase inhibitor (GSI). Currently, there are multiple clinical trials testing GSIs 
combined with other targeted agents and conventional chemotherapy37. However, 
challenges exist that include lack of a companion biomarker to identify patients who will 
benefit from NOTCH inhibition. Understanding how NOTCH can be activated in subsets 
of cancers may facilitate their utilization as drug targets. 
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In this study, we integrate experimental and computational models to investigate 
how stromal cells communicate with breast cancer to regulate expression of ISGs. In so 
doing, we define an anti-viral pathway that is activated by exosomes and RIG-I, and 
cooperates with NOTCH3 to regulate stroma-mediated expansion of therapy resistant 
cells. 
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Results 
Stromal cells induce the IRDS and increase breast cancer radiation resistance 
Previous reports indicate that ISGs can be modulated by the microenvironment111. 
To examine if the microenvironment can influence IRDS expression and contribute to 
RT/chemo resistance, we utilized metastatic MDA-MB-231 breast cancer cells (1833)112 
expressing a GFP-luciferase reporter and xenografted them with or without non-
transformed MRC5 human diploid fibroblasts used as stromal cells. Tumors containing 
admixed fibroblasts exhibited high expression of several IRDS genes including STAT1 
(Figure 1A), particularly from breast cancer cells (Figure 1B). In contrast, tumors arising 
from breast cancer cells alone had lower STAT1/ISG expression and remained primarily 
comprised of human breast cancer cells, suggesting poor stromalization by mouse cells. 
The presence of admixed fibroblasts enhanced the growth rate of breast cancer cells 
(Figure 1C), which is a defining property of carcinoma-associated fibroblasts (CAFs), as 
measured by the rate of change in bioluminescence signal at each time point. After RT, 
breast cancer cells from tumors without admixed fibroblasts promptly stopped growing and 
showed regression by day 24. In contrast, breast cancer admixed with fibroblasts showed 
dramatically reduced cell death (Figure 1D) and maintained significant growth even after 
RT (Figure 1C). In total, these observations suggest a relationship between tumor and 
stromal cell interaction, anti-viral signaling, and survival of cells adept at resisting DNA 
damage and sustaining tumor growth. 
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Table 1: IRDS Responder (IRDS-R) and IRDS Nonresponder (IRDS-NR) Breast 
Cancer Cells and Stromal Cell Lines 
Cell Line Subtype ER HER2 IRDS 
Induction 
Stromal Protection Microarray 
IRDS-R       
MDA-MB- 
231 (1833) 
Basal B (-)  + + + 
MDA-MB- 
231 
Basal B (-)  + + + 
HS578T Basal B (-)  + ND  
MDA-MB- 
436 
Basal B (-)  + +  
MDA-MB- 
157 
Basal B (-)  + +  
HCC1937 Basal A (-)  + + + 
       
IRDS-NR       
SKBR3 Luminal (-) (+) - -  
T47D Luminal (+)  - -  
MCF7 Luminal (+)  - - + 
HCC70 Basal A (-)  - -  
MDA-MB- 
468 
Basal A (-)   - + 
       
       
Cell Line Type   IRDS 
Induction 
Stromal 
Protection 
Microarray 
Stroma       
MRC5    + + + 
CAF61a    + +  
BJ    + +  
Hs27a    + +  
Hs5    + ND  
THP-1    - -  
 
Subtype, ER, and HER2 status were determined by other groups113. ND refers to not 
determined. In the case of Hs578T, difficulty separating breast cancer from stromal cells 
did not allow for accurate measurements of breast cancer cell death. Cell lines used for 
microarray and microarray-based studies are also indicated.  
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Figure 1. Stromal cells induce ISGs and protect basal-like breast cancer cells 
against radiation in a STAT1-dependent manner. A) Human MDA-MB-231 metastatic 
breast cancer cell (BrCa) line (1833) was admixed with or without MRC5 normal human 
fibroblasts (Stroma) and expression of IRDS genes was determined by qRT-PCR. B) 
GFP-labeled 1833 breast cancer cells with and without MRC5 fibroblasts were 
xenografted subcutaneously into nude mice and tumors imaged (20X) at day 14. STAT1 
intensity in breast cancer cells is quantitated for representative field shown. Scale bar is 
100 microns. C) Bioluminescence imaging (BLI) response of 1833 breast cancer cells with 
a luciferase reporter gene after xenografting with and without MRC5 fibroblasts. Tumors 
were irradiated with 8 Gy (day 0). Shown is change in photon flux over time (first derivative, 
mean ± SEM, n=5-10). Positive first derivative indicates growth, zero indicates no growth, 
and negative values denote regression. Data are a separate analysis of the control groups 
from Figure 9M. D) 1833 breast cancer cells were stained with GFP and TUNEL (red) 10 
days after RT. Percent TUNEL positive is shown. Scale bar is 100 microns. E) Breast 
cancer cells (Table 1) were classified as IRDS responders (IRDS-Rs) or IRDS non-
responders (IRDS-NRs). Heat map and scale shows breast cancer IRDS genes after 
mono-culture (M) or MRC5 co-culture (C). F) Cell death of IRDS-Rs and IRDS-NRs four 
days after 10 Gy RT in mono- (Mono) and co-culture (Co-cx) (n=3-10). G) Cell death of 
1833 IRDS-R after cisplatin chemotherapy (n=3) and after dose response. H) Gene Set 
Analysis shows changes in IRDS genes 48 hrs after co-culture vs mono-culture of IRDS-
Rs (left, also see Table 1), or after STAT1 knockdown in 1833 IRDS-R in co-culture (right). 
Top graph plots individual and overall gene scores, and bottom graph shows fold-change. 
I) Cell death of 1833 IRDS-R four days after 10 Gy RT using three independent siRNAs 
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to STAT1. J) BLI-based survival assay after 10 Gy RT (day 0) using luciferase-labeled 
1833 cells with shSTAT1 or control knockdown (shCont). Photon flux (x106) for each well 
is indicated. Shown is representative experiment (n=5). *p < 0.05. Unless noted, all bar 
plots in figure are mean ± SD of n biological replicates. 
 
Stroma-mediated IRDS induction and protection are STAT1-dependent and specific for 
basal-like breast cancers 
To better examine the relationship between IRDS expression and stroma-
mediated protection across different breast cancer and stromal cell combinations, we co-
cultured both cell types in vitro to model stroma-mediated resistance (referred to as co-
culture) and discovered that breast cancer cells can be divided into two groups. The first 
group, called “IRDS responders” (IRDS-Rs), is enriched in the basal-like subtype (Table 
1) and upregulated IRDS genes after interaction with MRC5 fibroblasts (Figure 1E). The 
second group, called “IRDS non-responders” (IRDS-NRs), is comprised of non-basal-like 
and some basal-like subtypes and failed to induce IRDS genes. Importantly, only IRDS-
Rs were protected by fibroblasts after RT (Figure 1F) or after chemotherapy (Figure 1G). 
Multiple other stromal cell lines (CAFs, bone marrow, fibroblasts) able to induce the IRDS 
were also able to promote resistance against RT (Figure 2A); however, not all stromal 
cells were protective, as illustrated by a macrophage cell line that neither induced the 
IRDS nor protected (Figure 2B). Genome-wide transcriptomic analysis from co-culture of 
IRDS-R compared to mono-culture (Table 1) demonstrated upregulation of nearly all IRDS 
genes in breast cancer (Figure 1H, Figure 2C, Table 2). Stroma-mediated induction of 
IRDS was specific to IRDS-R breast cancer (Table 3). Knockdown of STAT1 in 1833 
IRDS-R prior to co-culture with MRC5 fibroblasts depressed nearly all IRDS genes 
compared to control (Figure 1H) and also inhibited stroma-mediated resistance (Figure 
1I), a result observed with multiple different siRNAs targeting STAT1 (Figure 2D-E). Stable 
STAT1 knockdown (Figure 2D-E) also selectively inhibited the protective effects of MRC5 
fibroblasts as measured by an in vitro luciferase-based assay (Figure 1J). In the absence 
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of RT, disruption of STAT1 had negligible effects on growth with or without fibroblasts 
(Figure 2F). Thus, a subset of basal subtype breast cancers can interact with multiple 
stromal cell types to increase IRDS genes and RT/chemo resistance in a STAT1-
dependent manner. 
Figure 2. The ability of stromal cells to protect breast cancer cells against radiation 
is coupled to upregulation of IRDS genes. A) The 1833 IRDS-R cell line was grown in 
mono-culture (Mono) or co-cultured (Co-cx) with the indicated stromal cell line or with B) 
the macrophage cell line THP-1. CAF61a is a carcinoma-associated fibroblast cell line. 
Shown is a heat map of IRDS genes showing relative upregulation (red shades) or 
downregulation (blue shades). Grey is expression in mono-culture, which was used to 
normalize each gene. White indicates no data. On the right of each heat map is cell death 
four days after treatment with 10 Gy RT in either mono-culture or co-culture with the 
indicated cell lines (n=2). H10 stromal cells were not tested for stroma-mediated protection 
but is shown to allow for comparison in Figure 4K. C) Transcriptomic changes in breast 
cancer after co-culture with MRC5 fibroblasts reveal induction of IRDS genes. After co-
culture, breast cancer and MRC5 stromal cells were sorted by flow cytometry. Volcano 
plot shows microarray gene expression changes (x-axis) versus significance by q-value 
(y-axis). Horizontal black line represents a false discovery rate of 10%. Orange is high 
density of genes and yellow is low. Blue dots are IRDS genes. Green dashed line 
represents 1.5-fold change. See Table 2. D) Multiple independent siRNAs and an shRNA 
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to STAT1 were each introduced into the 1833 IRDS-R breast cancer cell line and analyzed 
for knockdown by qRT-PCR. Shown are knockdown levels compared to cells transfected 
with a control si/shRNA. E) Knockdown was also confirmed by immunoblotting for STAT1 
after transfection with siSTAT1 or shSTAT1. F) 1833 IRDS-R transfected with shSTAT1 
or control shRNA (shCont) were seeded in either mono-culture or co-culture with MRC5 
fibroblasts. At days 0, 4 and 6, cell growth was measured by luciferase-based 
luminescence. All bar plots in figure are mean ± SD. All gene expression assays were 
performed after 24-48 hrs of culture. 
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Table 2: Genes Upregulated in IRDS-R Breast Cancer Cells after Co-culture 
Gene ID Score(d) Fold Change 
TNFSF10 9.51175075 2.39654789 
PAPPA 9.50811651 1.73625789 
EGR1 9.15391015 2.33440593 
EDNRA 8.929463 5.42601126 
PAPPA 8.72827447 7.87175655 
CDH6 8.56804829 8.20739467 
CFB 8.55320523 2.11443065 
IFI44L 7.73843143 34.198318 
TMEM176A 7.49882318 2.26668984 
NA 7.49831933 2.37487425 
STAT2 7.20634429 1.84069078 
CCL2 7.19144971 5.28689347 
PAMR1 7.17076079 7.80477608 
OAS2 6.7050865 9.72737688 
MEIS1 6.67907311 5.14952985 
LTBP1 6.55554459 2.00106414 
MSC 6.5523153 1.8778532 
DKK3 6.49077312 7.20767782 
MIR21 6.39875367 1.60805803 
PIEZO2 6.39867122 5.20369927 
HGF 6.39818891 15.3752323 
IFI6 6.38646998 8.87480621 
IRF9 6.2546392 2.75398143 
XAF1 6.22233223 4.34260997 
TRIM22 6.13241982 6.31148865 
MMP2 6.11930698 10.5044086 
IFI16 6.10845758 1.71835165 
WNT5A 6.07738868 9.22868664 
STAT1 6.05976298 3.39204979 
SLFN11 6.02630643 3.49634883 
TCF21 6.01469106 2.76236241 
CFB 6.00374702 3.0328043 
ANGPTL2 5.98683165 4.1110645 
LRP1 5.98262926 2.76064673 
TRPA1 5.96005598 16.6919472 
TCF4 5.92808361 4.2274197 
ECM1 5.91936933 1.52084958 
GPC6 5.903451 1.85379347 
BDKRB1 5.89985196 10.3602752 
IFITM1 5.87899966 4.34361694 
VCAN 5.87813333 14.6981149 
CD248 5.75363674 3.9813116 
SGIP1 5.7515508 6.1586101 
FAP 5.74804294 5.72581044 
PARP9 5.73893329 5.19915479 
JAM3 5.71704795 3.30444238 
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IRDS induction is controlled by RIG-I 
Stroma-mediated IRDS induction and resistance requires live stromal cells and 
does not associate with expression and/or function of interferons or interferon receptors 
(Figure 4A-E). To explore alternative pathways to IRDS induction, we examined the 
transcriptome of IRDS-R breast cancer cells in MRC5 co-culture compared to mono-
culture. Among the upregulated genes (Table 2) were several PRRs known to activate 
ISGs. Random forest (RF) multivariable regression analysis114 of these and other similar 
PRRs demonstrated that increasing expression of RIG-I best explains the upregulation of 
IRDS genes by fibroblasts (Figure 3A). Accordingly, knockdown of RIG-I in 1833 IRDS-R 
inhibited IRDS gene induction after co-culture, while disruption of MYD88, which is 
required for signaling by multiple TLRs not predicted to regulate the IRDS, had no effect 
(Figure 3B, Figure 4F). Disruption of RIG-I by shRNA (Figure 4F) also partially reversed 
stroma-mediated resistance, as measured by short- and long-term survival (Figure 3C), 
without influencing general cell proliferation (Figure 4G). Concomitant disruption of the 
type one interferon receptor with RIG-I had no additive effect. Thus, STAT1/IRDS 
induction and stromal protection are primarily initiated through RIG-I rather than interferon 
receptors. 
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Figure 3. Stromal cell interaction increases exosomes that upregulate ISGs through 
a RIG-I anti-viral pathway. A) Importance scores (higher is more predictive) of PRRs 
from a multivariable random forest (RF) regression model to predict induction of IRDS 
after MRC5 co-culture with IRDS-Rs. The model explains 60.8% of the total variance. 
Adjusted effect of RIG-I on IRDS metagene expression is shown on right (red dashes are 
± two SE). B) Expression of IRDS genes after siRNA to RIG-I (top row) or MYD88 (bottom 
row) in 1833 IRDS-R. Shown is a representative experiment (n=3). C) Cell death of 1833 
IRDS-R after RT (n=4) and a representative BLI-based survival assay (n=2) after the 
indicated knockdown (RT on day 0). Photon flux (x106) for each well is shown. The control 
is same as Fig. 1J. D) Expression of IRDS genes in 1833 IRDS-R (middle) or MCF7 IRDS-
NR (right) after addition of conditioned media (CM) from MRC5 fibroblasts (Stroma), IRDS-
R or IRDS-NR (BrCa), or MRC5 co-culture with IRDS-Rs or IRDS-NRs (Co-cx). See 
schematic (left). E) CM collected after 48 hrs or the soluble fraction from CM (Soluble) 
was applied to 1833 IRDS-R and expression of IRDS genes was examined (n=4).  F) Fold 
induction of IRDS genes in 1833 IRDS-R after addition of co-culture CM or purified 
exosomes (n=5). G) NanoSight quantification of exosomes (left) from 1833 IRDS-R, 
MRC5 fibroblasts (Stroma), and MRC5 co-culture using either 1833 IRDS-R or IRDS-NR 
(MDA-MB-468 or MCF7). Immunoblot for TSG101 (right) using 1833 IRDS-NR and MDA-
MB-468 IRDS-NR. H) MRC5 fibroblasts (Stroma) or 1833 IRDS-R were labeled with green 
or red lipophilic dye in mono-culture (left and middle). For co-culture (right), MRC5 
(arrows) were labeled red and breast cancer cells green. Scale bar is 40 microns. I) 
Representative flow cytometry of DiD dye transfer from MRC5 stroma to 1833 IRDS-R or 
MDA-MB-468 IRDS-NR. J) Exosome transfer from co-culture after TSG101 knockdown 
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(left) and after addition of the co-culture CM cleared of debris and apoptotic bodies (right) 
(n=4). K) IRDS gene induction by co-culture CM after TSG101 knockdown in 1833 IRDS-
R, MRC5 stroma, or both (n=3). Gene expression and significance levels are relative to 
siControl. *p < 0.05. Unless noted, all bar plots in figure are mean ± SD of n biological 
replicates. 
Exosomes are transferred from stromal cells to breast cancer to increase IRDS 
Conditioned media (CM) from co-culture of IRDS-Rs with stromal fibroblasts, but 
not from stromal co-culture of IRDS-NRs or from mono-culture, upregulates IRDS genes 
when applied to mono-cultured IRDS-Rs (Figure 3D). Interestingly, CM from co-culture of 
IRDS-Rs also upregulates IRDS when applied to IRDS-NRs. These results suggest that 
stromal cell interaction with IRDS-Rs produces a secreted factor capable of activating 
RIG-I. Recent evidence suggests that some PRRs can be activated by exosomes. 
Consistent with a role for exosomes in IRDS activation, the exosome-depleted soluble 
fraction of CM poorly induced the IRDS (Figure 3E). Conversely, addition of purified 
exosomes, which were confirmed by electron microscopy and by analyses of size 
properties and markers (Figure 4H), was sufficient to induce IRDS genes (Figure 3F). 
To examine how co-culture with IRDS-Rs influences exosome secretion and 
possible transfer to breast cancer cells, exosomes were quantified by particle counting 
and by the exosome marker TSG101. Both methods indicated that more exosomes were 
present after co-culture of IRDS-Rs compared to either IRDS-NRs or mono-culture (Figure 
3G). To examine exosome transfer, stromal cells and/or breast cancer cells were 
differentially labeled with either red or green fluorescent lipophilic dye to mark exosomes. 
For both cell types, dye transfer in mono-culture appeared minimal (Figure 3H). In co-
culture, microscopy and flow cytometry revealed an apparent unidirectional transfer of 
exosomes from fibroblasts preferentially to IRDS-Rs but not to IRDS-NRs (Figure 3H-I, 
Figure 4I-J). Multiple stromal cell types capable of inducing the IRDS were also able to 
transfer exosomes to IRDS-Rs (Figure 4K). Transfer was also observed upon addition of 
co-culture CM cleared of debris and apoptotic bodies (Figure 3J). With both assays, 
31 
 
transfer was mitigated by knockdown of TSG101 (Figure 3J, Figure 6C), which is a 
regulator of exosome biogenesis. Accordingly, TSG101 disruption in fibroblasts, but not in 
breast cancer cells, also inhibited IRDS induction without affecting elevation in non-IRDS 
genes such as MMP1 and CXCL1 (Figure 3K, Figure 6D). Thus, IRDS-Rs, but not IRDS-
NRs, coerce an increase in secretion of exosomes by stromal cells that results in transfer 
to breast cancer cells and subsequent IRDS induction. 
Figure 4. Exosome transfer from stromal to breast cancer cells rather than direct 
interferon signaling is associated with resistance and IRDS induction in breast 
cancer. A) Induction of IRDS genes requires live stromal cells. 1833 IRDS-R breast 
cancer cells were grown in mono-culture (Mono) or cultured with MRC5 fibroblasts 
(Stroma), fibronectin (Fn), MatriGel (MG), or fixed MRC5 stromal cells (Fixed). Shown is 
expression of the indicated IRDS genes. B) Expression of interferons and IFN receptor 
genes do not change after stromal cell interaction. Shown is a heat map of microarray 
data from IRDS-R in mono- or co-culture. C) Type one and two interferons are not 
significantly increased after co-culture. Conditioned media from mono-culture of either 
1833 IRDS-R (BrCa), mono-culture of MRC5 cells (Stroma), or co-culture of both cells 
(BrCa + Stroma) was collected at the indicated days. Shown is protein concentration by 
ELISA for IFN-beta or IFN-gamma. D) Type one and type two interferon receptors are not 
32 
 
necessary for stroma-mediated protection. Shown is relative cell death four days after 10 
Gy RT for 1833 IRDS-R grown in either mono-culture or co-culture with MRC5 stromal 
cells. Either the type one (IFNAR1 or IFNAR2, top), type two (IFNGR1, bottom), or 
combination of receptors were disrupted by siRNA. E) Knockdown of type one interferon 
receptor inhibits MX1 gene induction by exogenous IFN-beta. Indicated units of IFN-beta 
were added to mono-culture of 1833 IRDS-R and MX1 expression was measured. F) 
Knockdown levels for IFN receptors, MYD88, and RIG-I. Shown are knockdown levels by 
qRT-PCR for each si/shRNA relative to cells transfected with a control si/shRNA. 
Knockdown of RIG-I by shRNA was confirmed by protein (inset). G) 1833 IRDS-R 
transfected with shRIG-I or control shRNA (shCont) were seeded in either mono-culture 
or co-culture with MRC5 stromal cells. At days 0, 4 and 6, cell growth was measured by 
luciferase-based luminescence. H) Purified exosomes (Exo) from co-culture conditioned 
media were confirmed by electron microscopy (EM), the presence of exosome markers 
(-actin, CD81, TSG101), and the absence of cytoplasmic (RIG-I) and nuclear (H2A.X) 
markers (top right). Total cell lysates (Cells) were used as comparison. Size distribution 
of exosomes from co-culture as measured from electron microscopy (bottom). I) 
Exosomes are primarily unidirectionally transferred from stromal cells to breast cancer. 
MRC5 stromal cells were labeled with DiD and 1833 IRDS-R were labeled with DiI lipid 
dyes. Shown is transfer from breast cancer to stromal cells (top row) and stromal to breast 
cancer cells (bottom row) in co-culture as measured by flow cytometry. Gates are based 
on fluorescence intensity in mono-culture. J) Exosomes are preferentially transferred to 
IRDS-R breast cancer cells. Breast cancer cells labeled with green lipid dye and stromal 
cells labeled with red dye were co-cultured. Shown are representative fluorescent 
microscopy images of the IRDS-R cell lines 1833 (top left) and MDA-MB-436 (top right), 
and the IRDS-NR cell lines SKBR3 (bottom left) and T47D (bottom right). White scale is 
40 microns. K) Transfer of exosomes from stromal to breast cancer cells is associated 
with stromal cells capable of inducing IRDS in breast cancer cells (IRDS Inducers). 
Conditioned media from co-cultures of 1833 IRDS-R with the indicated dye-labeled 
stromal cells was added to 1833 IRDS-R. Transfer was measured by percent dye positive 
cells using flow cytometry. All bar plots in figure are mean ± SD. Unless indicated, gene 
expression and exosome assays were performed after 24-48 hrs of culture or stimulation. 
 
Table 3: Genes Upregulated in IRDS-NR Breast Cancer Cells after Co-culture 
Gene ID Score(d) Fold Change 
PLAC8 14.5431909 28.09085581 
PRKCDBP 9.221590661 10.49678396 
XAF1 9.159420594 13.45391224 
IFI44L 8.630966681 52.79939189 
ADAMTS12 8.547922704 6.182649282 
SHC3 8.391804719 6.000001542 
HERC6 8.122650409 5.840422724 
ETV5 7.578174981 5.279498594 
GSTT2 7.445394817 5.44163875 
MX2 7.428942679 22.31605842 
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HERC5 7.021381942 8.603379553 
SLCO1B3 7.014907663 44.95708011 
CD68 6.801351721 8.175324573 
IFIT1 6.532348154 19.99911081 
STEAP1 6.396327872 13.63207023 
GFPT2 6.325927538 6.596892255 
VEGFC 6.062694438 7.596177013 
ACSL5 6.056073217 25.66990472 
TOX 5.911402089 3.777452313 
IRAK2 5.795246 4.7055435 
ITGA2 5.671427672 4.184668772 
OAS2 5.627284315 25.60423273 
CAPRIN2 5.607531074 6.306708439 
PTPRM 5.542675403 7.712387813 
EPSTI1 5.518995316 4.742798949 
IFI44 5.391417455 22.67533361 
DDX58 5.369773655 6.200664535 
IFIT2 5.352961567 11.83396763 
LY96 5.330794588 5.867075852 
SEMA7A 5.229840311 4.422835934 
MX1 5.189096757 14.92523243 
LARP6 5.143833741 2.879853859 
PLOD1 5.13750488 2.498201037 
IFI35 5.130687365 4.925987347 
TGM2 5.129137707 9.920706701 
EREG 5.084580087 11.83108307 
NDRG1 5.070357658 3.781942991 
BST2 5.037302933 11.83570251 
RAB34 5.029463527 4.773447437 
MYEOV 5.026889174 3.876167147 
CD22 5.012080297 3.640705892 
FLNB 4.972676373 2.248621915 
CDA 4.939545817 8.832433405 
PAQR5 4.912789473 4.724677753 
EPHA2 4.867721559 4.229377246 
CHST11 4.839302013 5.026698939 
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Exosome transfer is regulated by stromal RAB27B 
To determine whether the increased production of exosomes in co-culture primarily 
originated from stromal or breast cancer cells, we used a protein array of well-known 
exosome markers. This revealed that co-culture exosomes were much more similar to 
exosomes from fibroblasts compared to those from breast cancer cells (Figure 5A), 
arguing that enhanced exosome production in co-culture is primarily from stromal cells. 
Interrogation of stromal RAB GTPases commonly implicated in exosome secretion115 
revealed that stromal RAB27B transcript and protein were consistently induced after 
fibroblasts were co-cultured with IRDS-Rs but not with IRDS-NRs (Figure 5B, Figure 6A). 
Indeed, of all RAB GTPases on the microarray, RAB27B was elevated the most in 
fibroblasts after interaction specifically with IRDS-Rs (Figure 6B). Knockdown of RAB27B 
in fibroblasts (Figure 6C) inhibited the ability of CM from co-culture to stimulate IRDS 
genes (Figure 5C) but had no effect on non-IRDS genes such as MMP1 and CXCL1 
(Figure 6D). Accordingly, knockdown of RAB27B also interfered with exosome transfer 
from fibroblasts to IRDS-Rs (Figure 5D), a result observed with multiple siRNAs to 
RAB27B (Figure 6E). In contrast, inhibition of RAB27A, which was not differentially 
expressed in fibroblasts, had no effect (Figure 6F). In total, these data argue that exosome 
transfer from stromal to breast cancer cells and subsequent IRDS induction is regulated 
by stromal RAB27B.  
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Figure 5. Stromal exosomes are regulated by RAB27B and transfer 5’-triphosphate 
RNA to activate RIG-I in breast cancer cells. A) Exosomes were isolated from mono-
culture of MRC5 fibroblasts (Stroma) or 1833 IRDS-R (right) or from co-culture (left) and 
profiled by antibody array for the indicated exosome markers. GM130 is a check for 
cellular contamination. Positive (+) and negative (-) controls are labeled. B) Averaged 
microarray expression of the indicated RABs from MRC5 in mono-culture (Stroma) or after 
co-culture with IRDS-R or IRDS-NR are shown as a heat map. Immunoblot (right) for 
RAB27B protein expression in MRC5 after co-culture with MDA-MB-157 or 1833 IRDS-R 
(Figure 6A) compared to MRC5 mono-culture. C) IRDS expression in 1833 IRDS-R after 
addition of CM isolated from co-culture using MRC5 transfected with siRAB27B compared 
to siControl (n=3). D) Exosome transfer to 1833 IRDS-R after co-culture with or without 
RAB27B knockdown (left) or addition of co-culture CM cleared of debris and apoptotic 
bodies (right). E) Average IRDS gene expression (mean expression of IFIT1, MX1, and 
STAT1) in response to exosomes (Exo, n=5) or co-culture CM (n=6) plotted against RIG-
I levels after knockdown in 1833 IRDS-R. F) IRDS gene expression from two 
representative data points used to generate plot in Figure 3E are shown relative to 
siControl. G) IRDS gene expression after RNA from exosomes (ExoRNA), cellular RNA, 
or a positive control HCV RNA was transfected into 1833 IRDS-R with or without RIG-I 
knockdown (n=4). IFI16 is a non-IRDS gene used as a negative control. H) Expression of 
IRDS genes IFIT1 and MX1 resulting from transfection of ExoRNA after RNase treatment, 
or I) removal of 5’-monophosphate (5’-p) and/or 5’-triphosphate (5’-ppp) (n=3). An in vitro 
transcribed 5’-ppp RNA (IVT5’ppp) is used as a positive control. Shown are RNA motifs 
remaining after enzyme modification with alkaline phosphatase (AlkPase), Terminator 
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exonuclease (Term), and tobacco acid pyrophosphatase (TAP). IVT5’ppp serves as a 
control for RNA enzyme modification by AlkPase and TAP. J) Distribution of known gene 
transcripts and intergenic transcripts from rRNA-depleted exoRNA and cellular RNA from 
1833 IRDS-R co-culture (left). Distribution of major repetitive elements and transposable 
element classes for intergenic transcripts are shown on right. K) ExoRNA enrichment for 
major subfamilies of transposable elements and satellite sequences compared to cellular 
RNA. *p < 0.05. Unless noted, all bar plots in figure are mean ± SD of n biological 
replicates.  
 
5’-triphosphate exosome RNA activates RIG-I to induce the IRDS 
Since exosomes and RIG-I both influence the effects of stromal cells, we focused 
on a potential relationship between the two. When RIG-I was disrupted in 1833 IRDS-R, 
IRDS gene induction by co-culture CM and by purified exosomes was similarly inhibited 
(Figure 5E-F). RIG-I activation typically results from binding to viral RNA through 
recognition of specific motifs such as 5’-triphosphates rather than through sequence 
specificity45. To investigate if exosome RNA (exoRNA) can induce IRDS through RIG-I, 
exoRNA from co-culture exosomes was re-encapsulated into synthetic lipid vesicles and 
transfected into mono-culture 1833 IRDS-R. While total cellular RNA from co-culture failed 
to induce IRDS genes, exoRNA upregulated IRDS genes in a RIG-I-dependent manner to 
levels that were comparable to a viral HCV RNA used as a positive control (Figure 5G). In 
contrast, HCV RNA or exoRNA did not significantly increase non-IRDS genes such as 
IFI16, which normally responds to cytosolic DNA. Treatment with RNase but not DNase 
eliminated the ability of exoRNA, as well as an in vitro transcribed 5’-triphosphate control 
RNA (IVT5’ppp), to elevate IRDS genes (Figure 5H). Removal of 5’-phosphates revealed 
that the active RNA contains exposed 5’-phosphate ends and is not a typical protein-
coding mRNA with a 5’-cap (Figure 5I). Consistent with the known specificity of RIG-I for 
5’-triphosphates, IRDS induction was inhibited after specific removal of 5’-triphosphate 
from exoRNA or from the IVT5’ppp, while digestion of RNA containing 5’-
monosphosphates had no effect. Thus, exoRNA containing 5’-triphosphate activates RIG-
I to induce IRDS genes.  
37 
 
Sequencing of exoRNA isolated from co-culture of 1833 IRDS-R revealed no 
apparent match to viral genomes from 19 different viruses known to activate RIG-I. 
Instead, enrichment for human intergenic and non-coding transcripts was observed in 
exoRNA compared to total cellular RNA from co-culture (Figure 5J). In both cellular RNA 
and exoRNA, repetitive sequences accounted for a significant fraction of these intergenic 
transcripts; however, while snRNA-like repeats were the predominant class of repetitive 
elements in cellular RNA, transposable elements represented the largest class within 
exoRNA. Specifically, SINEs, LINEs, and LTR retrotransposons were markedly enriched 
among exoRNA repetitive elements, with the most prevalent subclasses augmented by 
10-fold or more (Figure 5K). Other repetitive sequences such as telomeric and centromeric 
satellite sequences were present at lower frequencies but demonstrated 100 to 1000-fold 
enrichment in exoRNA. Since transposable elements are one category of RNA 
polymerase III transcripts, which can have 5’-triphosphate motifs116,117, their enrichment 
suggests that they may contribute to exoRNAs capable of stimulating RIG-I. 
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Figure 6. Stromal cells capable of inducing breast cancer IRDS specifically 
upregulate RAB27B to control exosome transfer. A) RAB27B is increased in stromal 
cells after co-culture with IRDS-R breast cancer cells. Shown is a representative 
immunoblot for RAB27B expression in either MRC5 mono-culture (Mono) or co-culture 
with 1833 IRDS-R (Co-cx). Numbers indicate fold increase determined by densitometry. 
B) RAB27B is preferentially increased in MRC5 fibroblasts (Stroma) after co-culture with 
IRDS-R but not IRDS-NR breast cancer cells. Shown is heat map of relative expression 
of all RAB GTPases and similarly related RABs annotated on the microarray. Scale is 
shown. Values are normalized to mono-culture of MRC5.  RAB27B is marked by the arrow. 
C) Knockdown levels of TSG101 and RAB27B are shown by qRT-PCR relative to cells 
transfected with a control siRNA. D) Knockdown of TSG101 and RAB27B do not influence 
the ability of co-culture conditioned media to induce metastasis genes. Co-culture 
conditioned collected after knockdown of either TSG101 or RAB27B by siRNA was used 
to induce expression of CXCL1 or MMP1 in 1833 IRDS-R mono-culture. E) Knockdown 
levels of various siRNAs for RAB27B are shown by qRT-PCR relative to cells transfected 
with a control siRNA. On the right is exosome transfer using conditioned media from 1833 
IRDS-R co-cultured with dye-labeled MRC5 fibroblasts transfected with the indicated 
siRNAs to RAB27B. Conditioned media was added to 1833 IRDS-R and transfer 
measured flow cytometry. F) Knockdown of RAB27A does not affect exosome transfer to 
1833 IRDS-R.  
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Stroma-mediated paracrine anti-viral signaling and juxtracrine NOTCH3 signaling 
enhance transcription of NOTCH target genes 
Although RIG-I and STAT1 are necessary for stroma-mediated resistance, 
separation of breast cancer cells from stromal fibroblasts using a transwell filter large 
enough for exosome passage resulted in retained IRDS induction but loss of RT 
resistance (Figure 7A). This suggests that the anti-viral pathway may work with an 
additional juxtacrine pathway to control stroma-mediated protection. To explore this, we 
computationally constructed a juxtacrine interactome between IRDS-Rs and fibroblasts 
using differentially expressed genes from each cell type combined with protein-protein 
interaction data (Figure 8A). This revealed that NOTCH3 expression was increased in 
IRDS-R breast cancer cells after co-culture, and its membrane-bound ligand JAG1 was 
both induced in fibroblasts and constitutively elevated in IRDS-Rs. Protein analysis 
confirmed that NOTCH3 was expressed at low levels in 1833 IRDS-R, but both its 
expression and its cleaved intracellular domain increased after fibroblast interaction 
(Figure 7B). In contrast, expression of NOTCH1, 2, and 4 did not change.  
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Figure 7. STAT1 enhances the transcriptional response to juxtacrine NOTCH3 
signaling that is required for stroma-mediated protection. A) Cell death of 1833 IRDS-
R in co-culture after RT. MRC5 fibroblasts were separated by a transwell filter large 
enough to allow exosome passage (n=3). B) Immunoblot of the indicated NOTCH family 
members in 1833 IRDS-R after mono-culture (M) or co-culture (C). Arrow indicates 
cleaved intracellular domain. C) Expression of NOTCH target genes in IRDS-R and IRDS-
NR after co-culture, and D) after STAT1 knockdown in 1833 IRDS-R after co-culture. 
NOTCH targets were experimentally defined by GSI washout (Table 4) and used in Gene 
Set Analysis. E) Expression of the indicated NOTCH target gene primary transcript (PT) 
in 1833 IRDS-R (n=3). F) Expression of HEY1 PT in response to doxcycyline (Dox) 
induced NICD3 in 1833 IRDS-R with or without addition of co-culture CM (mean  SEM, 
n=6-8). Inset shows NICD3 levels after Dox addition (µg/ml). G) Expression of the 
indicated primary transcripts to NICD3 after addition of co-culture CM or CM depleted of 
exosomes (Exo dep). CM compared to CM depleted of exosomes is used for significance 
levels (mean  SEM, n=4-6). H) ENCODE ChIP data for STAT1 occupancy of the HEY1 
proximal promoter region is shown along the indicated genomic coordinates. Bar plots 
show STAT1 ChIP from 1833 IRDS-R with and without addition of CM (left) and after 
mono- or co-culture (right). Relative position upstream of the transcriptional start site 
(TSS) is labeled on the x-axis for each bar plot. Shown are two representative experiments 
(mean ± SD) out of four total. I) Expression of HEY1 and HES1 mRNA or primary 
transcripts in response to NICD3 and co-culture CM in 1833 IRDS-R with and without 
STAT1 knockdown (mean  SEM, n=4-7). p<0.10, *p < 0.05. Unless noted, all bar plots 
in figure are mean ± SD of n biological replicates.   
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To investigate how anti-viral signaling and NOTCH3 might interact, we explored 
whether STAT1 facilitates transcription of NOTCH-dependent genes. Gene set 
enrichment analysis of NOTCH target genes, which we defined by GSI washout 
experiments (Table 4), confirmed upregulation of NOTCH targets in IRDS-Rs but not 
IRDS-NRs after co-culture (Figure 7C). Knockdown of STAT1 not only inhibited stroma-
mediated upregulation of NOTCH target mRNAs (Figure 7D) but also blunted the primary 
transcripts for canonical NOTCH targets HE2 and HEY1 (Figure 7E), consistent with 
STAT1 exerting transcriptional control over these genes. To better characterize this, we 
utilized doxycycline inducible NOTCH3 intracellular domain (NICD3) to constitutively 
activate NOTCH3 in 1833 IRDS-R and added exosome-containing CM to initiate anti-viral 
signaling. As measured by the HEY1 primary transcript, CM augmented responsiveness 
to NICD3 (Figure 7F). Depletion of exosomes from CM inhibited this effect on the HEY1 
primary transcript (Figure 7G) and mRNA (Figure 8B), and similar results were noted for 
HE2. The exosome-dependent increase in HEY1 and HE2 transcripts in the absence of 
NICD3 induction is likely due to baseline NOTCH and/or leakiness of the inducible system. 
Table 4: Notch Target Genes Defined by GSI Washout 
 
 
 
  
Gene Symbol Average Fold Change 
HES1 17.46 
NOTCH3 10.94 
HEY2 5.86 
CDKN1A 3.53 
HES7 3.21 
HEYL 3.19 
HEY1 3.07 
MFNG 2.84 
DLL1 2.78 
HES2 2.55 
HES3 2.49 
DLK1 2.39 
JAG1 2.29 
HES4 1.75 
MAML1 1.61 
HES5 1.55 
DTX2 1.44 
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Interrogation of ENCODE data revealed STAT1 occupancy at several locations 
within active proximal promoters of multiple NOTCH targets, including HEY1 and HE2 
(Figure 7H, Figure 8C). Chromatin immunoprecipitation (ChIP) for STAT1 demonstrated 
that activation of anti-viral signaling by CM or by co-culture increased STAT1 occupancy 
in the HEY1 promoter, particularly between the TSS and -2kB where the ENCODE data 
were the most significant (Figure 7H). STAT1 ChIP analysis for HE2 was similar (Figure 
8C). Despite high constitutive NICD3, knockdown of STAT1 in 1833 IRDS-R decreased 
primary transcript and mRNA levels for HE2 and HEY1 after activation of anti-viral 
signaling, consistent with the functional importance of at least some of the STAT1 sites in 
cooperating with NICD3 (Figure 7I). In contrast, although NOTCH3 itself is a NOTCH 
target (Table 4), the proximal promoter of NOTCH3 appears devoid of STAT1 sites by 
ENCODE. Accordingly, CM had no effect on the NOTCH3 primary transcript (Figure 8D), 
suggesting that STAT1 affects transcription of NOTCH targets, rather than the NOTCH3 
gene. Thus, paracrine-activated STAT1 can cooperate with juxtacrine-activated NOTCH3 
to augment the transcriptional response of multiple NOTCH targets. 
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Figure 8. Juxtacrine NOTCH3-JAG1 cooperates with STAT1 to transcriptionally 
enhance NOTCH target genes in breast cancer. A) Computational construction of 
extracellular interactome between IRDS-R breast cancer and MRC5 stromal cells 
identifies NOTCH3 and JAG1. See Extended Experimental Procedures for details. Degree 
of gene expression after co-culture is color-coded (increasing shade of red is higher) in 
the directed interaction graph that displays either heterotypic or homotypic interactions. 
Black box shows NOTCH3/JAG1 interaction. Breast cancer and MRC5 genes can be 
either induced or expressed at higher levels in IRDS-R vs. IRDS-NR breast cancer cells 
in co-culture, as indicated in the label below each directed graph. Arrows go from genes 
expressed in cell listed first in the label to cell listed second. B) Depletion of exosomes 
inhibits the ability of co-culture conditioned media (CM) to enhance HEY1 and HES1 after 
NICD3 induction in 1833 IRDS-R. Relative expression of the indicated mRNA is shown 
(n=4-6, mean ± SEM). CM compared to CM depleted of exosomes (Exo dep) is used for 
significance levels (*p < 0.05, two-sample, one-tailed, t-test). C) STAT1 binds to the 
proximal promoter of HES1 after activation of anti-viral signaling. ENCODE ChIP data for 
STAT1 occupancy of the HES1 proximal promoter region is shown along the indicated 
genomic coordinates. Bar plots show STAT1 ChIP from 1833 IRDS-R with and without 
addition of co-culture CM. Relative position upstream of the transcriptional start site (TSS) 
is labeled on the x-axis. D) Anti-viral signaling does not influence the transcriptional 
response of NOTCH3 to NICD3. Relative expression of NOTCH3 primary transcript (PT) 
in response to increasing levels of NICD3 by doxycycline induction (µg/ml) with or without 
co-culture CM (n=6). Unless noted, all bar plots in figure are mean ± SD. Gene expression 
and ChIP assays were performed after 24-48 hrs of culture or stimulation. 
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STAT1 and NOTCH3 control stroma-mediated resistance through the expansion of 
therapy resistant breast cancer cells 
Both anti-viral and NOTCH signaling have roles in controlling normal and cancer 
stem cells109,118. Indeed, NOTCH and its target genes were previously shown to help 
maintain a subpopulation of CD44+CD24low+ cells that have tumor-initiating properties 
(e.g., increased mammosphere and tumor formation)110. Since tumor-initiating cells (TICs) 
are known to be resistant to RT/chemo, we investigated if stromal cell interaction might 
lead to the expansion of such therapy resistant cells (TRCs). Indeed, co-culture resulted 
in the upregulation of a gene signature associated with TICs119 (Figure 9A) and in the 
expansion of the CD44+CD24low+ subpopulation of 1833 IRDS-R (Figure 9B). This 
CD44+CD24low+ population is resistant to both RT and chemotherapy compared to 
CD44+CD24neg counterparts (Figure 9C) and enriches after genotoxic damage (Figure 
10A). Co-culture with fibroblasts prior to seeding increased mammosphere formation 
(Figure 9D), and knockdown of STAT1 or inhibition of NOTCH3 with either RNAi or GSI 
inhibited both mammosphere formation (Figure 9E) and enhancement of the TIC gene 
signature (Figure 9A). Similar STAT1-dependent stromal cell activation of NOTCH3 and 
expansion of mammospheres were observed in other IRDS-Rs as well (Figure 10B-D). 
Constitutive activation of NOTCH3 in mono-culture also led to modest expansion of both 
mammospheres and CD44+CD24low+ cells (Figure 9F, Figure 10E). In accordance with an 
expansion of CD44+CD24low+ TRCs, the proportion of surviving mammospheres was 
higher after irradiation of cells seeded from co-culture compared to mono-culture (Figure 
9G). Thus, these results suggest that STAT1 and NOTCH3 can drive expansion of breast 
cancer TRCs. 
Like with STAT1, knockdown of NOTCH3 with multiple different siRNAs inhibited 
both stroma-mediated expansion of breast cancer TRCs and resistance (Figure 9H, Figure 
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10F-G). Inhibiting JAG1 also inhibited RT resistance after co-culture with the greatest 
effect occurring after disruption in both 1833 IRDS-R and fibroblasts (Figure 9I, Figure 
10H), consistent with the interactome results showing JAG1 upregulation in both cell 
types. Expression of NICD3 in mono-culture 1833 IRDS-R partially recapitulated the 
protective effect of stromal cells (Figure 9J). Similarly, ectopic NICD3 partially rescued the 
effect of STAT1 knockdown on stromal cell protection (Figure 9K). These partial effects 
on resistance parallel the partial transcriptional responses of NOTCH target genes when 
only STAT1 or NOTCH3 were fully engaged. Together, these data suggest that stroma-
mediated resistance results from cooperation between STAT1 and NOTCH3 to expand 
and/or maintain breast cancer TRCs. 
Figure 9. Stromal cells drive the expansion of a subpopulation of therapy resistant 
breast cancer cells through anti-viral STAT1 and NOTCH3 signaling. A) Gene Set 
Analysis comparing IRDS-R in mono-culture versus co-culture with MRC5 fibroblasts, or 
comparing 1833 IRDS-R in co-culture transfected with siSTAT1 vs. siControl. B) 
Percentage of CD44+CD24low+ 1833 IRDS-R after co-culture with MRC5. All CD24low+ cells 
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are also CD44+. C) Survival of sorted CD44+CD24low+ and CD44+CD24neg cells after 10 Gy 
RT or 4 M doxorubicin (chemo). Number of mammospheres from 1833 IRDS-R after D) 
co-culture, or E) co-culture following knockdown of STAT1 (siS1), NOTCH3 (siN3), or 
control (siCt), or after treatment with the GSI DAPT. F) Number of mammospheres after 
NICD3 induction by doxycycline in mono-culture. G) Proportion of surviving 
mammospheres relative to untreated control in mono- or co-culture after 3 Gy RT. Cell 
death after 10 Gy RT following H) knockdown of NOTCH3 in 1833 IRDS-R, I) knockdown 
of JAG1 in 1833 IRDS-R, MRC5 (Stroma), or both (n=4), J) expression of NICD3 (n=7), 
or K) STAT1 knockdown with and without NICD3 expression (n=3-4). L) Cell death of 
IRDS-Rs and IRDS-NRs after 10 Gy RT and treatment with the GSI DAPT or DMSO (n=5-
10). M) Photon flux from mice xenografted subcutaneously with luciferase-labeled 1833 
IRDS-R with or without MRC5 fibroblasts (Stroma) and treated 7 days later with 8 Gy RT, 
the GSI DAPT, both, or untreated. Mean values (black “X”) are connected by blue line. 
Representative tumors after treatment are inset. In presence of stroma, tumor response 
was associated with RT (p < 0.001) and GSI (p=0.004). Without stroma, RT (p=0.019) but 
not GSI (p=0.79) was associated with response. N) Percentage of CD44+CD24low+ cells in 
tumors from mice xenografted with 1833 IRDS-R with and without MRC5 stroma 7 days 
after the indicated treatment. O) Survival of these mice, which are independent cohorts 
from that used in Fig. 5M. *p < 0.05. Unless noted, all bar plots in figure are mean ± SD of 
n biological replicates. 
 
NOTCH inhibition reverses stroma-mediated resistance of IRDS responders and improves 
survival in vivo 
Considering that the NOTCH3 and STAT1 pathways are necessary for stroma-
mediated resistance in IRDS-Rs, we investigated whether a GSI could selectivity reverse 
the protective effects of stromal cells. For IRDS-Rs, treatment with the GSI DAPT 
completely or partially reversed the protective effects of fibroblasts and had only small 
effects in mono-culture (Figure 9L). In contrast, for IRDS-NRs neither co-culture nor GSI 
discernibly affected cytotoxicity after RT. In vivo, admixing fibroblasts with luciferase-
labeled 1833 IRDS-R resulted in the upregulation of NOTCH targets (Figure 10I). 
Treatment with GSI alone decreased NOTCH targets (Figure 10J) but had only a mild or 
insignificant effect on breast cancer growth in the presence (p=0.083) or absence (p=0.67) 
of admixed fibroblasts (Figure 9M). With RT, the presence of fibroblasts protected breast 
cancer (p=0.026); however, three consecutive doses of GSI starting from the day of RT 
reversed this protection. Moreover, GSI prevented the in vivo enrichment of 
CD44+CD24low+ TRCs observed after RT (Figure 9N), and the combination of RT and GSI 
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rendered nearly 30% of mice tumor-free compared to 0% with RT or GSI alone (Figure 
9O). Thus, for IRDS-R basal-like breast cancers the combination of GSI and genotoxic 
therapy prevents stroma-mediated expansion of TRCs adept at tumor re-initiation. 
Figure 10. NOTCH3 expands therapy resistant tumor-initiating cells and can be 
targeted by GSI. A) CD44+CD24low+ subpopulation is enriched among surviving cells after 
RT. The 1833 IRDS-R breast cancer cells were irradiated with 10 Gy and the proportion 
of CD44+CD24low+ cells (blue) and CD44+CD24neg cells (grey) were measured by flow 
cytometry. The percentage of lives cells relative to an untreated control is also shown 
(red). B) In response to MRC5 stromal cells, MDA-MB-436 IRDS-R breast cancer cells 
induce NOTCH3 protein, and C) upregulate NOTCH target genes in a STAT1- and 
NOTCH3-dependent manner. Irrelevant lanes in the immunoblot were deleted. Relative 
expression of indicated NOTCH targets genes with and without knockdown of STAT1 or 
NOTCH3 is shown (n=3). D) Number of mammospheres from MDA-MB-436 IRDS-R after 
mono- or co-culture (left), or after co-culture following treatment with the GSI DAPT (right). 
E) Increase in CD44+CD24low+ subpopulation after ectopic NICD3 expression. Shown are 
results from flow cytometry using 1833 IRDS-R transfected with a control vector or a 
doxycycline-inducible NICD3 after addition of doxycycline (n=3). F) Knockdown of 
NOTCH3 using multiple different siRNAs inhibits stroma-mediated protection in co-culture. 
Knockdown was performed in 1833 IRDS-R. Shown is relative cell death four days after 
10 Gy RT (n=2). G) Knockdown levels of NOTCH3 using the individual siRNAs are shown 
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by immunoblot. H) Knockdown levels of JAG1 by qRT-PCR relative to cells transfected 
with a control siRNA. I) NOTCH target genes defined by GSI washout are elevated by 
MRC5 fibroblasts in vivo. Shown is a heat map of relative expression from xenografted 
1833 IRDS-R tumors with or without admixed MRC5 stromal cells. Expression is relative 
to values observed in tumors comprised of 1833 IRDS-R alone. J) On-target effects of 
GSI treatment in vivo. 1833 IRDS-R were xenografted with or without MRC5 fibroblasts 
and mice were treated with or without the GSI DAPT. After 48 hours, tumors were 
harvested and expression of the indicated genes was examined (n=3). In vitro protein and 
gene expression assays were performed after 48 hrs of culture. 
 
Expression of anti-viral and NOTCH3 pathways in primary human and mouse basal-like 
breast cancer 
To investigate potential disease relevance, we examined whether basal subtype 
primary human breast cancers show expression and activation of anti-viral/NOTCH3 
pathways in ways predicted by our experimental models. We first analyzed protein 
expression of RAB27B, STAT1 and NOTCH3 in primary human triple-negative breast 
cancers (TNBC), which overlap with the basal subtype. RAB27B showed strong stromal 
staining in 71% of TNBC tumors (Figure 11A). By image analysis, the intensity of STAT1 
preferentially exhibited a strong tumor-stroma border pattern also in 71% of TNBC 
samples. For NOTCH3, this tumor-stroma border pattern was more subtle, possibly 
because NOTCH3 and JAG1 are themselves NOTCH targets, but was discernible in 29% 
of TNBC cases. Examination of tumors from TNBC patient-derived xenografts (PDX) also 
demonstrated strong tumor-stroma border patterns for STAT1 and NOTCH3 (Figure 11B). 
Moreover, breast tumors from the K14cre;BRCA1F/F;p53F/F mice, which is a model of basal 
subtype breast cancer120, revealed patterns of staining similar to primary human TNBC 
(Figure 11B). In contrast, a distinct tumor-stroma border pattern was rarely observed in 
ER+ primary tumors for either STAT1 (14%) or NOTCH3 (0%) and was not observed in 
ER+ PDX tumors (Figure 12A). Thus, in both human and mouse basal-like tumors, key 
drivers of anti-viral/NOTCH3 signaling can show preferential localization around sites of 
tumor-stroma interaction. 
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Figure 11. Expression of anti-viral and NOTCH3 pathway predict IRDS and NOTCH 
target gene expression in primary human and mouse tumors. A) Expression of 
RAB27B, STAT1, and NOTCH3 in primary human triple negative breast cancer (TNBC), 
or B) in TNBC patient-derived xenografts (PDX) and basal-like tumors from 
K14Cre;BRCA1F/F;p53F/F conditional knockout mice. Arrows show representative areas of 
stroma. Insets for TNBC images show darker staining regions (red) segmented from 
lighter regions. Semi-quantitation of expression in stroma (S), tumor (T), or tumor-stroma 
borders (B) is indicated. Vertical bar is 200 microns. A total of seven primary TNBC tumors 
were scored. Two out of 2 PDX and 3 out of 3 mouse tumors gave similar results. Shown 
are representative images and semi-quantitation.  C) Box-and-whisker plots of expression 
values for the indicated RABs from primary human breast cancer stroma (Tumor) or 
normal stroma (Norm) using the Stroma series. D) Importance scores (higher is more 
predictive) from a RF regression model (variance explained: 55.1%) to predict breast 
cancer IRDS expression using the NKI295 series. Adjusted effect of RIG-I on IRDS 
expression (right). E) Heat map and scale showing expression of all available NOTCH 
receptors in breast cancer (brown) and NOTCH ligands in stroma (green) from the LCMD 
series. These were used to predict the average expression of NOTCH target genes in 
breast cancer (variance explained: 30.2 ± 1.1%) defined by GSI washout (NOTCH Meta). 
On the right are importance scores from Monte Carlo replications. 
 
To investigate whether similarities in localization of anti-viral and NOTCH3 proteins 
between in vivo tumors and in vitro models are accompanied by expected gene expression 
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changes in IRDS and NOTCH target genes, we used three distinct sets of gene expression 
data from primary human breast cancer. The Stroma series is a 53-sample set of breast 
cancer stroma and adjacent normal stroma, the NKI295 series is comprised of 295 primary 
human breast tumors confirmed to be largely cancer cells, and the LCMD series contains 
28 paired primary tumor and stroma samples that were separated by laser-capture 
microdissection. Consistent with breast cancer inducing stromal RAB27B, the Stroma 
series revealed higher RAB27B expression in tumor stroma compared to adjacent normal, 
while other RABs on average had similar or decreased expression (Figure 11C). Using 
the NKI295 series, RIG-I was the best predictor of IRDS status compared to other PRRs 
and interferon-related genes (Figure 11D). Of all available NOTCH family receptors and 
ligands on the LCMD series array (Figure 11E), breast cancer NOTCH3 and stromal JAG1 
were the best at predicting expression of breast cancer NOTCH targets (Table 4) as 
measured by their average expression (metagene). Moreover, when breast cancer 
NOTCH3 was paired with breast cancer RIG-I, and stromal JAG1 was paired with stromal 
RAB27B, high expression of the two pairs cooperatively predicted high NOTCH metagene 
expression (Figure 12B-C). In total, these data indicate that gene expression changes 
attributed to the anti-viral and NOTCH3 pathways can be observed in primary tumors.  
 
51 
 
Figure 12. Stromal RAB27B and JAG1, and breast cancer RIG-I and NOTCH3, 
cooperate to predict expression of breast cancer NOTCH target. A) STAT1 and 
NOTCH3 do not preferentially localize to tumor-stroma borders in ER-positive breast 
cancer. PDX tumors are on the top row and primary human tumors are on the bottom row. 
Black arrow marks a myoepithelial layer (non-cancer cells) that shows NOTCH3 staining. 
Black bar is 200 microns. For primary human tumors, 7 samples were analyzed. Shown 
are representative images. B) The mechanistic interactions between stroma and breast 
cancer genes can be inferred by statistical interactions. Statistical interactions are 
detected when the joint importance score of multiple genes is greater than the sum of 
individual importance scores. Stromal genes, RAB27B and JAG1, and breast cancer 
genes, RIG-I and NOTCH3, were used in a RF regression model to predict breast cancer 
NOTCH activation (model explains 35.3 ± 1.0% (SD) of the total variance). Top graph 
shows importance scores of each gene (blue dots). Middle plot shows model error rate 
(lower is better) for all pathway genes (blue dot). Bottom graph displays importance scores 
(blue dots) for the stromal genes, breast cancer genes, the sum of these values (Additive), 
and the joint importance score for all genes (Joint). For comparison, distribution of 
importance scores (grey) or error rates (yellow) for random genes is shown using box-
and-whisker plots with the 5% and 95% quantiles marked (red X). C) Adjusted effects of 
stromal and breast cancer genes on breast cancer NOTCH metagene expression from 
the RF model. Red dashed lines are ± two standard errors. D) NOTCH3 together with 
either breast cancer JAG1 or stromal JAG1 predicts NOTCH metagene expression. The 
LCMD series was used to predict breast cancer NOTCH metagene expression. NOTCH3 
and JAG1 in breast cancer (BrCa) and NOTCH ligands in stroma were used as x-variables 
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in a RF regression model. Gene expression is displayed in the heat map. Below the heat 
map is a plot of the distributions of importance scores from 100 Monte Carlo replications 
(used to obtain better estimates from a small sample size). The RF model explains 26.7 ± 
1.2% (SD) of the total variance.  
 
Because STAT1 enhances the transcriptional response to NOTCH3 in IRDS-R 
breast cancer, high NOTCH target gene expression is expected to associate with high 
NOTCH3/JAG1 and high STAT1 activity in basal subtype tumors. To examine this, we 
used the NKI295 series and substituted stromal JAG1 with breast cancer JAG1, as stromal 
genes cannot be evaluated and breast cancer JAG1 was comparable to stromal JAG1 at 
predicting NOTCH target gene expression (Figure 12D). For STAT1 activity, we used the 
clinical IRDS classifier since it includes STAT1, and STAT1 both regulates (Figure 1H) 
and correlates with IRDS status (Spearman’s correlation coefficient 0.79, p < 0.001). As 
expected, increasing NOTCH3 resulted in higher likelihood of NOTCH pathway activation 
(Figure 13A). The probability was highest when NOTCH3, JAG1, and IRDS were all high, 
particularly for basal subtype tumors (red dots, upper right plot), a result that was 
recapitulated in basal-like tumors from the K14cre;BRCA1F/F;p53F/F mouse model (Figure 
13B). Thus, these results suggest that anti-viral signaling preferentially facilitates the 
transcriptional response to NOTCH3 in primary human and mouse basal subtype tumors. 
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Figure 13. NOTCH3 and STAT1/IRDS cooperate to predict NOTCH target genes and 
clinical resistance to chemotherapy and RT preferentially in basal-like breast 
cancers. Prediction of NOTCH target gene expression by IRDS and NOTCH3/JAG1 in A) 
primary human tumors and in B) basal-like tumors from the K14Cre;BRCA1F/F;p53F/F 
conditional knockout mice. For human tumor analysis, the NKI295 series was used. The 
probability of NOTCH pathway activation as measured by the NOTCH metagene is shown 
on the y-axis with probabilities for basal (red dots) or non-basal (blue dots) tumors 
displayed separately. The percentage of tumors with greater than 80% probability of 
NOTCH activation is inset. A LOWESS regression line (black dashed line) is shown. IRDS 
and JAG1 were equally divided into low, intermediate, and high values. For mouse tumor 
analysis, IRDS, NOTCH3, and JAG1 expression were dichotomized into only high and low 
due to smaller sample size. Mean value is marked by red line. C) Heat map showing 
probabilities of NOTCH activation and NOTCH3 expression for each patient (columns) in 
the NKI295 series. All values are scaled between 0 and 1. Hatches below the heat map 
show status for IRDS(+), NOTCH3(hi), and the indicated molecular subtypes. On the right 
is Gene Set Analysis for the same TIC signature used in Fig. 5A and compares 
NOTCH3(hi)/IRDS(+) tumors to those that are NOTCH3(lo) and/or IRDS(-). D) Survival 
after adjuvant chemotherapy of patients from the NKI295 series stratified by NOTCH3 and 
IRDS. Overall p-value is shown. E) Hazard ratios and 95% confidence intervals from Cox 
regression analysis for breast cancer survival using NOTCH3 as a continuous variable, 
IRDS status (positive vs. negative), and MammaPrint (Mamma) metastasis signature 
status (positive vs. negative). All patients received adjuvant chemotherapy. Hazard ratio 
for NOTCH3 is per unit increase in expression. Analyses are also stratified by IRDS status 
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and basal vs. non-basal subtype tumors. Values are not shown if there are too few patients 
in the group. F) Relapse in irradiated region (local-regional control) after adjuvant RT. G) 
Hazard ratio from Cox regression for relapse in the Stroma series using stromal RAB27B 
as a continuous variable. H) Model of the tumor-stroma anti-viral/NOTH3 pathways 
controlling RT/chemo resistance. 
 
Anti-viral/NOTCH3 pathway genes predict clinical resistance to chemotherapy and RT 
Having shown that NOTCH3 and the IRDS contribute to predicting NOTCH 
activation in the NKI295 series, we examined whether both pathways function together to 
predict clinical resistance to chemotherapy and RT. NOTCH3 was dichotomized using a 
mean cut-point, and for consistency, IRDS status was defined using our original seven-
gene clinical classifier. Interestingly, 31% of NOTCH3(hi)/IRDS(+) tumors belonged to 
either the basal or claudin-low subtype (Figure 13C; p < 0.01 by chi-squared test), two 
basal-like subtypes that are enriched in cancer stem cell-like features121. Consistent with 
this, NOTCH3(hi)/IRDS(+) tumors showed enrichment of the same breast cancer TIC 
signature upregulated in IRDS-R cells after co-culture (Figure 13C and 9A), suggesting 
these tumors could also contain TRCs. Indeed, among the patients who received 
chemotherapy, those with the highest risk of breast cancer-specific death were 
NOTCH3(hi)/IRDS(+) (Figure 13D). Cox regression using continuous values rather than 
arbitrary cut-offs for NOTCH3 demonstrated that higher NOTCH3 augmented risk only 
among patients with tumors that were IRDS(+) and/or basal subtype (Figure 13E). The 
effect of both pathways on survival was distinct from metastasis risk as both were 
independent of the MammaPrint metastasis signature122, and neither were predictive 
among patients not receiving chemotherapy (Figure 14A). NOTCH3(hi)/IRDS(+) patients 
were also the most likely to fail RT (Figure 13F). Finally, using the Stroma series, we found 
that high stromal RAB27B predicted poor survival, while other RABs showed no 
association (Figure 13G and Figure 14B). In total, the anti-viral/NOTCH3 pathways predict 
clinical resistance, particularly for basal subtype tumors. 
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Figure 14. Breast cancer survival is neither predicted by IRDS and NOTCH3 in the 
absence of chemotherapy nor by multiple RABs. A) NOTCH3 and IRDS do not predict 
survival in patients who do not receive chemotherapy. Cox regression for breast cancer 
survival using NOTCH3 as a continuous variable, IRDS status (positive vs. negative), and 
MammaPrint (Mamma) metastasis signature status (positive vs. negative). Shown are 
hazard ratios (red dot), 95% confidence intervals (blue line), and p-values for patients who 
did not receive chemotherapy. Since NOTCH3 is a continuous variable, its hazard ratio is 
per unit increase in NOTCH3 expression. Analyses are also stratified by IRDS status and 
basal vs. non-basal subtype. B) Other RABs besides RAB27B that have been implicated 
in the regulation of exosome secretion do not predict breast cancer relapse. The indicated 
RAB gene from the Stroma series was used as a continuous variable in Cox regression. 
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Discussion 
We demonstrate that interaction of stromal cells with breast cancer cells results in 
paracrine and juxtacrine signaling events to drive stroma-mediated resistance (Figure 
13H). First, stromal cells increase RAB27B and transfer 5’-triphosphate RNA in exosomes 
to activate RIG-I anti-viral signaling in breast cancer cells. Second, breast cancer cells 
induce NOTCH3 to make the receptor available for engagement with JAG1. The paracrine 
and juxtacrine pathways converge as STAT1 facilitates the transcriptional response to 
NOTCH3, resulting in the expansion of therapy resistant TICs. Consistent with this, 
stromal cells mediate both decreased cell death and continued tumor growth after RT. 
Blocking the NOTCH pathway re-sensitizes tumors to RT, rendering mice tumor-free. 
These biological interactions between anti-viral and NOTCH3 signaling are mirrored by 
statistical evidence that they jointly influence NOTCH activation and treatment resistance 
in primary human basal-like breast cancers.  
The role of exosomes in cancer as mediators of cell-cell communication with the 
microenvironment has gained increasing attention. Functionally, exosomes have 
intriguing and elaborate roles in cancer progression and can transfer a variety of proteins, 
DNA, and RNA that can explain some of their effects84,123. Our data suggests that RNA 
contained within exosomes is enriched in non-coding transcripts and can activate RIG-I. 
Consistent with the known properties of RIG-I stimulatory viral RNA45, 5’-triphosphates are 
similarly required for exoRNA to activate RIG-I. Sequencing exoRNA revealed no 
evidence of viral transcripts, rather exoRNA was enriched in transposable elements and 
other repetitive sequences, many of which are known or putative RNA polymerase III 
transcripts. RNA polymerase III transcripts can contain 5’-triphosphates and likely are 
largely non-coding117. Although the quantity and diversity of non-coding human transcripts 
is large124 and RIG-I is not known to overtly show sequence-specific binding, the 
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enrichment for transposable elements and other repetitive elements in exosomes is 
interesting given the viral origins of some of these sequences116. Despite prolific 
incorporation into the genome, it is notable that these elements are normally 
transcriptionally silenced but can be de-repressed to high levels in cancer125. When 
expressed, these elements can also exhibit subcellular partitioning into the nucleus and 
the cytoplasm126. Accumulation of transposable elements can result in autoimmunity with 
elevated ISGs in normal tissue56. Thus, our results suggest that non-coding RNA found in 
exosomes and similar microvesicles127,128 may coax anti-viral responses to influence 
treatment resistance, potentially adding to the increasing evidence that atypical RNA 
transcripts can contribute to human disease.  
Both anti-viral/interferon signaling and the NOTCH pathway are known to regulate 
the maintenance of normal and cancer stem-like cells. Interestingly, inflammatory/stress 
signaling involving STAT can function with NOTCH signaling in development and in 
homeostasis to influence self-renewal35,129 (Kux and Pitsouli, 2014). For example, in 
Drosophila, inflammation and stress in the midgut leads to compensatory intestinal stem 
cell proliferation that is regulated by STAT. STAT can be activated non-cell autonomously 
by damaged cells, while distinct levels of NOTCH controls intestinal stem cell commitment 
and differentiation. Our findings that stromal fibroblasts can secrete exosomes to induce 
anti-viral signaling in breast cancer cells, and that STAT1 promotes NOTCH3-driven 
expansion of therapy resistant TICs, highlight an unexpected way that these two 
evolutionarily conserved pathways converge to influence cell fate in cancer.  
The mechanisms whereby basal-like tumors are preferentially protected by stroma 
through anti-viral/NOTCH3 signaling require further investigation. One mechanism 
indicated herein may be the capacity of basal-like breast cancer cells to coerce stromal 
cells to augment exosome secretion. RAB27B is uniquely induced in stromal cells by 
IRDS-R but not IRDS-NR breast cancer, and evidence from primary human tumors also 
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distinguishes it from other RABs. However, alternative methods to either increase 
exosome production in the microenvironment or instigate similar anti-viral signaling (e.g., 
immune cells) may also exist. Other factors that might contribute to differences in the way 
basal-like tumors respond to stroma include defects in the BRCA1 pathway, which have 
been associated with basal and claudin-low tumors121. It is notable that two of the IRDS-
R breast cancer cell lines have reported mutations in BRCA1130, and BRCA1 null mouse 
mammary tumors show evidence for the anti-viral/NOTCH3 pathway. As a cell extrinsic 
mechanism of resistance, the protective effect of stroma may be critical for certain breast 
cancers with intrinsic DNA damage sensitivity.  
Extrapolating the relevance of findings from model systems to human disease is 
often challenging. In this study, extensive statistical modeling of primary tumor expression 
data was used to support the mechanisms dissected from experimental models. 
Specifically, primary tumor data suggest that 1) RIG-I is a driver of the IRDS, 2) breast 
cancer NOTCH3 and stromal JAG1 are important regulators of NOTCH target gene 
expression, 3) NOTCH3 and STAT1 are localized to sites of tumor-stroma interaction, 4) 
STAT1 facilitates the transcriptional response to NOTCH3, 5) IRDS/STAT1 and NOTCH3 
identify patients with both high NOTCH target genes and chemo/RT resistant tumors, and 
6) high IRDS/NOTCH3 is preferentially observed in basal and claudin-low subtype primary 
tumors, which are known to be enriched in cancer stem cell-like features121. These 
observations, combined with pre-clinical studies showing that GSI can reverse the effects 
of stromal cells on TRC expansion, tumor growth after genotoxic damage, and survival 
suggest the disease relevance of our findings. Together, the anti-viral and NOTCH3 
pathways may serve as companion biomarkers and druggable targets for stroma-
mediated resistance. 
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CHAPTER 3: VIRUS MIMICRY IN THE TUMOR MICROENVIRONMENT ACTIVATES 
RIG-I THROUGH UNSHIELDING OF ENDOGENOUS RNA IN EXOSOMES 
Sections of this chapter have been adapted from the following manuscript: Nabet, B.Y., 
Qiu, Y., Shabason, J.E., Wu, T.J., Yoon, T., Kim, B.C., Marcotrigiano, J., and Minn, A.J. 
Stromal cells utilize viral mimicry to regulate breast cancer therapy resistance through 
exosomes and non-coding RNA. In revision at Cell. 
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Introduction 
The dynamic interaction and co-regulation of critical signaling pathways between 
cancer cells and stromal cells of the tumor microenvironment can significantly influence 
tumor progression and therapy response13. Through reciprocal signaling between these 
heterotypic cell types, cancer cell proliferation, cell death, and metabolism can be altered. 
Paracrine and juxtacrine signaling components that can be employed between cancer and 
stromal cells include RAS, WNT, NOTCH, STAT, and several others88,131,132. The 
importance of these tumor-stromal signaling cascades may be to help amplify critical 
oncogenic pathways in cancer cells to promote tumor progression, metastasis, and 
resistance 15. However, the mechanisms that govern how cancer and stromal cells interact 
to accomplish these events are not well understood. 
Another pathological condition that favors effective cell-cell communication to 
amplify critical signaling pathways is viral infection. Upon infection, cells induce an anti-
viral response that includes the upregulation of interferon-stimulated genes (ISGs)48. This 
response is driven by the recognition of viral RNA by pattern recognition receptors (PRRs), 
such as RIG-I 44. Recent evidence reveals that in addition to cell intrinsic anti-viral 
responses that occur after viral infection, mechanisms exist to propagate an anti-viral 
response from infected to uninfected cells. For example, viral RNAs can be packaged into 
exosomes 62,63, small extracellular vesicles that originate in multivesicular bodies and are 
also implicated in a myriad of processes related to cancer progression82,86,133. Secretion 
and transfer of exosomes to bystander cells can then result in recognition of exosome-
transferred viral RNA by PRRs78–80. This culminates in ISG induction within uninfected 
cells and tissue-level amplification of the anti-viral response. 
Across many common human cancers, a large proportion of patients have tumors 
that unexpectedly express high levels of ISGs38. A subset of breast cancer cells, which we 
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denote as ISG responders (ISG-Rs), can induce ISGs through cell-cell contact with 
stromal fibroblasts and the subsequent secretion of exosomes132. These exosomes 
contain RNA (exoRNA) that is enriched in non-coding transcripts. Upon transfer to ISG-R 
breast cancer cells, the exoRNA stimulates RIG-I, resulting in ISG induction and STAT1 
activation. STAT1 amplifies the NOTCH3 transcriptional response, resulting in expansion 
of tumor-initiating cells and therapy resistance. Consistent with these experimental 
findings, patients with tumors expressing high levels of ISGs are more likely to relapse 
after chemotherapy or radiation therapy. Thus, a subset of breast cancer cells can amplify 
oncogenic pathways through anti-viral signaling resulting from stromal cell contact. 
Activation of breast cancer RIG-I by exoRNA after encountering stromal cells is 
reminiscent of how viral infection of one cell population can propagate anti-viral responses 
to neighboring cells. Similar examples of PRRs recognizing exoRNA in the tumor 
microenvironment have been reported to influence cancer progression101,102. However, 
such potential examples of virus mimicry within a tumor raises questions on the similarities 
between cancer-associated anti-viral signaling and virus-mediated signaling. Moreover, 
given that cancer-associated anti-viral signaling is occurring in a sterile microenvironment, 
the nature of the endogenous RNA and how it activates RIG-I are unanswered questions. 
There are multiple properties that RIG-I utilizes to distinguish self from non-self 
RNA. Typically, RIG-I recognizes cytoplasmic double-stranded RNA that is 5’ 
triphosphorylated, generally short (<300bp), and has a blunt 5’ end45,52. For viral RNAs, 
polyuridine motifs can favor recognition (Saito et al., 2008), while RNA modifications such 
as 2-O-methylation can critically prevent RIG-I binding to 5’ capped cellular RNAs57,58. 
However, much of the RNA features and requirements for optimal RIG-I activation are 
based on synthetic and/or artificial RNAs in vitro. Emerging evidence indicates that 
endogenous RNA can function as a damage-associated molecular pattern (DAMP) to 
activate PRRs under a variety of pathological conditions, such as chemotherapy40–42, 
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radiation103,104, and autoimmunity55,105. How endogenous RNAs can function as DAMPs to 
activate PRRs while avoiding recognition under non-pathological conditions is not well 
understood. 
In this study, we investigate the concept of virus mimicry whereby breast cancer 
cells, like viruses, can provoke an anti-viral response in surrounding stromal cells. We 
examine how this leads to deployment of endogenous stromal RNA as a RIG-I-activating 
DAMP, resulting in the propagation of an anti-viral response to enhance tumor progression 
and therapy resistance.  
Results 
Stromal activation by breast cancer cell interaction is accompanied by an anti-viral 
response and stromal exosome transfer 
Previously, we demonstrated that breast cancer interaction with stromal fibroblasts 
increases the production of stromal exosomes. Upon transfer to breast cancer cells, the 
RNA in the exosomes (exoRNA) stimulates breast cancer RIG-I to initiate an anti-viral 
response that subsequently promotes resistance to radiation and chemotherapy. In this 
study, we sought to more closely examine similarities between this anti-viral response 
initiated by tumor and stromal cell interaction with how viruses instigate an anti-viral 
response that spreads from infected to uninfected cells. We first investigated major 
transcriptomic changes resulting from heterotypic interaction between MRC5 normal lung 
fibroblasts and ISG-R breast cancer cells, which induce ISGs upon co-culture with stromal 
cells132. This revealed that heterotypic cell interaction leads to stromal activation 
characterized by a transcriptional response dominated by upregulation (Figure 15A, left). 
Among these transcripts is an enrichment for hallmark gene sets134 for MYC and RAS 
oncogenic signaling, glycolysis, and cell cycle progression (Figure 15B, left). Stromal cells 
additionally induce multiple ISGs, and this was also observed in ISG-R breast cancer cells 
(Figure 15A). In fact, IFN signaling is among the predominant hallmark gene sets enriched 
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after co-culture in both cell types (Figure 15B). ISG-R breast cancer cells also show 
evidence for reciprocal RAS activation and enhanced expression of EMT genes expected 
to favor invasion, metastasis, and therapy resistance135. Thus, these data suggest that 
besides promoting aggressive features in breast cancer cells, heterotypic interaction leads 
to stromal activation events accompanied by a reciprocal anti-viral response. 
To examine if breast cancer interaction also mimics the ability of viruses to 
instigate exosome transfer, we labeled stromal cells with a stably expressed CD81-RFP 
exosome reporter (Figure 15C). This confirmed a high level of exosome transfer from 
stromal cells to 1833 ISG-R breast cancer cells, which is a metastatic derivative of MDA-
MB-231112. In contrast, co-culture of stromal cells with breast cancer cells that fail to induce 
ISGs, which we previously defined as ISG non-responders (ISG-NRs), show only modest 
transcriptomic changes in stromal cells, no stromal ISG induction (Figure 16A, left), and 
minimal exosome transfer to breast cancer cells (Figure 15C). Accordingly, no anti-viral 
response occurs in ISG-NR breast cancer cells after co-culture (Figure 16A, right). Thus, 
like viruses, ISG-R breast cancer cells not only can coerce an anti-viral response in 
stromal cells but can also promote exosome transfer to propagate anti-viral signaling. 
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Figure 15. Stromal cell activation and ISG induction occurs upon breast cancer cell 
interaction and results in stromal RNA transfer via exosomes. A) Gene expression of 
MRC5 fibroblasts (Stromal Cells) and ISG-R 1833 breast cancer cells (BrCa Cells) after 
co-culture versus mono-culture. Genes indicated in red are cancer-associated ISGs. 
Genes in blue are significantly upregulated either in stromal cells (left) or ISG-R breast 
cancer cells (right) after co-culture. B) Gene set analysis showing significantly enriched 
hallmark gene sets after co-culture versus mono-culture in fibroblasts and ISG-R breast 
cancer cells. Size of circles is proportional to number of genes, and circles are color-coded 
by FDR-adjusted p-value as indicated in the legend. Thickness of lines is proportional to 
genes shared between sets. Anti-viral response pathways (blue) and select stromal 
activation pathways (bold) are highlighted. C) MRC5 fibroblasts transduced with CD81-
RFP to track exosome transfer were co-cultured with CFSE-labeled ISG-R 1833 or ISG-
NR MCF7 breast cancer cells. Exosome transfer to breast cancer was quantified as 
percentage of breast cancer cells with RFP foci (right). D) Schema for measuring RNA 
transfer from stromal to breast cancer cells utilizing the uridine analog EU for fluorescence 
microscopy (green) or 4sU for streptavidin pull-down (orange). E) MRC5 fibroblasts were 
labeled with EU and co-cultured with DiD lipid-labeled 1833 breast cancer cells. Shown 
are representative images, with yellow arrows indicating EU-positive 1833 cells, and 
quantitation. F) Conditioned media (CM) from 4sU-labeled MRC5 fibroblasts grown in 
mono-culture (Stroma, orange) or co-cultured with 1833 breast cancer cells (Co-cx, blue) 
was isolated. Shown is relative 4sU RNA transfer to mono-cultured 1833 breast cancer 
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cells after addition of CM or exosome depleted CM (Co-cx Exo(-) CM) (n=5). Comparisons 
are made to DMSO control. G) Same as in (F) except CM was isolated from MRC5 or BJ 
4sU-labeled fibroblasts left in mono-culture or co-cultured with indicated ISG-R or ISG-NR 
breast cancer cells. Shown is relative 4sU RNA transfer after CM addition to each of the 
mono-cultured breast cancer cells (n=3). H) Allelic frequency of exoRNA SNPs from 
exosomes isolated from 1833 breast cancer (BrCa), MRC5 fibroblasts (Stroma), or from 
co-culture of both cell types (Co-cx). Analysis is based on SNPs present in exoRNA from 
breast cancer cells and not present in fibroblasts. Unless indicated, error bars are SEM of 
biological replicates and *p<0.05, **p<0.01, ***p<0.001. 
 
Stromal RNA is transferred to breast cancer cells by exosomes to mediate an anti-viral 
response 
After viral infection, viral RNA from infected cells can be packaged into exosomes 
for subsequent transfer to uninfected cells. To examine if RNA from stromal cells are 
similarly transferred to breast cancer cells by exosomes, we metabolically labeled MRC5 
stromal RNA with 5-ethynyl uridine (EU) prior to co-culture with ISG-R 1833 breast cancer 
cells that were fluorescently marked with lipid dye (Figure 15D). After 24 hours, over 40% 
of breast cancer cells acquired stromal cell RNA as measured by EU-modification by 
azide-linked fluorescein (Figure 15E). To assess the role of exosomes in this transfer, 
stromal cell RNA was similarly labeled with 4-thiouridine (4sU) prior to co-culture with 
breast cancer cells (Figure 15D and 16B). Application of the conditioned media (CM) from 
these co-cultures to mono-cultured breast cancer cells also resulted in stromal RNA 
transfer, as determined by streptavidin pull-down of biotinylated 4sU-labeled stromal RNA, 
but not when exosomes were depleted from the CM (Figure 15F). Exosome-mediated 
transfer of MRC5 stromal RNA was also observed using another ISG-R breast cancer cell 
line, MDA-MB-436, and from co-cultures using BJ fibroblast cells (Figure 15G). In contrast, 
markedly less stromal RNA was transferred by exosomes using CM from co-cultures with 
the ISG-NR breast cancer cell line MCF7 (Figure 15G).  
To corroborate the transfer of stromal RNA by exosomes, we also performed 
exoRNA SNP analysis using exosomes from mono-cultures of either ISG-R 1833 breast 
cancer cells or MRC5 stromal cells and compared SNP allelic frequencies to the exoRNA 
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from co-culture (Figure 15H). Multiple SNPs, primarily from mitochondrial RNA, were 
discovered to have an allelic frequency of near one in the exoRNA from breast cancer 
cells but near zero in stromal exoRNA. Examination of exoRNA from co-culture revealed 
that most of these SNPs maintained a frequency closer to zero, consistent with the 
exoRNA primarily originating from stromal cells. In total, these results suggest that similar 
to transfer of viral RNA from infected to uninfected cells, cellular RNAs are transferred 
from stromal to breast cancer cells in an exosome-dependent manner. 
 
Figure 16. ISG-NR breast cancer cells do not induce ISGs in stromal cells. A) Gene 
expression of MRC5 fibroblasts (Stromal Cells) and ISG-NR breast cancer cells (BrCa 
Cells) after co-culture versus mono-culture. Genes indicated in red are ISGs. Genes color-
coded blue are significantly upregulated in stromal cells after interaction with ISG-NR 
breast cancer cells. B) Percentage of 4sU-labeled RNA in indicated fibroblasts after 24 
hours compared to total RNA (n=3). Error bars are SEM of biological replicates. 
 
5’ triphosphate stromal exoRNA activates breast cancer RIG-I 
Classification of non-ribosomal exoRNA transcripts from stromal and breast 
cancer cell co-cultures reveals an enrichment in non-coding RNAs compared to cellular 
RNA (Figure 17A). These non-coding RNAs include repeat and transposable elements, 
snRNA, srpRNA, and others, but no viral RNAs were detected. Previously, we 
demonstrated that upon transfection this exoRNA activates the pattern recognition 
receptor RIG-I to induce ISGs in recipient breast cancer cells, and this activity requires a 
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5’ triphosphate (5’ppp) moiety. Thus, although the non-ribosomal portion of exoRNA 
demonstrates significant complexity, functional studies suggest that exoRNA ligands 
responsible for the breast cancer anti-viral response are 5’ppp exoRNA that binds to RIG-
I. To confirm this notion, we utilized CRISPR/Cas9 to knockout RIG-I in breast cancer cells 
and re-expressed either wild-type (WT) RIG-I or RIG-I with alanine substitution mutations 
in key lysine residues (K858 and K861) that make contacts with the 5’ppp motif (RIG-
IK858/861A)136 (Figure 18A-B). Co-culture-derived exosomes were purified (Figure 18C-D) 
and transfection of the exoRNA failed to induce ISGs in RIG-I KO breast cancer cells 
(Figure 17B). Re-expression of WT RIG-I rescued this defect whereas RIG-IK858/861A was 
markedly less effective at restoring activity. In contrast, cellular RNA failed to induce ISGs 
regardless of RIG-I status. Consistent with these findings, addition of exoRNA but not 
equimolar amounts of cellular RNA to recombinant RIG-I stimulates RIG-I ATP helicase 
activity as measured by ATP hydrolysis (Figure 17C). Thus, like the recognition of viral 
5’ppp RNA, these results provide evidence that 5’ppp exoRNA from stromal cells can 
directly activate RIG-I to induce an anti-viral response.  
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Figure 17. Stromal POL3-derived exoRNA activates breast cancer RIG-I in a 
5’triphosphate-dependent manner. A) Distribution of RNA classes found in cellular RNA 
and exosome RNA by RNA-seq after co-culture of 1833 breast cancer cells with MRC5 
stromal cells. Ribosomal RNA counts were removed. B) ISG expression after transfection 
of co-culture exoRNA or co-culture cellular RNA into 1833 control cells (WT), RIG-I 
knockout 1833 cells (KO), or RIG-I KO 1833 cells restored with either wild-type (KO + WT) 
or RIG-IK858/861A 5’ppp binding mutant (KO + MUT) (n=5). Baseline was established by 
mock transfection (see legend). C) ATP hydrolysis assay for RIG-I activation in response 
to increasing amounts of the indicated RNA. ExoRNA and cellular RNA are from co-culture 
of 1833 and MRC5 cells. 5’OH is a negative control and 5’ppp is a positive control (n=3). 
D) Immunoblot for RPC32 (POLR3G) and β-actin in sorted MRC5 fibroblasts after mono- 
or co-culture (top). Quantification of POLR3G protein expression relative to β-actin after 
co-culture (bottom). E) Expression of ISGs in sorted 1833 cells or F) RT-mediated cell 
death in 1833 cells after co-culture with MRC5 cells (CTL) or after siRNA knockdown of 
POLR3F in 1833 (BrCa), MRC5 (Stm), or both cell types (Co). Gene expression values 
are relative to sorted 1833 cells grown in mono-culture, and cell death was assessed 4 
days after 10 Gy RT (n=3). G) ISG expression in 1833 cells after addition of CM from 
DMSO or POL3 inhibitor (POL3i) treated co-cultures. Values are relative to 1833 cells 
grown in mono-culture (n=3). H) RT-mediated cell death of 1833 cells in mono-culture 
(Mono) or co-culture with MRC5 cells (Co-cx). Cells were grown in the presence of DMSO 
or POL3i and with (+CM) or without rescue using co-culture CM (n=3). I) ATP hydrolysis 
assay for RIG-I activation as shown in (C) except exoRNA from POL3i-treated co-cultures 
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was additionally assessed (n=3). J) Abundance (Log10) of RNA classes in 5’ppp-seq 
compared to exoRNA-seq. RNA classes depleted in 5’ppp-seq by approximately 10-fold 
or greater are shown on the left (n=4). K) Relative RNA polymerase III transcript levels in 
exosomes harvested from DMSO or POL3i-treated co-cultures (n=3). Unless indicated, 
error bars are SEM of biological replicates and *p<0.05, **p<0.01. 
 
Stromal RNA polymerase III generates 5’ppp exoRNA that activates the anti-viral 
response in breast cancer cells 
In the absence of viral infection, the main source of endogenous 5’ppp RNA is from 
RNA polymerase III (POL3) transcription59. Moreover, POL3 activity is known to be 
augmented by MYC activation137, which appeared specifically enhanced in stromal cells 
after ISG-R breast cancer cell interaction (Figure 15B, left). Therefore, we sought to 
examine if stromal POL3 generates the exoRNA that is transferred to breast cancer cells 
to activate anti-viral signaling. Indeed, the POL3 subunit POLR3G was upregulated in 
stromal cells after co-culture with breast cancer cells (Figure 17D and 18E). Knockdown 
of POL3 using an siRNA to the POLR3F subunit (Figure 18F) revealed that inhibiting POL3 
in stromal cells, but not breast cancer cells alone, significantly blunted breast cancer ISG 
induction (Figure 17E). Interrogation of functional consequences revealed that the ability 
of stromal cells to protect breast cancer cells after radiation was impaired with stromal 
POL3 knockdown, but unchanged after breast cancer POL3 knockdown (Figure 17F). 
Consistent with these findings, treatment with a POL3 small-molecule inhibitor138 also 
blunted stroma-mediated resistance and ISG induction in breast cancer cells after co-
culture (Figure 18G-H). To confirm that exoRNA is responsible for the effects resulting 
from inhibiting stromal POL3 RNA, we isolated CM from co-cultures treated with or without 
the POL3 inhibitor. CM isolated from co-cultures both induced ISGs when added to mono-
cultured breast cancer cells (Figure 17G) and re-established stroma-mediated radiation 
resistance that was abrogated by POL3 inhibition (Figure 17H). In contrast, CM from co-
cultures treated with POL3 inhibitor failed to induce ISGs, but expression of unrelated 
genes such as IFI16 was not affected (Figure 17G-H). Accordingly, exoRNA from POL3 
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inhibitor treated co-cultures also was defective in binding to recombinant RIG-I and 
stimulating ATP hydrolysis activity (Figure 17I). Thus, these results suggest that stromal 
POL3 generates exoRNA that activates breast cancer RIG-I to induce anti-viral signaling 
and stroma-mediated protection against DNA damage. 
To characterize the exoRNA generated by stromal POL3, we developed an 
approach to identify 5’ppp RNA by sequencing. For this, we utilized a set of enzymatic 
reactions to sequentially modify the 5’ end of RNA prior to library construction to deplete 
RNA lacking a 5’ppp modification (5’ppp-seq) (Figure 18I). Many coding and non-coding 
RNAs were depleted by approximately 10-fold or greater, consistent with the absence of 
a 5’ppp (Figure 17J, left). Examination of RNA classes that maintained or increased 
abundance revealed many exoRNA transcripts known to be under POL3 regulation, 
including tRNAs, srpRNA, Y RNA/snRNAs, and ALU/SINE RNAs (Figure 17J, right). As 
expected, inhibiting POL3 resulted in a decrease in the abundance of several of these 
5’ppp RNA in exosomes (Figure 17K). Thus, multiple 5’ppp exoRNAs regulated by stromal 
POL3 are present in exosomes and represent candidate RNA ligands for propagating an 
anti-viral response from stromal cells to breast cancer cells. 
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Figure 18. Stromal POL3 is required for maximal ISG induction in breast cancer 
cells. A) Immunoblot confirmation of Cas9 control (WT), RIG-I knockout (KO), and RIG-I 
KO 1833 cells restored with either wild-type (KO + WT) or RIG-IK858/861A 5’ppp binding 
mutant (KO + MUT). B) Immunoblot confirmation of RIG-I KO in ISG-R 1833 breast cancer 
cell line. RIG-I pathway activation was stimulated by Sendai virus (SeV) and assessed by 
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ISG15 induction. C) Nanosight quantification of size and quantity of a representative 
exosome purification. D) Purified exosome confirmation by electron microscopy negative 
staining. E) Gene expression of sorted MRC5 fibroblast RNA polymerase III subunit 
POLR3G after co-culture with ISG-R 1833 breast cancer. Values are relative to sorted 
MRC5 cells grown in mono-culture (n=3). F) Gene expression after indicated siRNA 
transfected in MRC5 cells (n=3). G) RT-mediated cell death in 1833 cells in mono-culture 
(Mono) or co-culture with MRC5 cells (Co-cx). Cells were grown in the presence of DMSO 
or POL3 inhibitor (Pol3i), and cell death was assessed 4 days after 10 Gy RT (n=3). H) 
ISG expression in sorted 1833 after co-culture with MRC5 cells in the presence of DMSO 
or POL3i. Gene expression values are relative to sorted 1833 cells grown in mono-culture 
(n=7). I) Schema for 5’triphosphate enriched RNA-seq (5’ppp-seq). Unless indicated, error 
bars are SEM of biological replicates and **p<0.01, ***p<0.001. 
 
RN7SL1 5’ppp exoRNA generated from tumor-stromal interaction demonstrates extensive 
protein unshielding 
As part of a strategy to identify a specific 5’ppp exoRNA from stromal cells that 
activates breast cancer RIG-I, we sought to examine differences in 5’ppp exoRNA 
abundance that correlate with differences in the ability of exosomes to induce anti-viral 
signaling. Toward this end, we took advantage of the observation that exosomes from co-
culture, but not stromal cell mono-culture, induce ISGs (Figure 19A). Because 5’ppp-seq 
may not be quantitative, we first performed RNA-seq from exosomes (exoRNA-seq) 
isolated from co-culture versus stromal mono-culture. Using these data, we specifically 
examined transcripts that were also identified by 5’ppp-seq. This revealed that most 5’ppp 
exoRNA does not or only modestly varies in abundance in exosomes from co-culture 
compared to stromal mono-culture (Figure 19B). In contrast, RN7SL1, or srpRNA, and 
RN7SL1 pseudo-genes stood out as abundant transcripts that markedly increase in 
exosomes from co-culture compared to stromal mono-culture (Figure 19B-C and 20A, 
Table 5). Accordingly, exoRNA derived from stromal mono-culture was less effective than 
co-culture exoRNA at eliciting an ISG response in breast cancer cells (Figure 20B). 
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Figure 19. 5’ppp RN7SL1 exoRNA generated by tumor-stromal interaction is 
unshielded. A) ISG expression in 1833 breast cancer cells after addition of exosomes 
from MRC5 stromal cell mono-culture (Strm) or co-culture of 1833 and MRC5 cells (Co-
cx) (n=3). Values are relative to mock control. B) ExoRNA and 5’ppp exoRNA enriched in 
co-culture exosomes. Shown is average expression (Log2) by exoRNA-seq in co-culture 
versus fold-change in co-culture compared to MRC5 stromal cell mono-culture (n=2). 
Transcripts identified by 5’ppp-seq are shown in red. ExoRNA was rRNA-depleted. C) 
Differentially expressed exoRNA from MRC5 mono-culture (Stroma) compared to co-
culture of 1833 and MRC5 cells (Co-cx) (n=2). D) Expression of co-culture cellular RNA 
(left) or co-culture exoRNA (right) versus degree of RNA binding protein (RBP) 
unshielding. RBP unshielding (y-axis) is determined by fold change in RNA expression 
after MNase treatment with or without detergent (n=2). Smaller y-axis values indicate more 
unshielding. Transcripts identified by 5’ppp-seq are denoted by solid circles and color-
coded based on normalized minimum free energy (MFE) to predict extent of double 
stranded RNA folding (lower MFE indicates more extensive double-stranded folding). E) 
Extent of RBP-shielding of 5’ppp RN7SL1 in cells (Cellular RNA) or exosomes (ExoRNA) 
isolated from either MRC5 stromal mono-culture (Strm) or co-culture of 1833 and MRC5 
cells (Co-cx). Proportion shielded is determined by MNase treatment with and without 
detergent followed by qRT-PCR (MNase-qRT-PCR) (n=3). Also shown are other RNAs 
with the indicated 5’ modification. F) Extent of RBP-shielding for cellular RNA (Cell) or 
exoRNA (Exo) isolated from co-cultures of the indicated ISG-R and ISG-NR breast cancer 
cells (labeled on right) with MRC5 fibroblasts. Proportion shielded is determined by 
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MNase-qRT-PCR (n=3). Unless indicated, error bars are SEM of biological replicates and 
*p<0.05, **p<0.01, ***p<0.001.  
 
Although high levels of RN7SL1 in co-culture exosomes appeared to be a 
candidate RIG-I ligand based on differential expression, it was unclear why the presence 
of this 5’ppp RNA in the cytoplasm or in exosomes produced by stromal mono-culture 
would not activate RIG-I. Moreover, RN7SL1 and possibly other 5’ppp exoRNAs contain 
extensive double-stranded regions, an important feature given that RIG-I efficiently 
recognizes dsRNA. Based on these considerations, we reasoned that alterations in 
binding by RNA binding proteins (RBPs) might influence the ability of endogenous RNA 
to activate anti-viral signaling. To examine this, we treated cells or exosomes with 
micrococcal nuclease (MNase) with or without membrane permeabilization prior to 
sequencing (MNase-seq) (Figure 20C). This revealed that exoRNAs are generally less 
susceptible to MNase-dependent degradation compared to cellular RNAs, suggesting that 
exoRNA is relatively more “shielded” by RBPs than their cellular counterparts (Figure 
19D). However, examination of 5’ppp RNA shielding combined with predicted RNA 
secondary structure as measured by normalized minimum free energy (MFE), 
demonstrated that RN7SL1 stands out as a 5’ppp exoRNA with extensive double-stranded 
structure (low MFE) that is extensively shielded in cells but highly unshielded in co-culture 
exosomes (Figure 19D and 20D, Table 5). In contrast, most other 5’ppp exoRNA has less 
predicted double-stranded structure and/or is significantly more shielded in exosomes 
compared to RN7SL1. Other 5’ppp RNA or RNA without a 5’ppp (i.e., 5’ cap mRNA and 
5’-monophosphate rRNA) generally are equally unshielded in cells and exosomes (Figure 
19D and 20D), while RN7SL1 exoRNA from stromal mono-culture shows comparable 
shielding compared to cells (Figure 19E). Unshielding of RN7SL1 exoRNA was also 
observed when other ISG-R breast cancer cells and stromal fibroblasts were co-cultured 
(Figure 19F), and when primary mouse lung fibroblasts were co-cultured with 
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K14cre;p53F/F;Brca1F/F murine breast cancer cells that also have hallmarks of ISG-R 
breast cancers (Figure 20E-H). In contrast, exosomes from co-culture of MCF7 ISG-NR 
breast cancer cells with stromal cells demonstrated significantly less unshielding (Figure 
19F). This, along with diminished exosome transfer (Figure 15C), correlates with the 
relative inability of ISG-NR breast cancer cells to induce anti-viral signaling after co-
culture. In total, these results suggest that after interaction with ISG-R breast cancer, 
stromal cells selectively deploy unshielded RN7SL1 in exosomes, an endogenous 5’ppp 
RNA with double-stranded structure.  
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Table 5: Differential Expression of 5'ppp-seq Identified Transcripts in Co-cx 
ExoRNA-seq vs. Stroma ExoRNA-seq 
GeneID Symbol log2FoldChange pvalue 
ENSG00000278771   6.36343356 3.40E-32 
RN7SL1 RN7SL1 5.954339049 0 
ENSG00000274012   5.766305089 4.26E-58 
ENSG00000274585 RNU2-1 1.473067514 0.000256183 
ENSG00000210194 MT-TE 0.788711237 0.445398803 
ENSG00000210107 MT-TQ 0.567573134 0.581029076 
ENSG00000200090   0.238632644 0.816585329 
ENSG00000198695 MT-ND6 -0.050443096 0.942091596 
RMSK1848423 tRNA-Val-GTY -0.289504941 0.781427256 
RMSK4489775 tRNA-Leu-CTA -0.399615749 0.675564238 
RMSK2896852 tRNA-Gly-GGA -0.451640769 0.661698379 
RMSK4094422 HY3 -0.543342632 0.626965648 
RMSK1903167 tRNA-Leu-TTG -0.647165683 0.399143989 
RMSK0284494 tRNA-Glu-GAG_ -0.711842908 0.133137812 
ENSG00000252316 RNY4 -0.713159963 0.014826978 
RMSK1848200 tRNA-Leu-CTY -0.75997998 0.45907332 
RMSK1898352 tRNA-Lys-AAG -0.786930354 0.235743198 
ENSG00000202354 RNY3 -0.788798711 0.019543371 
RMSK1900244 tRNA-Asp-GAY -0.844448884 0.0020408 
ENSG00000201098 RNY1 -0.904999318 0.000490539 
RMSK0444065 tRNA-Glu-GAG_ -0.907348767 0.002631367 
RMSK3874632 tRNA-Asp-GAY -0.960878858 0.003912964 
ENSG00000197958 RPL12 -0.99099727 0.246632743 
RMSK3556856 tRNA-Val-GTA -1.065156761 0.008702102 
RMSK1900901 tRNA-Val-GTY -1.077724916 0.323350684 
RMSK4003721 tRNA-Glu-GAG_ -1.078693607 0.202938517 
RMSK2406652 HY5 -1.081991716 0.016164226 
RMSK0254000 tRNA-Glu-GAG_ -1.138725411 0.071260176 
RMSK4629380 tRNA-Lys-AAA -1.153250435 0.216004512 
RMSK4442186 tRNA-Lys-AAG -1.254216659 0.002243703 
RMSK1899770 tRNA-Val-GTG -1.260921498 0.0174855 
RMSK0284470 tRNA-Leu-CTG -1.27201565 0.23295901 
RMSK2705056 tRNA-His-CAY_ -1.377096393 0.176061556 
RMSK5186324 tRNA-Gly-GGY -1.787469268 0.06272545 
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Figure 20. RN7SL1 is unshielded after tumor-stromal interaction. A) Relative 
expression of transcripts identified by 5’ppp-seq in exosomes from MRC5 mono-culture 
(Stroma) or MRC5 and 1833 co-culture (Co-cx). Values are relative to exoRNA from 
MRC5 mono-culture (n=3). B) ISG expression in 1833 cells after transfection of exoRNA 
or cellular RNA from MRC5 mono-culture (Strm) or co-culture of 1833 and MRC5 cells 
(Co-cx) (n=3). Values are relative to mock transfection. C) Schema for MNase-seq or 
MNase-qRT-PCR to analyze degree of RNA binding protein (RBP) shielding. D) Extent of 
RBP-shielding of 5’ppp RN7SL1 in cells (Cell) or exosomes (Exo) isolated from co-culture 
of 1833 and MRC5 cells. Proportion shielded is determined by MNase treatment with and 
without detergent followed by qRT-PCR (MNase-qRT-PCR) (n=3). Also shown are other 
RNAs with the indicated 5’ modification. E) Exosome transfer to ISG-R 
K14cre;p53F/F;Brca1F/F (KB1P) mouse breast cancer cells by differential lipid labeling of 
two populations of KB1P cells (Mono) or co-culture with primary mouse adult lung 
fibroblasts (ALFs) (Co-cx) (n=3). F) ISG expression in sorted ISG-R KB1P cells after co-
culture with ALFs. Gene expression values are relative to sorted KB1P cells grown in 
mono-culture (n=3). G) RT-mediated cell death in KB1P cells in mono-culture (Mono) or 
co-culture with ALFs (Co-cx). Cell death was assessed 4 days after 10 Gy RT (n=3). H) 
Extent of RBP-shielding of cellular RNA (Cell) or exoRNA (Exo) isolated from co-culture 
of KB1P cells and ALFs. Proportion shielded is determined by MNase-qRT-PCR (n=3). 
Unless indicated, error bars are SEM of biological replicates and *p<0.05, **p<0.01, 
***p<0.001. 
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Unshielded RN7SL1 exoRNA is transferred by stromal cells and stimulates breast cancer 
RIG-I 
To establish that unshielded RN7SL1 exoRNA generated by stromal cells can 
serve as a RIG-I ligand, we metabolically labeled stromal cell RNA with 4sU and assayed 
for transfer to breast cancer cells. This demonstrated that RN7SL1, but not other 5’ppp 
exoRNAs or exoRNA without 5’ppp, is transferred to breast cancer cells from multiple 
different stromal cells but only in the context of ISG-R breast cancer cell co-culture (Figure 
21A). Moreover, like exoRNA but not cellular RNA, transfection of ribozyme-cleaved in 
vitro transcribed RN7SL1 induces ISGs in breast cancer cells specifically in a RIG-I-
dependent manner (Figure 21B). As expected, the ability of RN7SL1 to stimulate RIG-I 
requires 5’ppp. Alkaline phosphatase treatment prior to transfection abolished ISG 
induction (Figure 22), and reconstitution of RIG-I KO cells with WT RIG-I but not RIG-
IK858/861A, which abolishes amino acid interactions with 5’ppp, restored anti-viral signaling 
after RN7SL1 transfection (Figure 21B). In vitro RIG-I ATP hydrolysis assay confirmed 
that RN7SL1, but not equimolar and a similarly sized GAPDH-derived RNA (GAPDH300), 
directly binds recombinant RIG-I (Figure 21C). Activation of recombinant RIG-I by RN7SL1 
was comparable to an equimolar amount of Sendai virus-derived RNA (DVG396). Thus, 
RN7SL1 is transferred from stromal cells to ISG-R breast cancer and can directly activate 
RIG-I. 
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Figure 21. Unshielded RN7SL1 exoRNA is transferred by stromal cells and 
recognized by breast cancer RIG-I. A) Conditioned media (CM) from 4sU-labeled MRC5 
fibroblasts co-cultured with either ISG-R (orange) or ISG-NR (blue) breast cancer cells. 
Shown is relative 4sU RNA transfer to breast cancer cells in mono-culture after addition 
of CM (n=3). B) ISG expression in 1833 breast cancer cells after transfection of co-culture 
exoRNA, cellular RNA, or RN7SL1 RNA.  RIG-I status of 1833 cells was wild type (WT), 
knocked out (KO), or knocked out and restored with either wild-type RIG-I (KO + WT) or 
RIG-IK858/861A (KO + MUT) (n=3). Values are relative to mock control. C) ATP hydrolysis 
assay for RIG-I activation by RN7SL1. Shown are increasing concentrations of RN7SL1 
or the indicated RNA ligands. 5’ppp and DVG396 are positive controls. 5’OH and 
GAPDH300 are negative controls (n=3). D) Schema to measure 4sU-labeled stromal RNA 
bound to breast cancer RIG-I after co-culture (Cell, top schema) or after addition of co-
culture conditioned media (CM bottom schema). E) Representative immunoprecipitation 
of FLAG-RIG-I, and F) quantitation of indicated 4sU-labeled MRC5 stromal RNA 
transferred and then bound to 1833 breast cancer RIG-I. Shown is relative binding to 
reconstituted wild type RIG-I (KO + WT, blue) or RIG-IK858/861A (KO + MUT, orange) after 
co-culture (Cell) or addition of co-culture CM (CM). Binding of 5’cap mRNAs are shown 
on the left and 5’ppp RNAs on the right (n=3). Unless indicated, error bars are SEM of 
biological replicates and *p<0.05, **p<0.01.  
 
To directly examine whether stromal RN7SL1 is transferred by exosomes and 
binds to breast cancer RIG-I, stromal cells were labeled with 4sU prior to co-culture with 
breast cancer cells. This was followed by tandem pull-down of stromal RNA bound to 
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breast cancer RIG-I by first immunoprecipitating FLAG-tagged breast cancer RIG-I and 
then isolating biotinylated 4sU-labeled stromal RNA with streptavidin beads (Figure 21D, 
top; Figure 21E). This sequential procedure revealed that stromal-derived RN7SL1, but 
not RNA without 5’ppp (i.e., capped mRNAs), specifically bound to WT RIG-I compared 
to RIG-IK858/861A (Figure 21F, top row). Moreover, other 5’ppp RNA found in exosomes such 
as RMRP showed markedly less binding. To assess if this transfer of stromal RN7SL1 is 
mediated by exosomes, CM isolated from 4sU-labeled stromal cells co-cultured with 
breast cancer cells was added to breast cancer cell mono-cultures (Figure 21D, bottom). 
Again, tandem pull-down demonstrated that stromal-derived RN7SL1, but not capped 
RNAs or RMRP 5’ppp RNA, specifically bound to breast cancer RIG-I when compared to 
RIG-IK858/861A, consistent with exosome-mediated transfer (Figure 21F, bottom row). Thus, 
after breast cancer interaction, stromal cells can transfer unshielded RN7SL1 in exosomes 
to directly activate RIG-I. These results suggest that similar to how viral RNA in exosomes 
can propagate an anti-viral response from infected to uninfected cells, stromal cells can 
disseminate an anti-viral response to breast cancer cells by deploying unshielded 
endogenous RN7SL1 in exosomes. 
 
Figure 22. RN7SL1 activity is 5’ppp dependent. ISG expression in 1833 breast cancer 
cells after transfection of in vitro transcribed RN7SL1 RNA or RN7SL1 RNA treated with 
alkaline phosphatase (+AlkPh) (n=3). TSG101 is a non-ISG not expected to change. 
Values are relative to mock control. Error bars are SEM of biological replicates and 
*p<0.05, **p<0.01. 
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SRP9 and SRP14 control RN7SL1 shielding and anti-viral stimulatory activity 
RN7SL1 is an abundant cellular RNA that complexes with signal recognition 
particle (SRP) proteins to control co-translational protein translocation139. Two SRP 
proteins, SRP9 and SRP14 normally bind the 5’ end of RN7SL1, potentially obscuring the 
5’ppp. Thus, to investigate whether SRP9 and/or SRP14 might influence recognition of 
RN7SL1 by RIG-I through RBP shielding, we examined the expression of SRP9/14 in 
exosomes. In contrast to cellular extracts, which showed relatively high levels of SRP9 
and SRP14, these proteins were not detectable in exosomes (Figure 23A). Therefore, we 
transiently overexpressed GFP-tagged SRP9 and SRP14 in stromal cells prior to co-
culture to determine if this could drive these SRP proteins into exosomes and potentially 
partially shield exosome RN7SL1 from recognition by breast cancer RIG-I (Figure 23B 
and 24A-C). Indeed, transiently increasing SRP9 and SRP14 in stromal cells was 
sufficient to direct expression of both tagged SRP proteins into exosomes (Figure 23C). 
This led to a significant increase in shielding of RN7SL1 exoRNA but not in 18S rRNA 
(Figure 23D). Consequently, stroma-mediated ISG induction in breast cancer cells was 
reduced, while expression of non-ISGs such as MMP1 and TSG101 was not affected 
(Figure 23E). We were also able to purify recombinant SRP9 (attempts to purify SRP14 
were not successful). Addition of SRP9 to in vitro transcribed RN7SL1 partially inhibited 
ATP hydrolysis by recombinant RIG-I but did not influence Sendai virus-derived RNA 
(DVG396) or unrelated 5’ppp or 5’OH control RNAs (Figure 23F). These results suggest 
that RBP shielding of cellular RN7SL1 by its SRP proteins may restrict inappropriate 
recognition by RIG-I in the cytoplasm. However, the absence of these RBPs in exosomes 
allows the transfer of unshielded RN7SL1 to neighboring cells, resulting in RIG-I 
activation. Thus, in a sterile tumor microenvironment, differential RBP shielding in cells 
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versus exosomes can enable endogenous RNAs to function as DAMPs and propagate 
anti-viral signaling. 
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Figure 23. Stromal SRP9 and SRP14 regulate RN7SL1 shielding and activation of 
breast cancer RIG-I. A) Immunoblot for the indicated proteins in co-culture cells and 
exosomes. Lysates used were normalized to absolute levels of RN7SL1 RNA. B) Flow 
cytometry (left) and fluorescence microscopy (right) for GFP expression after transfection 
of GFP-SRP9 and GFP-SRP14 in MRC5 fibroblasts. C) Immunoblot for the indicated 
proteins in co-culture cells and exosomes after GFP-SRP9 and GFP-SRP14 transfection 
in MRC5 fibroblasts. D) Extent of RBP-shielding for the indicated exoRNAs isolated from 
1833 breast cancer cells co-cultured with control (CTRL) or GFP-SRP9 and GFP-SRP14 
(SRP) transfected MRC5 fibroblasts. Proportion shielded is determined by MNase-qRT-
PCR (n=3). E) Relative expression of ISGs in sorted 1833 cells after co-culture with MRC5 
cells transfected with GFP-SRP9 and GFP-SRP14 (n=3). TSG101 and MMP1 are non-
ISGs not expected to change. F) Immunoblot for SRP9 pre-cleavage (lane 2) and post-
cleavage (lane 1) of the GST tag with TEV protease. RN7SL1 binding to RIG-I was 
measured by ATP hydrolysis assay with or without addition of equimolar amounts of 
recombinant SRP9 (n=3). 5’ppp and DVG396 are positive controls. 5’OH is a negative 
control. Unless indicated, error bars are SEM of biological replicates and *p<0.05, 
**p<0.01.  
 
 
Figure 24. Confirmation of SRP9/14 overexpression in stromal cells. Immunoblot for 
A) SRP9, B) SRP14, or C) GFP after transfection of GFP-SRP9 and GFP-SRP14 in MRC5 
fibroblasts. 
 
RN7SL1 unshielding is regulated by RNA-protein imbalance 
SRP9 and SRP14 regulate RN7SL1 shielding; therefore, we hypothesized that 
excess RN7SL1 RNA produced after tumor-stroma interaction may result in unshielded 
stromal RN7SL1. To examine if increased stromal POL3 activity after co-culture resulted 
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in increased RN7SL1, we isolated stromal cells from co-culture and analyzed relative RNA 
expression. As expected, stromal cells in co-culture with ISG-R breast cancer cells had 
elevated ISGs and increased levels of several POL3 transcripts, including RN7SL1 (Figure 
25A). Further, protein isolated from the same co-cultures showed no concomitant increase 
in stromal SRP9 or SRP14, suggesting that increase of RN7SL1 without simultaneous 
increase of SRP proteins could lead to unshielded RN7SL1 (Figure 25B). To assess if the 
converse was true, we utilized siRNA to knockdown SRP9 and SRP14 levels in stromal 
cells (Figure 25C). This lead to a specific ISG induction stromal cells with siSRP9/14 
(Figure 25C/D). To interrogate whether this knockdown resulted in the production of 
exosomes with unshielded RN7SL1 and ISG stimulatory activity, we added conditioned 
media from these stromal cells to breast cancer cells. Conditioned media isolated from 
siSRP9/14 stromal cells induced ISGs in recipient breast cancer cells (Figure 25E). 
Exosomes isolated from these same co-cultures were subjected to RN7SL1 unshielding 
assays and consistent with having lower levels of SRP9 and SRP14, both cellular and 
exosomal RN7SL1 were largely unshielded (Figure 25F). In total, unshielding of RN7SL1 
and its ability to propogate anti-viral signals results from a RNA to protein imbalance. 
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Figure 25. RN7SL1 unshielding is regulated by RNA-protein imbalance. A) Gene 
expression of MRC5 fibroblasts after co-culture with indicated ISG-R or ISG-NR breast 
cancer cells. Values are relative to sorted mono-culture MRC5 fibroblasts and TSG101 is 
a non-ISG not expected to change (n=3). B) Immunoblot for the indicated proteins in 
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MRC5 fibroblasts after co-culture. C) Immunoblot for the indicated proteins in MRC5 
fibroblasts after the indicated siRNA knockdown. D) Gene expression in MRC5 fibroblasts 
after the indicated siRNA knockdown (n=3). E) Gene expression in 1833 breast cancer 
cells after addition of conditioned media isolated from MRC5 fibroblasts with the indicated 
siRNA knockdown. TSG101 is a non-ISG not expected to change (n=3). F) Extent of RBP-
shielding for the indicated cellular and exosomal RNAs isolated from MRC5 fibroblasts 
after the indicated siRNA knockdown. Proportion shielded is determined by MNase-qRT-
PCR (n=3). Error bars are SEM of biological replicates and *p<0.05. 
 
MYC is responsible for POL3 output and subsequent RN7SL1 unshielding. 
The POL3 transcriptional machinery relies heavily on MYC for maximal 
activity137,140. Furthermore, it is hypothesized that areas of high POL2 transcriptional 
output, such as those under MYC control, result in concomitant POL3 output by providing 
an epigenetically favorable environment141. To assess if MYC is activated in stromal cells 
after interaction with breast cancer cells we co-cultured fibroblasts with GFP-tagged ISG-
R breast cancer cells. MYC activation as assessed by nuclear localization demonstrated 
that upon co-culture MYC is activated in a significant percentage of stromal cells; whereas, 
there is almost no activation in mono-culture (Figure 26A/B). To assess if RN7SL1 
unshielding and ISG stimulating capacity was MYC dependent, we utilized siRNA against 
MYC (Figure 26C). Addition of conditioned media isolated from co-cultures of ISG-R 
breast cancer cells and stromal cells with stroma-specific siRNA knockdown of MYC was 
no longer able to stimulate ISGs in recipient breast cancer cells to the same degree as 
those with a control siRNA (Figure 26D). Further, exosomes isolated from these 
experiments demonstrated a significant increase in RN7SL1 shielding after siRNA 
knockdown of MYC in fibroblasts prior to co-culture (Figure 26E). To assess if activation 
of MYC alone can result in production of ISG stimulating exosomes containing unshielded 
RN7SL1, we utilized mouse embryonic fibroblasts stably expressing a MYC-ER construct 
that allows for 4OHT-inducible activation of MYC (MYC-ER MEFs)142. Addition of 4OHT 
results in robust MYC expression and nuclear localization (Figure 26F). Further, 
exosomes isolated from MYC-ER MEFs after the addition of 4OHT induce ISGs in 
87 
 
recipient breast cancer cells (Figure 26G). Addition of 4OHT results in a significant 
increase in unshielded RN7SL1 in exosomes, whereas exosomes isolated from ethanol 
treated MEFs have significantly more shielded RN7SL1 (Figure 26H). To evaluate if these 
MYC-dependent changes were also POL3 dependent, MYC was activated in the presence 
of a POL3 inhibitor. Addition of a POL3 inhibitor to MYC activated MEFs reduced the ISG 
inducing capacity of equal amounts of exosomes added to recipient breast cancer cells 
(Figure 26I). As expected, RN7SL1 in exosomes isolated from MYC activated MEFs 
cultured with a POL3 inhibitor remained largely shielded (Figure 26J). Thus, MYC is both 
necessary and sufficient to enhance POL3 transcriptional output and produce unshielded 
RN7SL1 to function an anti-viral signal propagating DAMP.   
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Figure 26. MYC regulates POL3 activity and RN7SL1 output. A) MRC5 fibroblasts 
were co-cultured with GFP-tagged ISG-R breast cancer cells. Stromal MYC activation is 
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denoted by strong nuclear staining and absence of GFP signal and designated by the 
yellow arrows. B) Quantification of MYC activation in breast cancer and stromal cells 
before or after co-culture (n=3). C) Immunoblot for the indicated proteins after the indicated 
siRNA knockdown in MRC5 fibroblasts. D) ISG expression after addition of co-culture 
conditioned media with MRC5 fibroblasts harboring the indicated siRNA knockdown. 
TSG101 is a non-ISG not expected to change (n=3). E) Extent of RBP-shielding for the 
indicated exosomal RNAs isolated from co-cultures with MRC5 fibroblasts harboring the 
indicated siRNA knockdown. Proportion shielded is determined by MNase-qRT-PCR 
(n=3). F) MYC expression and localization in MYC-ER MEFs after treatment with 4OHT 
or vehicle control (ethanol). G) ISG expression in recipient breast cancer cells after the 
addition of purified exosomes from MYC-ER MEFs with or without 4OHT activation. 
TSG101 is a non-ISG not expected to change (n=3). H) Extent of RBP-shielding for the 
indicated exosomal RNAs isolated from MYC-ER MEFs after 4OHT activation. Proportion 
shielded is determined by MNase-qRT-PCR (n=3). I) ISG expression in recipient breast 
cancer cells after exosomes from 4OHT-activated MYC-ER MEFs with or without Pol3i 
were added. TSG101 is a non-ISG not expected to change (n=3). J) Extent of RBP-
shielding for the indicated exosomal RNAs isolated from MYC-ER MEFs after 4OHT 
activation with or without Pol3i. Proportion shielded is determined by MNase-qRT-PCR 
(n=3).   Error bars are SEM of biological replicates and *p<0.05.    
 
NOTCH1 regulates stromal MYC expression and activation 
Cell-cell contact is required for stromal activation mediated by ISG-R breast cancer 
cells132. Therefore, we interrogated a known cell-cell contact-dependent regulator of MYC 
signaling, the Notch pathway. NOTCH1 is a strong transcriptional regulator of MYC 
expression in various cancers143. Interestingly, we found that NOTCH1 is specifically 
activated by release of its Notch intracellular domain (NICD1) in stromal cells after co-
culture with ISG-R breast cancer cells, while NOTCH2-4 did not change in their expression 
or activation (Figure 27A). Moreover, this activation was γ-secretase dependent as 
treatment with a γ-secretase inhibitor (GSI) completed abrogated this activation (Figure 
27A). To assess NOTCH1 activation in human cancers, we utilized a panel of cancer-
associated fibroblasts (CAFs) isolated from breast cancer patients. We termed CAFs with 
the ability to induce ISGs in breast cancer cells ‘ISG-inducers’ (ISG-I), and those that could 
not induce ISGs in breast cancer cells ‘ISG-noninducers’ (ISG-NI). We find that ISG-I 
breast cancer cells induce NOTCH1 activation (Figure 27B). Moreover, treatment with a 
GSI to block NOTCH1 activity in co-culture significantly reduces stromal MYC expression 
90 
 
and activation (Figure 27C/D). To evaluate the role of these signaling pathways in breast 
cancer patients we interrogated breast cancer and stromal gene expression patterns in 28 
paired primary tumor and stroma samples that were separated by laser-capture 
microdissection (LCMD). Strikingly, those patients with highest breast cancer ISG 
signature expression also had highest stromal ISG signature expression, MYC signature 
expression, and NOTCH signature expression (Figure 27E). ISG signature expression in 
both cell types were highly correlated (Figure 27F, left). Stromal NOTCH and MYC 
signaling were highly correlated, suggesting their co-regulation (Figure 27F, middle). As 
expected based on our results, expression of the stromal MYC signature was highly 
correlated with expression of the breast cancer ISG signature (Figure 27F, right). Thus, 
our results suggest that stromal MYC activation in co-culture and cancer patients in 
NOTCH1 dependent.  
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Figure 27. Heterotypic tumor-stroma interaction induces stromal NOTCH1 and 
subsequent MYC expression and activation. A) Immunoblot of the indicated proteins 
in MRC5 fibroblasts or 1833 ISG-R breast cancer cells before or after co-culture and with 
or without GSI. B) GFP-tagged 1833 ISG-R breast cancer cells were co-cultured with ISG-
I or ISG-NI CAFs and NOTCH1 activation was denoted by increased NICD1 nuclear and 
cytoplasmic signal and designated by the yellow arrows. C) MRC5 fibroblasts were co-
cultured with GFP-tagged ISG-R breast cancer cells with or without GSI treatment. 
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Stromal MYC activation is denoted by strong nuclear staining and absence of GFP signal 
and designated by the yellow arrows. D) Quantification of MYC activation in breast cancer 
and stromal cells before or after co-culture (n=3). E) Expression of a ISG signature, 
NOTCH signature, or MYC signature primary tumor and stroma samples that were 
separated by laser-capture microdissection. F) Correlation of these signatures in patients 
from the same data set. Error bars are SEM of biological replicates and *p<0.05.    
 
Unshielded stromal RN7SL1 exoRNA promotes breast cancer progression and is present 
in the serum of cancer patients 
A cardinal feature of stromal fibroblasts in the tumor microenvironment is the ability 
to promote cancer progression and metastasis. Indeed, the ability of stromal cells to 
induce anti-viral signaling in breast cancer contributes to metastasis43 and/or the 
expansion of tumor-initiating cells132, which would be expected to favor breast cancer 
progression. To examine whether unshielded RN7SL1 in exosomes can contribute to 
tumor growth, we isolated exosomes from co-culture and from stromal mono-culture and 
performed direct intratumoral injections into subcutaneous 1833 ISG-R breast cancer 
xenografts. Consistent with having higher levels of unshielded RN7SL1, exosomes from 
co-culture accelerated tumor growth compared to exosomes isolated from stromal cells 
alone (Figure 28A). To directly assess if unshielded RN7SL1 can enhance tumor 
progression, RN7SL1 or GAPDH300 control RNA was encapsulated into liposomes and 
similarly delivered intratumorally. Only RN7SL1 could enhance tumor growth in a RIG-I-
dependent manner as no effect was observed with RIG-I KO or with GAPDH300 control 
RNA (Figure 28B). Examination of the tumor confirmed an increase in ISG expression, but 
not in unrelated genes like TSG101, specifically in tumors injected with RN7SL1 and 
expressing WT RIG-I (Figure 28C). Thus, these results suggest that unshielded RN7SL1 
transferred by exosomes can promote breast cancer progression. 
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Figure 28. Unshielded stromal RN7SL1 exoRNA promotes breast cancer 
progression and is present in the serum of cancer patients. A) 1833 breast cancer 
cells were xenografted subcutaneously into athymic mice and 10µg of exosomes from 
MRC5 stromal cell mono-culture or 1833 and MRC5 co-culture were injected 
intratumorally 3 times a week (n=5 per group). Shown are tumor growth curves. B) 1833 
breast cancer cells with (RIG-I KO) or without (RIG-I WT) knockout of RIG-I were 
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xenografted subcutaneously into athymic mice and 50ng of the indicated liposome-
encapsulated RNA was injected intratumorally 3 times a week (n=5 per group). Shown 
are tumor growth curves. C) Expression of ISGs measured by qRT-PCR with human 
specific primers from the indicated tumors from (B). TSG101 and MMP1 are non-ISGs not 
expected to change (n=5). D) Normalized photon flux from the lungs of athymic mice (left) 
tail-vein injected with luciferase-labeled 4175 ISG-R breast cancer cells (LM2) engineered 
with one of two independent shRNAs to RIG-I or a control shRNA (n=5 per group). 
Hematoxylin and eosin stain of mouse lung sections at experimental endpoint (right). E) 
Extent of RBP-shielding of mouse RN7SL1 or 18S rRNA from serum exosomes 2 weeks 
after mice were tail-vein injected for lung metastasis induction with 4175 breast cancer 
cells (LM2) or injected with PBS. Proportion shielded is determined by MNase-qRT-PCR. 
Mouse-specific primers were validated for specificity. F) Average distribution of exoRNA 
in each RNA class (left) or by POL3 regulation (right) from serum exosomes of breast 
cancer patients (n=2).  Only the top 200 highest expressed non-ribosomal RNA transcripts 
were considered. G) Extent of RBP-shielding of RN7SL1 or 18S rRNA from serum 
exosomes of cancer patients or normal volunteers without cancer (NM). Legend indicates 
samples from normal volunteers and cancer patients with or without tumor resection. 
Proportion shielded is determined by MNase-qRT-PCR. Unless indicated, error bars are 
SEM of biological replicates and *p<0.05, **p<0.01.  
 
 
Figure 29. Confirmation of RIG-I shRNA activity. Gene expression in 1833 breast 
cancer cells after transduction of control shRNA (CTL) or two independent RIG-I targeting 
shRNA (RIG-I #1 and RIG-I #2) (n=3). Error bars are SEM of biological replicates and 
**p<0.01. 
 
To study whether metastatic progression is associated with breast cancer RIG-I 
signaling and unshielded RN7SL1 exoRNA from stromal cells, we utilized 4175 human 
breast cancer cells, which are an ISG-R lung metastatic derivative of MDA-MB-231144. 
Inhibiting RIG-I expression in 4175 cells using two independent shRNAs (Figure 29) 
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resulted in a significant defect in lung metastatic colonization, indicating the importance of 
RIG-I signaling in breast cancer cells (Figure 28D). Compared to non-tumor bearing mice, 
interrogation of exoRNA from serum of mice with wild-type 4175 lung metastases revealed 
more unshielding of mouse RN7SL1 but not 18S rRNA as measured using mouse-specific 
primers (Figure 28E). These data suggest that lung metastases from human breast cancer 
cells can result in greater amounts of circulating unshielded RN7SL1 in exosomes 
originating from mouse stromal cells. To corroborate these findings, we also examined 
exoRNA from the serum of a small cohort of cancer patients (Table 6). To the extent 
possible, we mimicked the analysis in mice by examining RN7SL1 in patients after tumor 
resection. This facilitated assessment of RN7SL1 exoRNA from stromal cells and allowed 
better comparison to normal controls without cancer. ExoRNA-seq from two patients 
confirmed that RN7SL1 and POL3 transcripts are present at high levels and among the 
predominant non-rRNA transcripts in exosomes from cancer patients (Figure 28F). 
Compared to healthy controls, this RN7SL1 exoRNA was significantly less shielded in 
cancer patients having had tumor resection, suggesting that RN7SL1 from remaining 
cancerized stroma is more unshielded than from normal cells (Figure 28G). Although 
cellular origin could not be determined, RN7SL1 exoRNA from two available patients with 
gross tumors prior to any therapy also showed similar results, arguing that RN7SL1 
unshielding was not solely due to confounding factors related to tumor resection. 
Together, these findings suggest that unshielded stromal RN7SL1 in exosomes can 
propagate anti-viral signaling in the tumor microenvironment to enhance breast cancer 
progression or metastasis. 
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Table 6: Characteristics of patients analyzed for exosome RN7SL1 shielding 
ID Sex Status Age Cancer Type Resection 
H1 Female Healthy 42 None N/A 
H2 Female Healthy 77 None  N/A 
H3 Female Healthy 24 None N/A 
H4 Female Healthy 52 None  N/A 
H5 Female Healthy 27 None N/A 
H6 Male Healthy 27 None  N/A 
H7 Male Healthy 27 None N/A 
H8 Male Healthy 44 None  N/A 
H9 Male Healthy 49 None N/A 
H10 Male Healthy 57 None  N/A 
C1 Female Cancer 52 Breast Yes 
C2 Female Cancer 49 Breast Yes 
C3 Female Cancer 49 Breast Yes 
C4 Female Cancer 72 Breast Yes 
C5 Female Cancer 55 Breast Yes 
C6 Female Cancer 49 Breast Yes 
C7 Male Cancer 82 Pleomorphic undifferentiated sarcoma No 
C8 Female Cancer 33 Cervical squamous cell carcinoma  No 
 
 
Discussion 
In this study, we describe a phenomenon of virus mimicry whereby the interaction 
between breast cancer cells and stromal fibroblasts share several similarities with how 
virus infected cells relay anti-viral signals to surrounding cells. First, upon encounter with 
breast cancer cells, stromal cells mount an anti-viral response analogous to virally infected 
cells by upregulating ISGs and other genes associated with anti-viral signaling. In fact, 
interferon and anti-viral signaling are dominant pathways induced among hundreds of 
upregulated transcripts. Second, like virally infected cells that can package viral 5’ppp 
RNA into exosomes to function as pathogen-associated molecular patterns (PAMPs), 
stromal cells that have encountered breast cancer cells increase the abundance of 
endogenous POL3-derived and RBP-devoid 5’ppp RN7SL1 in exosomes to function as 
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DAMPs. Moreover, after interaction between stromal cells and ISG-R breast cancer cells, 
production of DAMP-laden exosomes can increase ten-fold132. After paracrine transfer, 
the PAMP/DAMPs stimulate PRRs to propagate the anti-viral response. In the case of 
cancer, RIG-I activation in breast cancer cells by stromal RN7SL1 can result in STAT1-
mediated amplification of the NOTCH3 pathway, as previously described132. 
Consequently, this interaction favors tumor progression, resistance to therapy, and tumor-
initiation capacity. In total, these data demonstrate how cancers can employ virus mimicry 
in the tumor microenvironment to coerce stromal cells to disseminate anti-viral signals that 
amplify oncogenic signaling pathways (Figure 30). 
 
Figure 30. Model of virus mimicry and unshielding of stromal RN7SL1 to activate 
breast cancer RIG-I through exosome transfer. 
 
Viral PAMPs are under selective pressure to avoid immune recognition, while 
endogenous RNA DAMPs must avoid recognition by PRRs under non-pathological 
conditions. Thus, our discovery that RN7SL1 is a cancer-associated DAMP presented a 
conceptual problem. Specifically, given its abundance in the cytoplasm, it was unclear 
how RN7SL1 could both function as a DAMP in exosomes but at the same time avoid 
recognition by RIG-I while in the cytoplasm. Indeed, it has long been recognized that RNA 
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modification and subcellular localization may be insufficient to prevent inappropriate 
activation by endogenous and abundant POL3 5’ppp transcripts, arguing that unknown 
mechanisms must exist145. Our findings on how differential RBP shielding of endogenous 
RN7SL1 can control DAMP activity and PRR activation provide an explanation for how 
this discrimination can be achieved. In the cytoplasm, RN7SL1 is nearly completely 
shielded by RBPs, presumably SRP proteins. In particular, SRP9 and SRP14 are known 
to interact with the 5’ end of RN7SL1 and we show that these RBPs interfere with RIG-I 
recognition and activation. In exosomes generated from stromal activation by ISG-R 
breast cancer cells, SRP9/14 are absent and results in unshielding of RN7SL1 and 
recognition by RIG-I in recipient cells. These data also indicate that the stimulatory effects 
of high affinity RNA ligands for RIG-I measured in vitro, may be superseded in vivo by 
RBP shielding. Thus, control of RBP shielding may be a critical regulatory layer that 
prevents inappropriate PRR activation, especially of abundant RNAs, while concurrently 
allowing for a readily available and rapidly deployable DAMP. 
When stromal cells encounter breast cancer cells, the initiating event that mimics 
viral infection and leads to the deployment of RN7SL1 as a DAMP is currently unknown. 
Cell-cell contact between stromal and breast cancer cells is required as conditioned media 
from breast cancer cells does not induce ISGs in stromal cells. Indeed, abnormal cell-cell 
contact between epithelial cells and fibroblasts, which are often separated by a basement 
membrane, typically occurs under pathological situations such as wounding or with 
invasive carcinoma. Thus, one possibility is that this heterotypic interaction itself may 
represent a “damage” signal that initiates DAMP release by the stromal compartment. 
Although the mechanism for this potential damage signal is unknown, recent evidence 
demonstrates that oncogenic signals involved in cell-cell regulation such as the Hippo 
pathway can lead to the secretion of extracellular vesicles containing RNA DAMPs146. 
Consistent with a role for oncogenic signaling, we show that there is a pronounced 
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transcriptional upregulation characteristic of cellular activation in stromal cells after contact 
with ISG-R breast cancer cells, as well as an increase in hallmark genes associated with 
MYC and RAS activation. Interestingly, POL3 activity is augmented by MYC137 and by 
nearby RNA polymerase II (POL2) occupancy141. This suggests that high MYC and POL2 
transcriptional output resulting from interaction with ISG-R breast cancer cells may 
enhance POL3-driven RN7SL1 levels in stromal cells. If binding by RBPs such as 
SRP9/14 are limiting, an ensuing increase in unshielded RN7SL1 may lead to its export 
into exosomes. We find that NOTCH1-mediated MYC activation is able to enhance 
RN7SL1 RNA output without a concomitant increase in SRP protein production, resulting 
in an excess of RN7SL1 that is unbound by RBPs. Thus, unshielded RN7SL1 may be a 
consequence of stromal activation after inappropriate interaction with epithelial cells. This 
aberrant stromal activation may be a trigger for virus mimicry. 
Besides transferring viral RNA, the ability to horizontally transfer DAMPs may also 
be an important feature of virus infection, further illustrating how tumor-supporting stromal 
cells may borrow queues from virally infected cells. Consistent with this, virions have been 
described to contain not only RN7SL1 in the absence of SRP proteins but multiple other 
endogenous non-viral RNAs94–97. The role of these non-viral RNAs in virions has not been 
well characterized; however, it has been postulated that they might stimulate innate 
immune signaling98. Our results would support this notion and suggest that RN7SL1 in 
virions may act as a potent activator of RIG-I like it does in exosomes. Alternatively, in 
addition to containing viral RNA, exosomes secreted by infected cells may also package 
unshielded RN7SL1 capable of RIG-I activation. Therefore, whether in virons or in 
exosomes, cells under viral attack may help to ensure a broad anti-viral response by 
packaging endogenous DAMPs alongside viral RNA PAMPs. In support of this concept, 
recent studies show that cells infected by viruses can package the nucleoside second-
messenger cGAMP into secreted virions to trigger a STING-dependent interferon 
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response in recipient cells99,100. In total, these observations suggest that horizontal transfer 
of DAMPs to promulgate anti-viral signaling is a key feature of virus mimicry. Moreover, 
RBP unshielding of endogenous RNAs may have broad implications for innate immune 
sensing not only for cancer but also during host-virus interactions. 
In the context of cancer, this study, together with previous work, demonstrates that 
unshielded RN7SL1 activates RIG-I to amplify NOTCH3 signaling, resulting in expansion 
of tumor-initiating cells. Accordingly, tumor growth, metastasis, and therapy resistance are 
augmented. Consistent with how horizontal dissemination of DAMP signals can influence 
metastasis, cell-cell interaction between breast cancer and astrocytes have been shown 
to facilitate breast cancer brain metastasis through transfer of cGAMP via gap junctions43. 
Other instances of exoRNA activating stromal or host cell PRRs to enhance metastasis 
have also been described101,102. This includes non-coding RNAs such as microRNAs that 
activate toll-like receptors. In the case of the ISG-R breast cancer cells used in this study, 
MYD88-dependent TLRs do not have an appreciable role in stromal-mediated anti-viral 
signaling132. Moreover, of all 5’ppp transcripts identified in exosomes, only RN7SL1 was 
highly abundant, strongly unshielded, and predicted to have extensive double-stranded 
folding. Nonetheless, we do not rule out contributions from other exoRNAs as DAMPs in 
our study or in other cellular contexts. Similar to how defense against different viruses may 
rely on distinct PRRs to optimally engage different viral PAMPs, diverse forms of virus 
mimicry in cancer may sense different, altered, or inappropriately expressed endogenous 
RNAs using various innate immune sensors. The extent to which differential RBP shielding 
impacts these DAMP-PRR combinations remains unknown but is likely an important 
determinant for activation. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Exosomes and ncRNA are Mediators of Cell-to-Cell Communication in the Tumor 
Microenvironment 
In these studies, we detail a complex mechanism of breast cancer tumor-stromal 
interaction that enhances tumor progression and therapy resistance. This interaction is 
characterized by both paracrine anti-viral signals and juxtacrine Notch pathway activation 
that converge at various stages. Here, we find that heterotypic interaction of basal-like 
breast cancer cells and stromal fibroblasts activates NOTCH1 in the stroma, which results 
in the activation stromal MYC. Consequently, MYC enhances stromal POL3 transcriptional 
output of RN7SL1, a highly structured, short, 5’ppp ncRNA. This POL3 transcriptional 
activity in not matched with an upregulation of canonical RN7SL1 RBP binding partners, 
SRP9 and SRP14, and results in an excess of unbound RN7SL1 transcript. Thus, stromal 
RN7SL1 is found in its unshielded form in the exosomes produced after tumor-stromal 
interaction and acts as a DAMP. Recipient breast cancer cells directly recognize 
unshielded RN7SL1 as a pathogenic nucleic acid through the PRR, RIG-I. This initiates 
an anti-viral signaling cascade resulting in the upregulation of ISGs.  
Concomitantly, paracrine signals originating from presentation of stromal JAG1 to 
activate breast cancer NOTCH3, result in the release of the NOTCH3 intracellular domain, 
NICD3. The anti-viral and Notch pathways converge as STAT1 and NICD3 
transcriptionally cooperate to maximize Notch pathway output that is responsible for 
therapy resistance. These seemingly distinct pathways overlap at the initiation and effector 
stages of tumor-stromal interaction to promote tumorigenicity. In vivo, we find that 
combining radiation therapy with a GSI reverses the breast cancer therapy resistance 
conferred by stromal cells. Further, breast cancer patients harbor evidence of circulating 
unshielded RN7SL1, while healthy donor exosomal RN7SL1 is largely shielded. 
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Expression of these pathways is also predictive of conventional treatment failure, as those 
patients with high ISGs and high NOTCH pathway expression have significantly worse 
prognosis. In total, we identify and characterize a conserved pathway by which co-
expression networks in breast cancer cells and the surrounding stroma can drastically 
influence tumor progression, metastasis, and therapy resistance.  
Figure 31. Model of tumor-stromal juxtacrine and paracrine pathway activation in breast 
cancer.  
 
Shielding of Nucleic Acids Regulates PRR Activation 
The characteristics of RNA required for RIG-I activation are well studied147. 
Typically, RIG-I is maximally activated by short, double-stranded, and 5’triphosphorylated 
RNA. These are all hallmark features of viral RNA that RIG-I is best characterized to bind. 
Under normal conditions many cellular RNA that match these characteristics are present; 
however, RIG-I does not bind to them at baseline. The authors of the initial study that 
identified 5’ppp RNA as a RIG-I ligand highlighted that many cellular RNA species are 
also 5’ppp and abundant in the cytoplasm; therefore, they speculated these RNA must 
avoid recognition by unknown mechanisms145. Therefore, we hypothesized that protein 
shielding may be a mechanism of avoiding RIG-I recognition. Viruses often shield their 
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5’ppp and double-stranded RNA regions with nucleocapsid proteins to avoid RIG-I 
recognition148,149. The largest source of double-stranded, 5’ppp cellular RNA is RNA 
polymerase III. Much of the POL3 transcriptome functions in RNPs for a variety of 
essential cellular process and are largely shielded under normal conditions.  
We found that if properly presented, a POL3 transcript, RN7SL1, can act as a 
potent RIG-I ligand. Normally, RN7SL1 is bound by SRP proteins as part of the RNP 
known as the signal recognition particle. In exosomes originating from tumor-stromal co-
culture, SRP proteins are absent and RN7SL1 is unshielded and can act as a DAMP to 
activate RIG-I and ISGs. We demonstrate this by metabolically labeling stromal RNA and 
observing its interaction by breast cancer RIG-I upon co-culture and exosome transfer. 
Unshielded RN7SL1 in exosomes is reminiscent of how many retrovirus virions package 
unshielded RN7SL1 and other POL3 transcripts98. While the function of these host 
transcripts in virions is unknown, our data suggests that RN7SL1 may also act as a DAMP 
in these viral infections. This is likely a host defense mechanism to activate ISGs and 
achieve tissue-level amplification of anti-viral responses. Similar instances of DAMP 
packaging in virions have been described where the STING activator cGAMP traffics in 
virions and extracellular vesicles after viral infection99,100. It is thought that cGAMP traffics 
in virions as a specific and potent DAMP to prime uninfected cells of impending infection. 
We propose that RN7SL1 may function in a similar fashion; however, due to its highly 
abundant and cytoplasmic nature, it is only available for deployment as a DAMP if it is 
unshielded. In total, our results suggest that protein shielding is a major determinant of 
RIG-I recognition of both self and non-self nucleic acids.   
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Unshielded RN7SL1 as a Regulator and Biomarker of Treatment Resistant Breast 
Cancer 
The clinical management of cancer requires increasingly requires personalized 
treatment strategies. These treatment strategies often require an understanding of the 
individual patient’s cancer mutational and expression profile. At present, interrogating this 
complex landscape is achieved by tissue-based methods after surgery or biopsy150. These 
methods have several drawbacks: 1) they are unable to capture the heterogeneity of tumor 
and tumor microenvironment, 2) they require a detectable tumor in an area that can be 
biopsied or surgically removed, and 3) they often cannot be obtained repeatedly over the 
course of disease and treatment progression. Therefore, there is considerable interest in 
the development of tools to interrogate blood-based biomarkers for cancer detection, 
prognosis, and monitoring of treatment efficacy151. There have been significant advances 
in developing and implementing technology for the detection of circulating tumor DNA 
(ctDNA), which, can accurately diagnose and monitor treatment progression in certain 
cancers152,153.  Further, enrichment for cancer-derived exosomes with protein markers and 
identification of KRas mutations can accurately diagnose pancreatic cancer at early 
stages75. While these approaches have extensive capabilities to detect ctDNA with 
exquisite sensitivity and specificity, they are limited by the assessment of mutational 
status. In order to further increase the power of liquid biopsy approaches it would be 
valuable to develop methods that facilitate novel applications, such as identification of 
therapeutic vulnerabilities not based on mutational status, enumeration of cancer specific 
mRNA isoforms, and interrogation of cancer gene expression networks.  
One potential approach for facilitating these novel applications would be analysis 
of cell-free RNA. While circulating cell-free RNA has been difficult to assess, exosomal 
RNA provides a readily available and tractable source of circulating RNA. We identified 
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unshielded RN7SL1 as both a regulator of breast cancer tumor progression as well as a 
biomarker of disease. In cancer patients compared to healthy donors we find an 
abundance of unshielded RN7SL1. In TNBC, where no liquid biomarker has been 
described, unshielded RN7SL1 provides a potential opportunity for clinical translation4. 
Exosomes and exosomal RNA is readily purified from less than 500µL of serum or plasma 
in less than four hours. Our MNase-based shielding assays take less than 24 hours from 
start to finish and produce consistent results. While much work remains to be done to bring 
these shielding assays to the clinic, it represents a promising avenue to consider. 
Tumor-Stroma Co-Expression Networks are a Promising Drug Target 
The tumor microenvironment is a driver of cancer initiation, progression, 
metastasis, and therapy resistance. Therapies that account for these complex interactions 
must be developed and implemented. Strategies to target the tumor microenvironment 
have been attempted with varied success. Most prominently, the tumor vasculature can 
be targeted by blocking the predominant proangiogenic molecule,  vascular endothelial 
growth factor (VEGF), with monoclonal antibodies154. Such blocking antibodies were 
approved by the FDA in for the treatment of metastatic colon cancer in 2004 and 
subsequently for many other cancers alone or in combination with other therapies. While 
it presents a mild clinical benefit for many cancers, VEGF blockade in breast cancer is 
ineffective. The FDA withdrew approval of VEGF blocking antibodies for patients with 
HER2-negative cancers due to its lack of therapeutic benefit and significant toxicity155. 
Targeting cancer-associated inflammation by inhibition of tumor-associated macrophages 
(TAM) has found significant preclinical success156. Additionally, targeting of 
microenvironmental signaling pathways such as cyclooxygenase-2 (COX2), transforming 
growth factor beta (TGFβ), JAK-STAT, TNF-α, and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) have been both preclinically and clinically 
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successful157,158. While these successes are promising, drawbacks include toxicity due to 
broad targeting of nonpathogenic stroma, acquisition of resistance mechanisms by both 
the tumor stroma and cancer cells, and lack of sufficient biomarkers to optimally treat 
patient subsets.   
The most clinically beneficial strategies to target the tumor microenvironment may 
be to target pathways of tumor-stromal crosstalk. Combinatorial therapy in cancer has 
proven to be an efficacious treatment strategy in most cancers159,160. Rational combination 
of conventional cytotoxic therapies with targeted therapy, immunotherapy, and distinct 
cytotoxic therapies is the current standard of care in many cancers. Targeting of tumor-
stroma interactions provides an opportunity to target both subsets with a single agent. Our 
data would suggest that specific therapies that target co-expression pathways can serve 
as a combinatorial single-agent therapy. For example, ISG and NOTCH pathway 
activation in both stromal and breast cancer cells supports tumorigenesis, progression, 
and therapy resistance. We have demonstrated that the activation of these pathways is 
intimately intertwined; therefore, we would predict that targeting of one pathway should 
cripple the other. Indeed, we find that the combination of radiation therapy and GSI results 
in remarkable tumor regression in xenograft models of breast cancer. We posit that this is 
due to simultaneous targeting of tumor and stromal ISG and NOTCH pathways. Therefore, 
it is imperative to expand these findings to other tumor-stromal interaction networks, such 
as RAS pathway activation and cGAS/STING pathway activation43,131.    
Exosomal Activation or Suppression of Anti-Tumor Immune Responses 
We have identified exosomes and exosomal RNA as a conduit for tumor-fibroblast 
crosstalk that influence and accelerate various stages of breast cancer tumor progression. 
While fibroblasts are the predominant stromal subtype in breast cancer, infiltrating myeloid 
and lymphoid cells may also play a significant role. The immunogenic role of exosomes 
107 
 
are well-characterized106. Exosomes can be immune activating by directly and indirectly 
activating dendritic cells by modulation of antigen presentation. They may also directly 
activate natural killer (NK) cells, macrophages, B cells, and T cells. Recently, it was also 
demonstrated that activation of canonically oncogenic signals can result in the release of 
immune activating exosomes that results in robust tumor clearance146. Exosomes can also 
be immune suppressive by inhibiting cytotoxic activity of effector CD4 and CD8 T cells, 
and NK cells. They can further suppress immune activation by inhibiting DC differentiation 
and promotion of myeloid-derived suppressor (MDSC) differentiation. In total, there is a 
clear interaction with exosomes and the immune system. The role of RNA-sensing 
pathways in the activation or suppression of innate and adaptive immune system is 
understudied. It is unclear whether activation of these pathways in the tumor 
microenvironmental milieu would activate or suppress anti-tumor immune responses. How 
exosomes contribute to this balance in breast cancer is not yet understood. Generally, 
fibroblast activation in breast cancer is thought to be immune suppressive161; therefore, 
exosomes containing unshielded RN7SL1 may function to maintain an immunologic 
environment that is favorable to tumor progression.  
Clinical trials utilizing antibody-based blockade of immune checkpoints such as 
CTLA4 and PD1/PDL1 have resulted in remarkable and durable responses. Unfortunately, 
the majority of patients do not respond to these therapies alone due to adaptive and 
acquired resistance mechanisms162. Therefore, there is considerable interest in the 
combination of immunotherapies and targeted or conventional cytotoxic therapies for the 
treatment of solid cancers163,164. Understanding the immune suppressive or activating role 
of exosomes present in the tumor microenvironment can ultimately lead to the rational 
combination of therapies. In particular, breast cancer can be largely immunologically 
silent. If exosomes containing unshielded RN7SL1 are demonstrated to be 
immunosuppressive, then it would suggest patients harboring evidence of circulating 
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unshielded RN7SL1 not be treated with immune checkpoint blockade alone, but in 
combination with GSI to cripple tumor-stroma interactions. If the converse is true, then 
those patients may be promising candidates for single agent immune checkpoint 
blockade. Beyond biomarkers, exosomes are emerging as candidates for delivery of 
therapeutics165. RNA lipoplexes have shown promise in activation of antigen presenting 
cells and mediating rejection of murine tumors in combination with immunotherapy166. 
However, systemic autoimmune responses may result from potent delivery of nonspecific 
synthetic   RNA and liposomes. Therefore, endogenous unshielded RN7SL1 
encapsulated into autologous exosomes may result in safer treatment strategies. In total, 
exosomes provide another opportunity to personalize and adapt conventional and 
emerging therapies for breast cancer patients.  
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CHAPTER 5: MATERIALS AND METHODS 
Cell Culture and Cell Sorting 
Cell culture and cell sorting were completed as previously described132. All cell lines were 
confirmed to be mycoplasma-free with repeated testing. All human breast cancer and 
stromal cell lines were cultured at 37oC in DMEM supplemented with 10% FBS, 100U/ml 
penicillin and 100µg/ml streptomycin, and 2mM l-glutamine. The KB1P mouse breast 
cancer cell lines from K14cre;p53F/F;Brca1F/F mice120 were cultured in RPMI. All co-culture 
experiments were performed in DMEM with exosome-depleted FBS. Breast cancer cells 
were labeled with 7.5µM 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
(CFSE) and mixed 1:1 with stromal cells. Cell populations with a purity of at least 98% 
were used for RNA or protein isolation.   
Cell Death Assays 
Sytox cell death assays were completed as previously described132. In brief, mono- or co-
cultures were irradiated after 48 hours with 10 Gy using a Cs-137 Gammacell 40 
EXACTOR. Cell death of CFSE-labeled breast cancer cells was measured at 96 hours 
post-radiation by flow cytometry using Sytox-Red (Invitrogen). Relative cell death was 
calculated by comparing mono and co-culture cell death.  
Cell Culture Exosome Isolation 
Cell cultures used to isolate exosomes were grown in exosome-depleted media prepared 
by ultracentrifugation of FBS for 3 hours at 100,000xg. Exosomes were isolated from 
conditioned media collected at 48-72 hours by serial high speed ultracentrifugation as 
previously described167 or using 10% final concentration of polyethylene-glycol and low 
speed centrifugation, as previously described168. Purity was examined by electron 
microscopy by negative staining, protein analysis by immunoblotting, and quantified by 
NanoSight N1000 analysis. For exosome injection experiments, protein was quantified by 
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Lowry method, and equivalent volume of 10µg of exosomes were injected. For exosome 
depletion, conditioned media was ultracentrifuged for 8-16hours.  
Serum Exosome Collection 
Serum from patients with cancer were obtained through the UPENN RadOnc Biosample 
Repository. Blood was collected using yellow top Vacutainer (BD) and centrifuged at 
3000rpm for 10 minutes. The samples were then frozen at -80oC until use. Serum from 
healthy donors was obtained commercially (Innovative Research). For exosomes from 
human or mouse serum, 500µl of serum was spun at 2000xg for 15 minutes, filtered 
through a 0.22µm filter, and then purified by serial high speed ultracentrifugation. 
EU Labeling and Quantification 
Stromal cells were labeled with 100µM 5-Ethynyl Uridine (EU) for 24 hours, and breast 
cancer cells were labeled with DiD (1:200) for 10 minutes at 37oC. Both cells types were 
then washed and co-cultured for 8 or 24 hours on glass coverslips. EU was then visualized 
by Alexa Fluor 488 azide (Alexa Fluor® 488 5-carboxamido-(6-azidohexanyl), 
bis(triethylammonium salt))169. Percentage of double positive cells that matched breast 
cancer cell morphology were scored as EU+ breast cancer cells.  
4sU RNA Transfer Quantification 
Stromal cells were labeled with 200µM 4sU (4-Thiouracil) for 24 hours, washed, and either 
left in mono-culture or co-cultured with breast cancer cells. Conditioned media was 
isolated after 24 hours and added to mono-cultured breast cancer cells. Breast cancer 
cells were harvested 24 hours later and RNA extracted. 4sU-labeled RNA was specifically 
biotinylated with HPDP-Biotin and enriched with streptavidin-conjugated magnetic beads, 
as previously described170. Transfer of stromal-derived RNA was determined by 
quantification of total 4sU-labeled RNA in recipient breast cancer cells compared to total 
RNA or by qRT-PCR.  
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4sU-FLAG-RIP 
Stromal cells were labeled with 200µM 4sU (4-Thiouracil), washed, and co-cultured with 
breast cancer cells with RIG-I CRISPR KO, RIG-I KO with re-expression of FLAG-tagged 
RIG-I or RIG-IK858/861A for 48 hours. Co-cultures were harvested and 100mg of wet cell 
pellet was lysed by sonication (five, one-second bursts, medium output) in RSB-200 buffer 
(20mM Tris pH 7.5, 200mM NaCl, 2.5mM MgCl2, 0.5% NP-40, 0.1% Triton X-100, 0.2 
U/uL RNase Inhibitor, and one tablet of protease inhibitors). Post-lysis, FLAG-RIG-I was 
immunoprecipitated with prebound and washed FLAG-M2 beads (Sigma) using 30uL of 
beads per 100mg of wet cell pellet for 2-3 hours at 4oC. Beads were then washed three 
times with RSB-200. RNA was extracted with TRIzol reagent utilizing linear acrylamide as 
a carrier. 4sU-labeled RNA was then enriched as described above.  
Gene Targeting and Expression 
Gene knockdown by siRNA was completed using SMARTPool siRNAs (Thermo) and 
transfected using 20nM siRNA and RNAiMax (Invitrogen) transfection reagent. For stable 
knockdowns, shRNAs were cloned into the pGIPZ vector and transduced by virus using 
pCMV-VSV-G and pHR8.2ΔR envelope and packaging vectors in HEK293T cells. 
Transduced cells were selected using 1-2µg/ml of puromycin. Wild-type and 
K858A/K861A binding mutant of RIG-I was cloned into the pOZ-N vector (a kind gift from 
Roger Greenberg). Transduced cells were then selected with IL-2 receptor magnetic 
beads and expression was confirmed by Western blot for FLAG, HA, and RIG-I. RIG-I 
restoration was functionally confirmed by RIG-I pathway activation in response to Sendai 
virus infection. SRP9 and SRP14 were transiently transfected with pGFH-9 (Addgene 
plasmid # 39538) and pGFH-14c (Addgene plasmid # 39541), both gifts from Katharina 
Strub. Gene knockout by CRISPR was accomplished using pSpCas9(BB)-2A-GFP 
(PX458), a gift from Feng Zhang (Addgene plasmid # 48138). RIG-I was knocked out 
utilizing the protocol described171. In brief, two distinct guide RNAs cloned into the 
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pSpCas9(BB)-2A-GFP backbone were transiently transfected into breast cancer cells. 
After 48 hours, single cells were sorted into 96 well single cell clones based on highest 
GFP expression. Clones were confirmed to have no RIG-I expression by immunoblot and 
pooled. RIG-I KO in the pooled clones were functionally confirmed by RIG-I pathway 
activation in response to Sendai virus infection.   
Recombinant Protein Production and Purification 
Recombinant SRP9 was produced by subcloning the SRP9 cDNA from pGFH-9 plasmid 
into the pET Hi12 GST TEV LIC cloning vector (1G), a gift from Scott Gradia (Addgene 
plasmid # 29655). Recombinant protein was produced in BL21 competent E. coli and 
captured with Glutathione Sepharose beads (GE Healthcare). GST-tagged TEV Protease 
(Sigma) was used to cleave GST-SRP9.  
In Vivo Mouse Studies 
All mouse studies were completed in accordance with ULAR and IACUC regulations. For 
exosome injection studies, 1 x 106 1833 breast cancer cells were injected with Matrigel 
(Corning) into the flanks of 6-8 week old athymic nude mice and 10µg of mono- or co-
culture exosomes were directly injected into the tumors 3 times a week. For RNA injection 
studies, 50ng of 7SL or GAPDH300 RNA encapsulated into RNAiMax liposomes were 
directly injected into the tumors 3 times a week.  Subcutaneous tumor growth was 
measured by caliper. For lung colonization studies, 2 x 105 luciferase-labeled 4175 breast 
cancer cells were injected in the tail vein. Injections were confirmed by immediate imaging 
using a Xenogen IVIS 100 system. Serum was isolated from mice by cardiac puncture. 
Exosome RNA Sequencing 
Exosome RNA was extracted with TRIzol and library preparation was completed using the 
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB) modified so that the 
RNA was not fragmented prior to library preparation.  ERCC controls (Invitrogen) were 
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added into all exosome RNA samples. Libraries were sequenced on Illumina HiSeq 2500 
with 100 base paired end reads.  
Microarray Data Processing and Normalization 
Gene expression data for ISG-R and ISG-NR breast cancer cells co-culture with MRC5 
fibroblasts have been described132 and available at the GEO (GSE60998). ISG-R cell lines 
included: MDA-MB-231, MDA-MB-231 (1833), and HCC1937.  ISG-NR cell lines included: 
MCF7 and MDA-MB-468. Pre-processing, filtering, and differential gene expression 
analysis were performed as previously described132. Gene set analysis was performed 
using the piano R package and Reactome gene sets downloaded from the Molecular 
Signatures Database v5.1 (http://software.broadinstitute.org/gsea/msigdb). The gene set 
for upregulated cancer associated ISGs has been previously described 38. 
MNase qRT-PCR and RNA Sequencing 
Either whole cells or whole exosomes were incubated at 37oC for 30 minutes in MNase 
Buffer (25mM Tris-HCl, 2.5mM CaCl2, 50mM NaCl, 1X PBS), with or without MNase and 
with or without 0.1% Triton X-100. Pre-MNase treatment, 10ng of DVG396 RNA was 
spiked-in to control for differences in MNase activity with or without detergent. Post-MNase 
treatment, TRIzol LS reagent was used to purify RNA using linear acrylamide as a carrier, 
and ERCC Controls (Invitrogen) were spiked-in to account for differences in efficiency of 
RNA extraction. For RNA sequencing studies, libraries were prepared from purified RNA 
using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB) without 
further RNA fragmentation. Libraries were sequenced on Illumina HiSeq 2500 with 100 
base paired end reads. For qRT-PCR studies, percent shielded was quantified by ΔΔCt 
method normalizing to DVG396 spike-in and MNase without detergent.  
RNA-seq data analysis 
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For exosome RNA-seq and MNase RNA-seq analysis, reads were trimmed first using 
cutadapt v1.9172 with parameters -q 10 -m 30 -O 4. Trimmed reads were then aligned to 
ERCC controls, rRNAs sequences as well as RN7SL1 by using bowtie2173.  The remaining 
reads were aligned to the GRCh38 reference genome using STAR v2.4.0k174 with 
parameters --outFilterMultimapNmax 100 --outFilterMismatchNmax 999 --
outFilterMismatchNoverLmax 0.06. Primary aligned reads were counted against 
GENCODE annotation v21175 and RepeatMasker annotation (UCSC Genome Browser) 
using Subread v1.4.6176 with parameters -s 2 -minReadOverlap 10. The DESeq2 R 
package version 1.10177 was used for differential gene expression analysis. ERCC 
controls were used for inter-sample normalization.  
5’ triphosphate RNA Sequencing 
To enrich for 5’triphosphate RNA, 0.1-2 µg of exosomal RNA was prepared by first 
degrading 5’monophosphate RNA with Terminator 5´-Phosphate-Dependent 
Exonuclease (Epicentre), then converting 5’triphosphate to 5’p with RNA 5’ 
Polyphosphatase (Epicentre), to allow for specific ligation of RNA adaptor P5_RNA to 
RNAs that originally have 5’ triphosphate. Then, cDNAs were synthesized by using a 
primer with 5’ random 9mer (P7_N9), and amplified with NEBNext PCR reagents (NEB) 
by using the same protocol as other RNA-seq libraries. Libraries were sequenced on 
Illumina HiSeq 2500 with 100 base paired end reads. Only the first reads of the paired end 
reads were used in data analysis.  Reads were trimmed and aligned the same as RNA-
seq analysis.  Primary reads that matched the 5’ end of annotated features were counted.  
In Vitro Transcription 
In vitro transcription was performed using of PCR amplified cDNA templates that 
contained Hepatitis Delta Virus Ribozyme to ensure homogenous 3’ ends of the transcripts 
of interest178. In vitro transcription was completed with the MEGAshortscript T7 
Transcription Kit (ThermoFisher) according to manufacturer’s instructions. RNA was 
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DNase treated and phenol/chloroform purified. After thermocycling to ensure ribozyme 
cleavage, correct size transcripts were gel purified. 
RIG-I ATPase Assays 
RIG-I ATPase assays were performed as previously described57. In brief, increasing 
amounts of RNA (10-60nM) were added to a constant quantity of RIG-I (5nM) in the 
presence of 1mM ATP. ATP hydrolysis was measured with the EnzChek Phosphate Assay 
Kit (ThermoFisher) after 60-90 minutes at 37oC. ATP hydrolysis was then measured by 
absorbance of 360nm compared to background. A 19-mer 5’triphosphate dsRNA 
(Invivogen) and DVG396 were used as positive controls and a 19-mer 5’OH dsRNA 
(Invivogen) and an in vitro transcribed 300bp ssRNA stretch of GAPDH (GAPDH300) were 
used as negative controls. 
Protein Analysis 
Protein was extracted using 2X SDS lysis buffer, separated by 4%–12% SDS-PAGE, 
transferred to a PVDF membrane, blocked with 5% nonfat milk in PBS-Tween (0.01%), 
and probed with the antibodies described. Protein was visualized using ECL (SuperSignal 
West Pico, Thermo). 
qRT-PCR Gene Expression Analysis 
Total RNA was isolated and purified from cells using TRIzol reagent (Invitrogen). cDNA 
was synthesized using the High Capacity RNA-to-cDNA kit (ABI) according to 
manufacturer’s instructions. qRT-PCR was performed using Power SYBR Green PCR 
MasterMix (ABI) on the TaqMan 7900 (ABI). Relative expression levels were defined using 
the ΔΔCt method and normalizing to 18S rRNA, β-Actin and GAPDH. 
 
Cell Lines Used in All Studies  
The cell lines used are provided in the table below: 
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Human Mouse 
ISG-R ISG-NR Fibroblast ISG-R Fibroblast 
MDA-MB-231 (1833) MCF7 MRC5 KB1P ALF 
MDA-MB-231 (4175) MDA-MB-468 BJ   
MDA-MB-436     
HCC1937     
 
Primers Used in qRT-PCR 
The primers used in qRT-PCR are provided in the tables below: 
Human:  
  Forward Reverse 
GAPDH GCTCAGACACCATGGGGAAGG TTCCCGTTCTCAGCCTTGAC 
18S GTTCAGCCACCCGAGATTGA CCCATCACGAATGGGGTTCA 
ACTB GCCCTGAGGCACTCTTCCA CGGATGTCCACGTCACACTTC 
IFIT1 GGCTGCCTAATTTACAGCAACC GGCATTTCATCGTCATCAATGG 
MX1 CGACACGAGTTCCACAAATG AAGCCTGGCAGCTCTCTACC 
ISG15 GAGAGGCAGCGAACTCATCT CTTCAGCTCTGACACCGACA 
RIG-I CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
POLR3G GATGACGATGATGCCGCAGA GGTTGCCTCATCCATGTTGT 
POLR3F AGGCTCCACCAGTCACAGAC TGCCATTAACAGAAATCAACAAA 
STAT1 TTACTCCAGGCCAAAGGAAG TTCAGCTGTGATGGCGATAG 
7SK GGGTTGATTCGGCTGATCT GGGGATGGTCGTCCTCTT 
RN7SL1 GTGTCCGCACTAAGTTCGG TATTCACAGGCGCGATCC 
hsRN7SL1 GCTACTCGGGAGGCTGAGGCT TATTCACAGGCGCGATCC 
RMRP AAAGTCCGCCAAGAAGCGTA CTGCCTGCGTAACTAGAGGG 
RPPH1 AGCTTGGAACAGACTCACGG AATGGGCGGAGGAGAGTAGT 
RNU2 CGTCCTCTATCCGAGGACAAT CGGAGCAAGCTCCTATTCCA 
TSG101 AGAAGGGGCGTGATAGACCT CACTGAGACCGGCAGTCTTT 
MMP1 TGTGGTGTCTCACAGCTTCC TTTTCAACTTGCCTCCCATC 
 
Mouse: 
  Forward Reverse 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
18S CCCCATGAACGAGGGAATT GGGACTTAATCAACGCAAGCTT 
STAT1 ACAACATGCTGGTGACAGAGCC TGAAAACTGCCAACTCAACACCTC 
ISG15 CCAGTCTCTGACTGTGAGAGC GCATCACTGTGCTGCTGGGAC 
MX1 GACCATAGGGGTCTTGACCAA AGACTTGCTCTTTCTGAAAAGCC 
mmRN7SL1 GCTACTCGGGAGGCTGAGACA TATTCACAGGCGCGATCC 
 
Spike-In Controls 
 Forward Reverse 
DVG396 ACTGGGTCATTCCCTGACCA CCCTCAGGTTCCTGATCTCAC 
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ERCC04 TGGGGCGAGTATTCCCAATG TGGGGAAATTTGGGAAGCAGT 
ERCC95 CTTGCCTGCTGCATGTTGTG GAGCGATAGCGGTTAAGCCA 
ERCC108 GCCGCTGTTGCGTAAATCAA AGCCGACTGCTGCTCATATC 
ERCC130 GTACTGACCAGCGTCACACA GCGTGCGGTCAATCATCTTC 
 
Adaptors for 5’ Triphosphate RNA Sequencing 
P5_RNA ACACUCUUUCCCUACACGACGCUCUUCCGAUCU 
P7_N9 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNN 
 
Antibodies Used for Immunoblotting  
The primers for immunoblotting are provided in the table below: 
 Company Catalog Number Dilution 
β-actin Cell Signaling 4970 1:10000 
SRP9 Proteintech 11195-1-AP 1:500 
SRP14 Proteintech 11528-1-AP 1:500 
GFP Abcam ab6673 1:500 
RPC32 Santa Cruz sc-21754 1:200 
RIG-I Cell Signaling 3743 1:500 
ISG15 Santa Cruz sc-50366 1:200 
FLAG Sigma F1804  1:2000 
HA Santa Cruz sc-7392 1:500 
 
Gene Targeting Sequences  
The sequences for siRNA, shRNA and CRISPR gRNA are listed in the tables below:  
siRNA: 
  Sequence Catalog Number 
CTRL Non-Targeting #1 D-001810-01-20 
POLR3F SMARTpool L-019240-01-0005 
 
shRNA:  
  Sequence Catalog Number 
CTRL GIPZ Non-Silencing shRNA  RH8346 
RIG-I #1 TTAAATTTGTCGCTAATCC V2LHS-199776 
RIG-I #2 TAAAGTCCAGAATAACCTG V2LHS_197176 
 
CRISPR: 
  gRNA Sequence 
RIG-I #1 GGGTCTTCCGGATATAATCC 
RIG-I #2 GGATTATATCCGGAAGACCC 
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